WO2011046812A1 - Phospholipases, nucleic acids encoding them and methods for making and using them - Google Patents
Phospholipases, nucleic acids encoding them and methods for making and using them Download PDFInfo
- Publication number
- WO2011046812A1 WO2011046812A1 PCT/US2010/051903 US2010051903W WO2011046812A1 WO 2011046812 A1 WO2011046812 A1 WO 2011046812A1 US 2010051903 W US2010051903 W US 2010051903W WO 2011046812 A1 WO2011046812 A1 WO 2011046812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- nucleic acid
- phospholipase
- sequence
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- This invention relates generally to phospholipase enzymes, polynucleotides encoding the enzymes, methods of making and using these polynucleotides and polypeptides.
- the invention provides phosphatidylinositol- specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them.
- Industrial methods and products comprising use of these phospholipases are provided. Also provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix.
- NHSs non hydratable phospholipids
- the methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and/or removed from the lipids.
- methods for removing NHPs, hydratable phospholipids, and lecithins (known collectively as "gums") from vegetable oils to produce a degummed oil or fat product that can be used for food production and/or non- food applications.
- methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins can be practiced on either crude or water-degummed oils.
- provided herein are methods for obtaining phospholipids from an edible oil.
- Crude vegetable oils obtained from either pressing or solvent extraction methods are a complex mixture of triacylglycerols, phospholipids, sterols, tocopherols, free fatty acids, trace metals, and other minor compounds. It is desirable to remove the phospholipids, free fatty acids and trace metals in order to produce a quality salad oil with a bland taste, light color, and a long shelf life or oil suitable for transformation into a feedstock ready for chemical or enzymatic conversion into a biofuel (methyl- or ethyl- esters), bio-plastic (epoxidized oil), and other traditional petroleum based materials.
- biofuel methyl- or ethyl- esters
- bio-plastic epoxidized oil
- phospholipids The removal of phospholipids generates almost all of the losses associated with the refining of vegetable oils. Most phospholipid molecules possess both a hydrophilic functional group and lipophilic fatty acid chains, they tend to be excellent natural emulsifiers.
- the functional group in phospholipids may be any of several of a variety of known types, a few of which are illustrated in scheme 1 below.
- Phospholipids containing the functional groups -choline, -inositol and - ethanolamine have the greatest affinity for water, while the acids, acid salts (Calcium (Ca), Magnesium (Mg), and Iron (Fe)), and -ethanolamine salts (Ca, Mg, and Fe) have much lower affinities for water.
- Phosphatidic acid and the salts of phosphatidic acid are commonly known as "non hydratable phospholipids" or NHPs. Table 1 contains relative rates of hydration of different phospholipids as reported by Sen Gupta, A. K., Fette Seifen Anstrichstoff 88 pages 79 - 86 (1986).
- Calcium, magnesium, and iron salts of phospholipids are formed by an enzyme present in oilseeds, phospholipase D (PLD).
- PLD phospholipase D
- the enzyme remains dormant within the mature seed until the protective coating of the seed has been damaged during storage or seed "preparations" prior to removal of the oil.
- the reaction of PLD within the seed will cleave the -choline, -inositol, -serine or -ethanolamine from the phosphate group yielding the Phosphatidic Acid (PA).
- PA Phosphatidic Acid
- the cleavage occurs in the presence of an abundance of divalent metals (Ca, Mg, and Fe), the NHPs are formed.
- the phosphatidic acid calcium ion complex is shown below:
- Phospholipids are commonly measured in oil as "phosphorus content" in parts per million. Table 2 sets forth the typical amounts of phospholipids present in the major oilseed crops, and the distribution of the various functional groups as a percentage of the phospholipids present in the oil.
- Table 3 below provides typical phospholipid amounts and distributions for soybean gums.
- "as is” means the typical phospholipid composition removed from vegetable oil with the entrained oil (2 molecules of phospholipids and 1 molecule of oil), yielding an Acetone Insoluble content of 67 %.
- "Normalized” means the phospholipid composition without any oil present, yielding an Acetone Insoluble content of 100 %.
- phosphatidylserine, phosphatidylinositol, and phosphatidic acid into either their lyso- or phospho- forms greatly changes the economics of the degumming in a modern industrial refining operation.
- the conversion of all of the phospholipids into their lyso- forms eliminating the neutral oil loss represents an increase in oil yield of up to 1.4 %, while converting all the phospholipids into their phospho- forms represents an oil yield increase up to 3.0 % for a crude oil over water degumming containing 1000 ppm of phosphorus.
- Phospholipids can be partially or totally removed from vegetable oils through several different known means.
- the most commonly used processes in the industry are water degumming, acid degumming, caustic refining and enzymatic degumming.
- Phospholipases are enzymes that hydrolyze the ester bonds of phospholipids. Corresponding to their importance in the metabolism of phospholipids, these enzymes are widespread among prokaryotes and eukaryotes. The phospholipases affect the metabolism, construction and reorganization of biological membranes and are involved in signal cascades. Several types of phospholipases are known which differ in their specificity according to the position of the bond attacked in the phospholipid molecule.
- Phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes are a family of eukaryotic intracellular enzymes that play an important role in signal transduction processes.
- the PI-PLC catalyzed reaction is:
- PLC phospholipase C
- PLC enzymes belong to the family of hydrolases and phosphodiesterases.
- PLC participate in phosphatidylinositol 4,5-bisphosphate (PIP 2 ) metabolism and lipid signaling pathways in a calcium-dependent manner.
- PIP 2 phosphatidylinositol 4,5-bisphosphate
- PLC isoforms can differ in their mode of activation, expression levels, catalytic regulation, cellular localization, membrane binding avidity and tissue distribution.
- PLCs are described in, for example, Carmen, G., /. Biol. Chem. 270 (1995) 18711-18714, Jianag, Y., /. Biol. Chem, 271 (1996) 29528-29532, Waggoner, D., /. Biol. Chem. 270 (1995) 19422-19429, Molecular Probes Product Sheet 2001, and Sano et al. , Am. J. Physiol. Lung Cell Mol. Physiol. 281:844-851, 2001.
- Phospholipase Al enzymes remove the 1 -position fatty acid to produce free fatty acid and l-lyso-2-acylphospholipid.
- Phospholipase A2 Phospholipase A2 (PLA2) enzymes remove the 2-position fatty acid to produce free fatty acid and l-acyl-2-lysophospholipid.
- PLA1 and PLA2 enzymes can be intra- or extra-cellular, membrane-bound or soluble. Intracellular PLA2 is found in almost every mammalian cell.
- Phospholipase C PHC
- polypeptides and polynucleotides encoding polypeptides having a phosphatidylinositol-specific phospholipase C (PI-PLC) or equivalent enzyme activity, and/or another phospholipase activity, including a phospholipase A, B, C, D, patatin, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) or equivalent enzyme activity, and methods of making and using these polynucleotides and polypeptides.
- polypeptides e.g., enzymes, having a phospholipase activity, e.g., phospholipase A, B, D or C activity, e.g.
- PI-PLC phosphatidylinositol-specific phospholipase C
- the enzymatic activities of the polypeptides and peptides as provided herein include (comprise or consist of) a phospholipase activity, a phospholipase C activity, or a phosphatidylinositol-specific phospholipase C (PI-PLC) activity, including hydrolysis of lipids, acidolysis reactions (e.g., to replace an esterified fatty acid with a free fatty acid), transesterification reactions (e.g., exchange of fatty acids between triacylglycerides), ester synthesis, ester interchange reactions and lipid acyl hydrolase (LAH) activity.
- acidolysis reactions e.g., to replace an esterified fatty acid with a free fatty acid
- transesterification reactions e.g., exchange of fatty acids between triacylglycerides
- ester synthesis ester interchange
- polypeptides as provided herein are used to synthesize enantiomerically pure chiral products.
- the polypeptides as provided herein can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals.
- polypeptides as provided herein can be used in food processing, brewing, bath additives, alcohol production, peptide synthesis, enantioselectivity, hide preparation in the leather industry, waste management and animal waste degradation, silver recovery in the photographic industry, medical treatment, silk degumming, biofilm degradation, biomass conversion to ethanol, biodefense, antimicrobial agents and disinfectants, personal care and cosmetics, biotech reagents, in increasing starch yield from corn wet milling, and as pharmaceuticals such as digestive aids and antiinflammatory (antiphlogistic) agents.
- compositions e.g., phospholipase, phospholipase C, phosphatidylinositol-specific phospholipase C (PI-PLC)
- methods for producing low phospholipid oils e.g., oils with a lower phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and/or phosphatidic acid content.
- Any oil e.g. vegetable oil, e.g. canola oil, soybean oil, or animal oil or fat, e.g., tallow, can be treated with a composition, or by a method, as provided herein.
- Any foods, edible items, or baking, frying or cooking products can comprise a vegetable oil or animal fat that has been treated with a composition or by a method as provided herein.
- Vegetable oils modified to be lower phospholipid oils can be used in any foods, edible items or baking or cooking products, e.g., sauces, marinades, condiments, spray oils, margarines, baking oils, mayonnaise, cooking oils, salad oils, spoonable and pourable dressings and the like.
- oils such as vegetable oils, e.g., canola oil or soybean oil, and foods or baking or cooking products, including sauces, marinades, condiments, spray oils, margarines, mayonnaise, baking oils, cooking oils, frying oils, salad oils, spoonable and pourable dressings, and the like, wherein the oil or food, baking or cooking product has been modified using an enzyme as provided herein.
- vegetable oils e.g., canola oil or soybean oil
- foods or baking or cooking products including sauces, marinades, condiments, spray oils, margarines, mayonnaise, baking oils, cooking oils, frying oils, salad oils, spoonable and pourable dressings, and the like, wherein the oil or food, baking or cooking product has been modified using an enzyme as provided herein.
- these vegetable oils e.g.
- polypeptides for example, enzymes and catalytic antibodies, having a phospholipase activity, e.g., phospholipase C, e.g.
- PI-PLC phosphatidylinositol-specific phospholipase C
- thermostable and thermotolerant enzymatic activities thermostable and thermotolerant enzymatic activities
- fatty acid specific or fatty acid selective activities thermostable and thermotolerant enzymatic activities
- low or high pH tolerant enzymatic activities polynucleotides encoding these polypeptides, including vectors, host cells, transgenic plants and non-human animals, and methods for making and using these polynucleotides and polypeptides.
- nucleic acids encoding a polypeptide having a phospholipase, e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme activity, and
- sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection
- sequence comparison algorithm is a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall -p blastp - d "nr pataa" -F F, and all other options are set to default;
- (ii) encoding a polypeptide have an amino acid sequence as set forth in SEQ ID NO:6 and having at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty- three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine or thirty or more, or all, of the amino acid changes or substitutions (mutations) consisting of those described in Table 12, Table 13, Table 14 and/or Table 15, or equivalent amino acid changes or substitutions (mutations), or any combination thereof; or
- nucleic acid comprising SEQ ID NO:5 and encoding a polypeptide having at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty- one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine or thirty or more, or all, of the amino acid changes (mutations) consisting of those described in Table 12, Table 13, Table 14 and/or Table 15, or equivalent amino acid changes or substitutions (mutations), or any combination thereof,
- stringent conditions comprise a wash step comprising a wash in 0.2X SSC at a temperature of about 65°C for about 15 minutes;
- nucleic acid comprising or consisting of the sequence SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO: 10; or
- phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme activity but lacking a native signal sequence or proprotein amino acid sequence;
- PI-PLC phosphatidylinositol-specific phospholipase C
- a polypeptide having the phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme activity but lacking a native promoter sequence
- nucleic acid of (c) further comprising a heterologous promoter sequence or other transcriptional regulatory sequence
- nucleic acid sequence of any of (a) to (d) further comprising nucleic acid encoding a heterologous amino acid sequence, or further comprising a heterologous nucleotide sequence
- nucleic acid of (e) wherein the nucleic acid encoding the heterologous amino acid sequence comprises, or consists of, a sequence encoding a heterologous
- leader signal sequence, or a tag or an epitope, or the heterologous nucleotide sequence comprises a heterologous promoter sequence
- heterologous nucleotide sequence encodes a heterologous (leader) signal sequence comprising or consisting of an N- terminal and/or C-terminal extension for targeting to an endoplasmic reticulum (ER) or endomembrane, or to a plant endoplasmic reticulum (ER) or endomembrane system, or the heterologous sequence encodes a restriction site;
- phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermostable;
- phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermostable
- phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermotolerant;
- phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermotolerant
- the isolated, synthetic or recombinant nucleic acid encodes a polypeptide or peptide having a phospholipase, e.g. a phospholipase C, e.g. a
- PI-PLC phosphatidylinositol-specific phospholipase C activity, which is thermostable.
- the polypeptides and peptides encoded by nucleic acids as provided herein, or any polypeptide or peptide as provided herein, can retain enzymatic or binding activity (e.g., substrate binding) under conditions comprising a temperature range of between about - 100°C to about -80°C, about -80°C to about -40°C, about -40°C to about -20°C, about - 20°C to about 0°C, about 0°C to about 5°C, about 5°C to about 15°C, about 15°C to about 25°C, about 25°C to about 37°C, about 37°C to about 45°C, about 45°C to about 55°C, about 55°C to about 70°C, about 70°C to about 75°C, about 75°C to about 85°C, about 85 °C to about 90°C, about
- thermostable polypeptides that retain a phospholipase, e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity, at a temperature in the ranges described above, at about pH 3.0, about pH 3.5, about pH 4.0, about pH 4.5, about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, about pH 7.5, about pH 8.0, about pH 8.5, about pH 9.0, about pH 9.5, about pH 10.0, about pH 10.5, about pH 11.0, about pH 11.5, about pH 12.0 or more.
- a phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity
- PI-PLC phosphatidylinositol-specific
- polypeptides as provided herein can be thermotolerant and can retain a phospholipase, e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity after exposure to a temperature in the range from about -100°C to about -80°C, about -80°C to about -40°C, about -40°C to about -20°C, about -20°C to about 0°C, about 0°C to about 5°C, about 5°C to about 15°C, about 15°C to about 25°C, about 25°C to about 37°C, about 37°C to about 45 °C, about 45 °C to about 55°C, about 55°C to about 70°C, about 70°C to about 75°C, about 75°C to about 85°C, about 85°C to about 90°C, about 90°C to about 95°C, about 95°C
- thermotolerant polypeptides retain a phospholipase, e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity, after exposure to a temperature in the ranges described above, at about pH 3.0, about pH 3.5, about pH 4.0, about pH 4.5, about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, about pH 7.5, about pH 8.0, about pH 8.5, about pH 9.0, about pH 9.5, about pH 10.0, about pH 10.5, about pH 11.0, about pH 11.5, about pH 12.0 or more.
- a phospholipase e.g. a phospholipase C, e.g. a phosphatidylinositol-specific phospholipase C (PI-PLC) activity
- PI-PLC phosphatidylinositol-specific
- nucleic acid probes or amplification primers for isolating, making and/or identifying a nucleic acid encoding a polypeptide having a phospholiplase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity.
- a nucleic acid probe e.g., a probe for identifying a nucleic acid encoding a polypeptide having a phospholiplase, e.g. phospholipase C, e.g.
- PI-PLC phosphatidylinositol-specific phospholipase C activity
- the probe can comprise an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a sequence comprising a sequence as provided herein, or fragments or subsequences thereof.
- the probe can comprise an oligonucleotide comprising at least about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 consecutive bases of a nucleic acid sequence as provided herein, or a subsequence thereof.
- an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide having a phospholiplase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity comprises a primer pair comprising or consisting of a primer pair capable of amplifying a nucleic acid comprising a sequence as provided herein, or fragments or subsequences thereof.
- One or each member of the amplification primer sequence pair can comprise an oligonucleotide comprising at least about 10 to 50 consecutive bases of the sequence.
- methods of amplifying a nucleic acid encoding a polypeptide having a phospholiplase comprise amplification of a template nucleic acid with an amplification primer sequence air capable of amplifying a nucleic acid sequence as provided herein, or fragments or subsequences thereof.
- a phospholiplase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity
- PI-PLC phosphatidylinositol-specific phospholipase C
- vectors, expression cassettes, expression vectors, plasmids, or cloning vehicles comprise a nucleic acid as provided herein or subsequence thereof.
- the vector, expression cassette, expression vector, plasmid, or cloning vehicle can comprise or is contained in a viral vector, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage, an artificial chromosome, an adenovirus vector, a retroviral vector or an adeno-associated viral vector; or, a bacterial artificial chromosome (BAC), a
- PAC bacteriophage Pl-derived vector
- YAC yeast artificial chromosome
- MAC mammalian artificial chromosome
- expression cassettes comprise a nucleic acid as provided herein or a subsequence thereof.
- the expression cassette can comprise the nucleic acid that is operably linked to a promoter.
- the promoter can be a viral, bacterial, mammalian or plant promoter.
- the plant promoter can be a potato, rice, corn, wheat, tobacco or barley promoter.
- the promoter can be a constitutive promoter.
- the constitutive promoter can comprise CaMV35S.
- the promoter can be an inducible promoter.
- the promoter can be a tissue-specific promoter or an environmentally regulated or a developmentally regulated promoter.
- the promoter can be, e.g., a seed- specific, a leaf-specific, a root- specific, a stem-specific or an abscission-induced promoter.
- the expression cassette can further comprise a plant or plant virus expression vector.
- a host cell or a transformed cell comprises a nucleic acid as provided herein.
- the host cell or a transformed cell can be a bacterial cell, a mammalian cell, a fungal cell, a yeast cell, an insect cell or a plant cell.
- the plant cell can be a potato, wheat, rice, corn, tobacco or barley cell.
- the transformed cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, such as bacterial cells, fungal cells, yeast cells, mammalian cells, insect cells, or plant cells.
- Exemplary bacterial cells include any species within the genera Escherichia, Bacillus, Streptomyces, Salmonella, Pseudomonas and
- transgenic non-human animals comprise a nucleic acid as provided herein or a vector, expression cassette, expression vector, plasmid, or cloning vehicle as provided herein.
- the transgenic non-human animal can be a mouse, a rat, a goat, a rabbit, a sheep, a pig or a cow.
- a transgenic plant or seed comprises a nucleic acid as provided herein or a vector, expression cassette, expression vector, plasmid, or cloning vehicle as provided herein.
- plant is a corn plant, a sorghum plant, a potato plant, a tomato plant, a wheat plant, an oilseed plant, a rapeseed plant, a soybean plant, a rice plant, a barley plant, a grass, a cottonseed, a palm, a sesame plant, a peanut plant, a sunflower plant or a tobacco plant; the transgenic seed.
- the seed is a corn seed, a wheat kernel, an oilseed, a rapeseed, a soybean seed, a palm kernel, a sunflower seed, a sesame seed, a rice, a barley, a peanut, a cottonseed, a palm, a peanut, a sesame seed, a sunflower seed or a tobacco plant seed.
- an antisense oligonucleotide or inhibitory RNA comprising or consisting of a nucleic acid as provided herein.
- isolated, synthetic or recombinant polypeptides have a phospholiplase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity, or polypeptides capable of generating an immune response specific for a phospholiplase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) (e.g., an epitope); and in alternative aspects peptides and polypeptides as provided herein comprise a sequence:
- heterologous amino acid sequence or heterologous moiety comprises, or consists of a heterologous (leader) signal sequence, a tag, a detectable label or an epitope;
- heterologous (leader) signal sequence comprises or consisting of an N-terminal and/or C-terminal extension for targeting to an endoplasmic reticulum (ER) or endomembrane, or to a plant endoplasmic reticulum (ER) or endomembrane system;
- phospholipase C e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) catalyzes a reaction comprising:
- phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermostable;
- phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity is thermostable
- the isolated, synthetic or recombinant polypeptide can comprise the polypeptide as provided herein that lacks a signal (peptide) sequence, e.g., lacks its homologous signal sequence, and in one aspect, comprises a heterologous signal (peptide) sequence.
- the isolated, synthetic or recombinant polypeptide can comprise the polypeptide as provided herein comprising a heterologous signal sequence, such as a heterologous phospholipase or non-phospholipase (e.g., non-phospholipase, non- phospholipase C or non-phosphatidylinositol-specific phospholipase C (PI-PLC)) signal sequence.
- chimeric proteins comprise a first domain comprising a signal sequence as provided herein and at least a second domain.
- the protein can be a fusion protein.
- the second domain can comprise an enzyme.
- the enzyme can be a
- phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) as provided herein, or, another enzyme.
- phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) as provided herein, or, another enzyme.
- PI-PLC phosphatidylinositol-specific phospholipase C
- the phospholipase e.g. phospholipase C, e.g. phosphatidylinositol- specific phospholipase C (PI-PLC) activity comprises a specific activity at about 37°C in the range from about 100 to about 1000 units per milligram of protein.
- the phospholipase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity comprises a specific activity from about 500 to about 750 units per milligram of protein.
- the phospholipase activity comprises a specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein.
- the phospholipase activity comprises a specific activity at 37°C in the range from about 750 to about 1000 units per milligram of protein.
- the thermotolerance comprises retention of at least half of the specific activity of the phospholipase at 37°C after being heated to an elevated temperature.
- the thermotolerance can comprise retention of specific activity at 37°C in the range from about 500 to about 1200 units per milligram of protein after being heated to an elevated temperature.
- the isolated, synthetic or recombinant polypeptides as provided herein comprise at least one glycosylation site.
- glycosylation can be an N-linked glycosylation.
- the polypeptide can be glycosylated after being expressed in a P. pastoris or a S. pombe or in plants, such as oil producing plants e.g. soy bean, canola, rice, sunflower, or genetically-modified (GMO) variants of these plants.
- GMO genetically-modified
- PI-PLC phosphatidylinositol-specific phospholipase C activity under conditions comprising about pH 7, pH 7.5, pH 8.0, pH 8.5, pH 9, pH 9.5, pH 10, pH 10.5, pH 11, pH 11.5, pH 12.0 or more.
- protein preparations comprise a polypeptide as provided herein, wherein the protein preparation comprises a liquid, a solid or a gel.
- heterodimers as provided herein comprise a polypeptide and a second domain.
- the second domain can be a polypeptide and the heterodimer can be a fusion protein.
- the second domain can be an epitope or a tag.
- homodimers as provided herein comprise a polypeptide as provided herein.
- immobilized polypeptides as provided herein have a phospholipase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity, wherein the polypeptide comprises a polypeptide as provided herein, a polypeptide encoded by a nucleic acid as provided herein, or a polypeptide comprising a polypeptide as provided herein and a second domain.
- a phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity
- the polypeptide comprises a polypeptide as provided herein, a polypeptide encoded by a nucleic acid as provided herein, or a polypeptide comprising a polypeptide as provided herein and a second domain.
- a polypeptide as provided herein can be immobilized on a cell, a vesicle, a liposome, a film, a membrane, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, a crystal, a tablet, a pill, a capsule, a powder, an agglomerate, a surface, a porous structure, an array or a capillary tube, or materials such as grains, husks, bark, skin, hair, enamel, bone, shell and materials deriving from them.
- isolated, synthetic or recombinant antibodies which specifically binds to a polypeptide as provided herein.
- the isolated, synthetic or recombinant antibodies are monoclonal or polyclonal antibodies, or are antigen binding fragments thereof.
- provided herein is an hybridoma comprising an antibody provided herein.
- an array comprising an immobilized polypeptide, immobilized nucleic acid, or an antibody as provided herein, or a combination thereof.
- methods of isolating or identifying a polypeptide have a phospholipase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity comprising the steps of: (a) providing an antibody as provided herein; (b) providing a sample comprising polypeptides; and (c) contacting the sample of step (b) with the antibody of step (a) under conditions wherein the antibody can specifically bind to the polypeptide, thereby isolating or identifying a polypeptide having a phospholipase, e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) activity.
- a phospholipase e.g. phospholipase C
- PI-PLC phosphatidylinositol-specific phospholipas
- methods of making an anti-phospholipase antibody comprise administering to a non-human animal a nucleic acid as provided herein or a polypeptide as provided herein or subsequences thereof in an amount sufficient to generate a humoral immune response, thereby making an anti-phospholipase antibody.
- methods of making an anti-phospholipase antibody comprising administering to a non- human animal a nucleic acid as provided herein or a polypeptide as provided herein or subsequences thereof in an amount sufficient to generate an immune response.
- methods of producing a recombinant polypeptide comprise the steps of: (A) (a) providing a nucleic acid as provided herein, wherein the nucleic acid is optionally linked to a promoter, wherein the nucleic acid comprises a nucleic acid as provided herein; and (b) expressing the nucleic acid of step (a) under conditions that allow expression of the polypeptide, thereby producing a recombinant polypeptide; or
- step (B) the method of (A), further comprising transforming a host cell with the nucleic acid of step (a) followed by expressing the nucleic acid of step (a), thereby producing a recombinant polypeptide in a transformed cell.
- methods for identifying a polypeptide having a phospholipase activity comprise the steps of: (a) providing a polypeptide as provided herein; (b) providing a phospholipase substrate; and (c) contacting the polypeptide with the substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of a reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product detects a polypeptide having a
- methods for identifying a phospholipase substrate comprise the steps of: (a) providing a polypeptide as provided herein; (b) providing a test substrate; and (c) contacting the polypeptide of step (a) with the test substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of a reaction product identifies the test substrate as a phospholipase substrate.
- methods of determining whether a test compound specifically binds to a polypeptide comprise the steps of: (a) expressing a nucleic acid or a vector comprising the nucleic acid under conditions permissive for translation of the nucleic acid to a polypeptide, wherein the nucleic acid comprises a nucleic acid as provided herein; (b) providing a test compound; (c) contacting the polypeptide with the test compound; and (d) determining whether the test compound of step (b) specifically binds to the polypeptide.
- methods of determining whether a test compound specifically binds to a polypeptide comprise the steps of: (a) providing a polypeptide as provided herein; (b) providing a test compound; (c) contacting the polypeptide with the test compound; and (d) determining whether the test compound of step (b) specifically binds to the polypeptide.
- methods for identifying a modulator of a phospholipase activity comprise the steps of: (A) (a) providing a polypeptide as provided herein; (b) providing a test compound; (c) contacting the polypeptide of step (a) with the test compound of step (b) and measuring an activity of the phospholipase, wherein a change in the phospholipase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the phospholipase activity; (B) the method of (A), wherein the phospholipase activity is measured by providing a phospholipase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product, or, an increase in the amount of the substrate or a decrease in the amount of a reaction product; (c) the method of (B), wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product with the test compound
- methods for isolating or recovering a nucleic acid encoding a polypeptide with a phospholipase activity from a sample comprise the steps of: (A) (a) providing a polynucleotide probe comprising a nucleic acid as provided herein; (b) isolating a nucleic acid from the sample or treating the sample such that nucleic acid in the sample is accessible for hybridization to a polynucleotide probe of step (a); (c) combining the isolated nucleic acid or the treated sample of step (b) with the
- step (a) the method of (A), wherein the sample is or comprises an environmental sample;
- methods for isolating or recovering a nucleic acid encoding a polypeptide having a phospholipase activity from a sample comprising the steps of: (a) providing an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide having a phospholipase activity, wherein the primer pair is capable of amplifying a nucleic acid as provided herein; (b) isolating a nucleic acid from the sample or treating the sample such that nucleic acid in the sample is accessible for hybridization to the amplification primer pair; and, (c) combining the nucleic acid of step (b) with the amplification primer pair of step (a) and amplifying nucleic acid from the sample, thereby isolating or recovering a nucleic acid encoding a polypeptide having a phospholipase activity from a sample.
- the sample is an environmental sample, e.g., a water sample, a liquid sample, a soil sample, an air sample or a biological sample, e.g. a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell.
- a biological sample e.g. a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell.
- One or each member of the amplification primer sequence pair can comprise an oligonucleotide comprising at least about 10 to 50 or more consecutive bases of a sequence as provided herein.
- methods of increasing thermotolerance or thermostability of a phospholipase polypeptide comprise glycosylating a phospholipase polypeptide, wherein the polypeptide comprises at least thirty contiguous amino acids of a polypeptide as provided herein; or a polypeptide encoded by a nucleic acid sequence as provided herein, thereby increasing the thermotolerance or thermostability of the phospholipase polypeptide.
- the phospholipase specific activity can be thermostable or thermotolerant at a temperature in the range from greater than about 37°C to about 95°C.
- a recombinant phospholipase e.g. phospholipase C, e.g. phosphatidylinositol-specific phospholipase C (PI-PLC) polypeptide in a cell
- PI-PLC phosphatidylinositol-specific phospholipase C
- methods for generating a variant of a nucleic acid encoding a polypeptide with a phospholipase activity comprise the steps of: (A) (a) providing a template nucleic acid comprising a nucleic acid as provided herein; and (b) modifying, deleting or adding one or more nucleotides in the template sequence, or a combination thereof, to generate a variant of the template nucleic acid; (B) the method of (A), further comprising expressing the variant nucleic acid to generate a variant phospholipase polypeptide; (C) the method of (A) or (B), wherein the modifications, additions or deletions are introduced by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene
- methods for modifying codons in a nucleic acid encoding a phospholipase polypeptide comprise the steps of: (a) providing a nucleic acid encoding a polypeptide with a phospholipase activity comprising a nucleic acid as provided herein; and, (b) identifying a codon in the nucleic acid of step (a) and replacing it with a different codon encoding the same amino acid as the replaced codon, thereby modifying codons in a nucleic acid encoding a phospholipase.
- methods for producing a library of nucleic acids encoding a plurality of modified phospholipase active sites or substrate binding sites, wherein the modified active sites or substrate binding sites are derived from a first nucleic acid comprising a sequence encoding a first active site or a first substrate binding site comprise the steps of: (A) (a) providing a first nucleic acid encoding a first active site or first substrate binding site, wherein the first nucleic acid sequence comprises a nucleic acid as provided herein, and the nucleic acid encodes a phospholipase active site or a phospholipase substrate binding site; (b) providing a set of mutagenic
- oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and, (c) using the set of mutagenic
- oligonucleotides to generate a set of active site-encoding or substrate binding site- encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized, thereby producing a library of nucleic acids encoding a plurality of modified phospholipase active sites or substrate binding sites;
- B the method of (A), comprising mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system, Gene Site Saturation Mutagenesis (GSSM), or a synthetic ligation reassembly (SLR);
- C the method of (A) or (B), comprising mutagenizing the first nucleic acid of step (a) or variants by a method comprising error- prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis,
- methods for making a small molecule comprise the steps of: (a) providing a plurality of biosynthetic enzymes capable of synthesizing or modifying a small molecule, wherein one of the enzymes comprises a phospholipase enzyme encoded by a nucleic acid as provided herein; (b) providing a substrate for at least one of the enzymes of step (a); and (c) reacting the substrate of step (b) with the enzymes under conditions that facilitate a plurality of biocatalytic reactions to generate a small molecule by a series of biocatalytic reactions.
- methods for modifying a small molecule comprise the steps of: (A) (a) providing a phospholipase enzyme, wherein the enzyme comprises a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein; (b) providing a small molecule; and (c) reacting the enzyme of step (a) with the small molecule of step (b) under conditions that facilitate an enzymatic reaction catalyzed by the phospholipase enzyme, thereby modifying a small molecule by a phospholipase enzymatic reaction; (B) the method of (A), comprising a plurality of small molecule substrates for the enzyme of step (a), thereby generating a library of modified small molecules produced by at least one enzymatic reaction catalyzed by the phospholipase enzyme; (C) the method of (A) or (B), further comprising a plurality of additional enzymes under conditions that facilitate a plurality of biocatalytic reactions
- phospholipase enzyme comprise the steps of: (A) (a) providing a phospholipase enzyme, wherein the enzyme comprises a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein; and (b) deleting a plurality of amino acid residues from the sequence of step (a) and testing the remaining subsequence for a phospholipase activity, thereby determining a functional fragment of a phospholipase enzyme; or, (B) the method of (A), wherein the phospholipase activity is measured by providing a phospholipase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product.
- methods for whole cell engineering of new or modified phenotypes by using real-time metabolic flux analysis comprise the steps of: (a) making a modified cell by modifying the genetic composition of a cell, wherein the genetic composition is modified by addition to the cell of a nucleic acid as provided herein; (b) culturing the modified cell to generate a plurality of modified cells; (c) measuring at least one metabolic parameter of the cell by monitoring the cell culture of step (b) in real time; and, (d) analyzing the data of step (c) to determine if the measured parameter differs from a comparable measurement in an unmodified cell under similar conditions, thereby identifying an engineered phenotype in the cell using real-time metabolic flux analysis; (B) the method of (A), wherein the genetic composition of the cell is modified by a method comprising deletion of a sequence or modification of a sequence in the cell, or, knocking out the expression of a gene; (C) the method of (A) or (B), further comprising selecting a cell
- methods of making a transgenic plant comprise the following steps: (a) introducing a heterologous nucleic acid sequence into a plant cell, wherein the heterologous nucleic sequence comprises a nucleic acid sequence as provided herein, thereby producing a transformed plant cell; and (b) producing a transgenic plant from the transformed cell.
- the step (a) can further comprise introducing the heterologous nucleic acid sequence by electroporation or microinjection of plant cell protoplasts.
- the step (a) can further comprise introducing the heterologous nucleic acid sequence directly to plant tissue by DNA particle
- the step (a) can further comprise introducing the heterologous nucleic acid sequence into the plant cell DNA using an Agrobacterium tumefaciens host.
- the plant cell can be a potato, corn, rice, wheat, tobacco, or barley cell.
- methods of expressing a heterologous nucleic acid sequence in a plant cell comprise the following steps: (a) transforming the plant cell with a heterologous nucleic acid sequence operably linked to a promoter, wherein the heterologous nucleic sequence comprises a nucleic acid as provided herein; (b) growing the plant under conditions wherein the heterologous nucleic acid sequence is expressed in the plant cell.
- detergent compositions comprising the phospholipase polypeptide as provided herein, or a phospholipase polypeptide encoded by a nucleic acid as provided herein.
- the phospholipase is a nonsurface- active phospholipase or a surface-active phospholipase.
- the phospholipase is formulated in a non-aqueous liquid composition, a cast solid, a lyophilized powder, a granular form, a particulate form, a compressed tablet, a pellet, a gel form, a paste, an aerosol, or a slurry form.
- methods for washing an object comprise the steps of: (a) providing a composition comprising a phospholipase polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein; (b) providing an object; and (c) contacting the polypeptide of step (a) and the object of step (b) under conditions wherein the composition can wash the object.
- compositions comprising a phospholipase polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein.
- methods for ameliorating, treating or preventing lipopoly saccharide (LPS)-mediated toxicity comprise administering to a patient a pharmaceutical composition comprising a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid sequence as provided herein.
- a pharmaceutical composition comprising a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid sequence as provided herein.
- provided herein are pharmaceuticals, pharmaceutical precursors and pharmaceutical compositions comprising a polypeptide as provided herein or a polypeptide encoded by a nucleic acid as provided herein.
- methods of manufacturing a pharmaceutical, a pharmaceutical precursor or a pharmaceutical composition comprising addition of a polypeptide encoded by a nucleic acid as provided herein to a pharmaceutical, a pharmaceutical precursor or a
- the pharmaceutical composition is used for preventing, treating or ameliorating lipopoly saccharide (LPS)-mediated toxicity, or to detoxify an endotoxin, or deacylating a 2' or a 3' fatty acid chain from a lipid A.
- LPS lipopoly saccharide
- methods for detoxifying an endotoxin comprise contacting the endotoxin with a polypeptide as provided herein or a polypeptide encoded by a nucleic acid as provided herein.
- methods for making a variant phospholipase coding sequence having increased expression in a host cell comprise modifying a nucleic acid as provided herein, such that one, several or all N-linked glycosylation site coding motifs are modified to a non-glycosylated motif.
- compositions comprising a mixture of phospholipase enzymes comprising: (a)(i) a phospholipase polypeptide as provided herein or polypeptide encoded by a nucleic acid as provided herein, and (ii) at least one second enzyme; (b) the composition of (a), wherein the at least one enzyme is a phospholipase enzyme; or (c) the composition of (b), wherein the at least one second phospholipase enzyme comprises a polypeptide as set forth in SEQ ID NO:2 and/or SEQ ID NO:4, or at least one of the variant PLC enzymes as described in Tables 8 and 9.
- methods for making a biofuel comprise the steps of: (A) (a) providing a phospholipase polypeptide as provided herein, or a phospholipase enzyme encoded by a nucleic acid as provided herein, or a composition comprising a polypeptide as provided herein; (b) providing a composition comprising a lipid or an alkyl ester; (c) contacting the phospholipase polypeptide of (a) with the composition of (b); (B) the method of (A), wherein the composition comprising a lipid or an alkyl ester is, or comprises, an oil and/or a fat; or (C) the method of (A) or (B), wherein the composition comprising a lipid or an alkyl ester is, or comprises, an algae, a vegetable oil, a straight vegetable oil, a virgin vegetable oil, a waste vegetable oil, an animal fat, a grease, a tallow,
- fuels e.g. biofuels, e.g. biodiesel
- methods that comprise the steps of: (A) (a) providing a phospholipase polypeptide as provided herein, or a phospholipase enzyme encoded by a nucleic acid as provided herein, or a composition comprising a polypeptide as provided herein; b) providing a composition comprising a lipid or an alkyl ester; (c) contacting the phospholipase polypeptide of (a) with the composition of (b); (B) the method of (A), wherein the composition comprising a lipid or an alkyl ester is, or comprises, an oil and/or a fat; or (C) the method of (A) or (B), wherein the composition comprising a lipid or an alkyl ester is, or comprises, an algae, a vegetable oil, a straight vegetable oil, a virgin vegetable oil, a waste vegetable oil, an animal fat,
- a distillers dried soluble comprises a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein, or a composition as provided herein.
- a biomass comprising (a) a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein, or a composition as provided herein; (b) the biomass of (a), wherein the biomass is, or comprises, an animal, algae and/or plant biomass, or a lipid-comprising or lignocellulosic biomass, or a waste material.
- a petroleum-based product comprising: (a) a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein, or a composition as provided herein; (b) made by a method comprising use of a polypeptide as provided herein, or a polypeptide encoded by a nucleic acid as provided herein, or a composition as provided herein; or (c) the petroleum-based product of (a) or (b) comprising an oil, a biodiesel or a gasoline, or a bioethanol, biobutanol, biopropanol or a biomethanol; or a mixture of bioethanol, biobutanol, biopropanol, biomethanol and/or biodiesel and gasoline.
- NHPs Non Hydratable Phospholipids
- the method comprises a) mixing an aqueous acid with an edible oil to obtain an acidic mixture having pH of less than about 4; and b) mixing a base with the acidic mixture to obtain a reacted mixture having pH of about 6-9.
- mixing in steps a) and/or b) creates an emulsion that comprises the aqueous phase in average droplet size between about 15 ⁇ m to about 45 ⁇ m.
- mixing in steps a) and/or b) creates an emulsion that comprises at least about 60% of the aqueous phase by volume in droplet size between about 15 ⁇ m to about 45 ⁇ m in size, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase. In certain embodiments, mixing in steps a) and/or b) creates an emulsion that comprises at least about 60, 70, 80, 90,93, 95, 96, 97, 98, or 99% of the aqueous phase by volume in droplet size between about 20 ⁇ m to about 45 ⁇ m in size.
- the method further comprises degumming the reacted mixture with water or an enzyme to obtain a degummed oil.
- the mixing in steps a) and/or b) is carried out with a high shear mixer with a tip speed of at least about 1400 cm/s, 1600 cm/s, 1800 cm/s, 2000 cm/s, 2100 cm/s, 2300 cm/s, 2500 cm/s, 3000 cm/s, or 3500 cm/s.
- the acid is selected from the group consisting of phosphoric acid, acetic acid, citric acid, tartaric acid, succinic acid, and a mixture thereof. Any acid deemed suitable by one of skill in the art can be sued in the methods provided herein.
- the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium silicate, sodium carbonate, calcium carbonate, and a combination thereof.
- the method for hydration of non hydratable phospholipids in an edible oil further comprises a step of water or enzymatic degumming to obtain a degummed oil.
- a step of water or enzymatic degumming to obtain a degummed oil.
- NHPs hydration is followed by enzymatic treatment and removal of various phospholipids and lecithins. Such methods can be practiced on either crude or water-degummed oils.
- an oil degumming method comprises a) mixing an aqueous acid with an edible oil to obtain an acidic mixture having pH of about 1 to 4, b) mixing a base with the acidic mixture to obtain a reacted mixture having pH of about 6-9, and c) degumming the reacted mixture with water or an enzyme to obtain a degummed oil.
- mixing in steps a) and/or b) creates an emulsion that comprises an aqueous phase in average droplet size between about 15 ⁇ m to about 45 ⁇ m.
- mixing in steps a) and/or b) creates an emulsion that comprises at least about 60% of an aqueous phase by volume in droplet size between about 15 ⁇ m to about 45 ⁇ m in size, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- provided herein is a method for removing NHPs, hydratable phospholipids, and lecithins (known collectively as "gums") from vegetable oils to produce a degummed oil or fat product that can be used for food production and/or nonfood applications.
- the degumming methods provided herein utilize water, various acids and/or various bases or a combination thereof.
- provided herein is a method for enhancing the reaction rate of a phospholipase used in an enzymatic degumming method, such that the enzyme reaction has a duration of less than about one hour.
- provided herein is a method for degumming an oil composition in which both hydratable and non-hydratable phospholipids can be treated in a single process, wherein an enzyme reaction is completed in less than about one hour.
- a method for hydrolyzing, breaking up or disrupting a phospholipid-comprising composition comprising:
- step (A) (a) providing a phospholipase polypeptide; (b) providing a composition comprising a phospholipid; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the phospholipase hydrolyzes, breaks up or disrupts the phospholipid-comprising composition;
- composition comprises a phospholipid- comprising lipid bilayer or membrane
- composition comprises a plant cell, a bacterial cell, a yeast cell, an insect cell, or an animal cell.
- a method for liquefying or removing a phospholipid-comprising composition comprising:
- step (b) providing a composition comprising a phospholipid; and (c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the phospholipase removes or liquefies the phospholipid-comprising composition.
- a method for purification of a phytosterol or a triterpene comprising:
- AI (Ala) providing a composition comprising a phospholipase polypeptide
- step (Ale) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a
- (DI) the method of (CI), wherein the vegetable oil comprises a coconut oil, canola oil, cocoa butter oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, oil derived from a rice bran, safflower oil, sesame oil, soybean oil or a sunflower oil;
- the phytosterol or a triterpene comprises a ⁇ -sitosterol, a campesterol, a stigmasterol, a stigmastanol, a ⁇ -sitostanol, a sitostanol, a desmosterol, a chalinasterol, a poriferasterol, a clionasterol or a brassicasterol.
- a method for refining an oil or a fat comprising:
- step (Ale) contacting the polypeptide of step (Ala) with the composition of step (Alb) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition;
- step (Alb) the method of (Al), wherein the polypeptide is in a water solution that is added to the composition;
- (Kl) the method of any of (Al) to (Jl), comprising addition of an emulsion-breaker and/or heat or cooling to promote separation of an aqueous phase;
- (LI) the method of any of (Al) to (Kl), comprising degumming before the contacting step to collect lecithin by centrifugation and then adding a PLC, a PLC and/or a PLA to remove non-hydratable phospholipids;
- (Ml) the method of any of (A 1) to (LI), comprising water degumming of crude oil to less than 10 ppm phosphorus for edible oils and subsequent physical refining to less than about 50 ppm phosphorus for biodiesel oils; or
- provided herein is a method for degumming an oil or a fat comprising
- step (al) providing a composition comprising a phospholipase polypeptide
- step (bl) providing a composition comprising an phospholipid-containing fat or oil
- step (cl) contacting the polypeptide of step (al) and the composition of step (bl) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition.
- a phospholipid-containing composition comprising:
- step (A-lc) contacting the polypeptide of step (A-la) with the composition of step (A- lb) before, during or after the physical refining;
- (B-l) the method of (A-l), wherein the polypeptide is added before physical refining and the composition comprising the phospholipid comprises a plant and the polypeptide is expressed transgenically in the plant, the polypeptide is added during crushing of a seed or other plant part, or, the polypeptide is added following crushing or prior to refining;
- (D-l) the method of (A-l), wherein the polypeptide is added after physical refining: in an intense mixer or retention mixer prior to separation; following a heating step; in a centrifuge; in a soapstock; in a washwater; or, during a bleaching or a deodorizing step; or
- (E-l) the method of any of (A-l) to (D-l), further comprising adding a phospholipase A (PLA), a phospholipase B (PLB), phospholipase C (PLC),
- PLA phospholipase A
- PLB phospholipase B
- PLC phospholipase C
- PLD phospholipase D
- PLD phospholipase D
- a phospholipid-containing composition comprising:
- step (Ale) contacting the polypeptide of step (Ala) with the composition of step (Alb) before, during or after the caustic refining;
- (Dl) the method of any of (Al) to (Bl), wherein the polypeptide is added after caustic refining: in an intense mixer or retention mixer prior to separation; following a heating step; in a centrifuge; in a soapstock; in a washwater; or, during bleaching or deodorizing steps;
- a method for deacylating a 2' or a 3' fatty acid chain from a lipid A comprising contacting the lipid A with a phospholipase polypeptide.
- a process for reducing gum mass and increasing neutral oil (triglyceride) gain through reduced oil entrapment comprising:
- step (Ale) contacting the polypeptide of step (Ala) and the composition of step (Alb) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition for a time sufficient to reduce gum mass and increase neutral oils;
- provided herein is an oil or fat produced by the methods provided herein.
- the enzymes for use in the methods provided herein include enzymes having phospholipase activity.
- the phospholipase activity comprises, for example, a phospholipase C (PLC) activity, a phospholipase A (PLA) activity, including a phospholipase Al or phospholipase A2 activity, a phospholipase B (PLB) activity, including a phospholipase B 1 or phospholipase B2 activity, a phospholipase D (PLD) activity, including a phospholipase Dl or a phospholipase D2 activity.
- the enzymes for use herein comprise polypeptides having a
- PI-PLC phosphatidylinositol-specific phospholipase C
- A, B, C, D phosphatidylinositol-specific phospholipase C
- PAP phosphatidic acid phosphatases
- LAH lipid acyl hydrolase
- the enzyme for use in the methods provided herein is selected from a phospholipase A, phospholipase C, phosphatidyl-inositol specific phospholipase C, or a combination thereof. In certain embodiments, the enzyme for use in the methods provided herein is selected from a phospholipase C, phosphatidyl-inositol specific phospholipase C, or a combination thereof. In certain embodiments, the enzyme for use in the methods provided herein is phosphatidyl-inositol specific phospholipase C enzyme as described elsewhere herein.
- the enzyme for use in the methods provided herein is selected from phospholipase C, and an enzyme comprising SEQ ID NO:8. In certain embodiments, the enzyme for use in the methods provided herein is an enzyme comprising SEQ ID NO:8.
- the phospholipids obtained by the methods provided herein include a variety of phospholipids, including, but not limited to phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS),
- PC phosphatidylcholine
- PE phosphatidylethanolamine
- PS phosphatidylserine
- PI phosphatidylinositol
- PA phosphatidic acid
- LPC lysophosphatidylcholine
- LPE lysophosphatidylethanolamine
- LPS lysophosphatidylserine
- lysophosphatidylinositol LPI
- LP A lysophosphatidic acid
- C choline
- E ethanolamine
- S serine
- I inositol
- choline C
- E ethanolamine
- S serine
- I inositol
- Figure 1 schematically illustrates an exemplary vegetable oil refining process using the phospholipases of the invention.
- Figure 2 schematically illustrates an exemplary degumming process of the invention for physically refined oils, as discussed in detail, below.
- FIG. 3 schematically illustrates phosphatide hydrolysis with a phospholipase C of the invention, as discussed in detail, below.
- FIG. 4 schematically illustrates an exemplary caustic refining process of the invention, and illustrates an alternative embodiment comprising application of a phospholipase C of the invention as a "Caustic Refining Aid” (Long Mix Caustic Refining), as discussed in detail, below.
- a phospholipase C of the invention as a "Caustic Refining Aid” (Long Mix Caustic Refining), as discussed in detail, below.
- Figure 5 schematically illustrates application of a phospholipase C of the invention as a degumming aid, as discussed in detail, below.
- Figure 6 schematically illustrates an exemplary caustic refining process of the invention, and illustrates an alternative embodiment comprising application of a phospholipase C of the invention as a "Caustic Refining Aid” (Long Mix Caustic Refining), as discussed in detail, below.
- FIG. 7 illustrates another variation of methods of the invention where two centrifugation steps are used in the process, as discussed in detail, below.
- FIG 8 illustrates another variation of methods of the invention where three centrifugation steps are used in the process, as discussed in detail, below.
- Figure 9 illustrates another exemplary variation of this process using acid treatment and having a centrifugation step before a degumming step, as discussed in detail, below.
- Figure 10 illustrates the weight- fraction of individual phospholipid (PL) species phosphatidic acid (PA), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylcholine (PC) relative to the total PL remaining after treatment with the mutant phospholipases of the invention.
- PL phospholipid
- PA phosphatidic acid
- PE phosphatidylethanolamine
- PI phosphatidylinositol
- PC phosphatidylcholine
- Figure 11 illustrates the "Gene Site Saturation Mutagenesis" or "GSSM” upmutants selected for inclusion in the GeneReassembly Library, which includes exemplary phospholipases of the invention.
- Figure 12 illustrates an exemplary alcohol process that can incorporate use of enzymes of this invention.
- Figure 13 provides phospholipid composition of the recovered wet gums in the control examples.
- Figure 14 provides phospholipid comparisons for the control examples versus the examples using the methods provided herein where pH in step b) is adjusted to pH 7.0.
- Figure 15 compares the neutral oil lost to the gum phase in the control neutral pH reactions versus the pH adjusted reactions at a pH of 7.0, side -by-side.
- Figure 16 compares the neutral oil lost to the gum phase of various pH conditions where a phospholipase A 1 is utilized.
- Figure 17 depicts droplet distribution for aqueous phase obtained according to the process of Example 17A.
- Figure 18 depicts droplet distribution for aqueous phase obtained according to the process of Example 17B.
- Figure 19 depicts droplet distribution for aqueous phase obtained according to the process of Example 17C.
- Figure 20 depicts droplet distribution for aqueous phase obtained according to the process of Example 17D.
- Figure 21 depicts comparative droplet distribution for aqueous phase obtained according to the processes of Examples 17A, 17B, 17C and 17D.
- the present invention provides polypeptides having a phosphatidylinositol- specific phospholipase C (PI-PLC) or equivalent enzyme activity, and/or another phospholipase activity, including a phospholipase A, B, C, D, patatin, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) or equivalent enzyme activity, polynucleotides encoding them, antibodies that bind specifically to them, and methods for making and using them.
- PI-PLC phosphatidylinositol- specific phospholipase C
- PAP phosphatidic acid phosphatases
- LAH lipid acyl hydrolase
- PI-PLC phosphatidylinositol-specific phospholipase C
- enzymes of the invention can efficiently cleave glycerolphosphate ester linkage in oils, such as vegetable oils, e.g., oilseed phospholipids, to generate a water extractable phosphorylated base and a diglyceride.
- phospholipases of the invention can have a lipid acyl hydrolase (LAH) activity; or can cleave glycerolphosphate ester linkages in
- a phospholipase of the invention is specific for one or more specific substrates, e.g., an enzyme of the invention can have a specificity of action for PE and PC; PE an PI; PE and PS; PS and PC; PS and PI; PI and PC; PS, PI and PC; PE, PI and PC; PC, PE and PS; PE, PS and PI; or, PE, PS, PI and PC.
- a phospholipase of the invention e.g., a
- phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme or equivalent activity) can be used for enzymatic degumming of oils, e.g. crude oils, because the phosphate moiety is soluble in water and easy to remove. The diglyceride product will remain in the oil and therefore will reduce losses.
- the PLCs of the invention can be used in addition to or in place of PLAls and PLA2s in commercial oil degumming, such as in the
- ENZYMAX® process where phospholipids are hydrolyzed by PLA1 and PLA2.
- the phospholipases of the invention are active at a high and/or at a low temperature, or, over a wide range of temperature, e.g., they can be active in the temperatures ranging between 20°C to 90°C, between 30°C to 80°C, or between 40°C to 70°C.
- the invention also provides phospholipases of the invention having activity at alkaline pHs or at acidic pHs, e.g., low water acidity.
- the phospholipases of the invention can have activity in acidic pHs as low as pH 6.5, pH 6.0, pH 5.5, pH 5.0, pH 4.5, pH 4.0, pH 3.5, pH 3.0, pH 2.5, pH 2.0 or more acidic (i.e., ⁇ pH 2.0).
- the phospholipases of the invention can have activity in alkaline pHs as high as pH 7.5, pH 8.0, pH 8.5, pH 9.0, pH 9.5, pH 10.0 or more alkaline (i.e., > pH 10.0).
- the phospholipases of the invention are active in the temperature range of between about 40°C to about 70°C, 75°C, or 80°C, or more, under conditions of low water activity (low water content).
- the invention also provides methods for making PLCs and/or modifying the activity of exemplary phospholipases of the invention to generate enzymes with alternative desirable properties, e.g., phosphatidylinositol-specific phospholipase C (PI- PLC) enzyme activity having alternative substrates, or activities under various environmental conditions, e.g., of varying temperatures, pHs and the like.
- PI- PLC phosphatidylinositol-specific phospholipase C
- phospholipases generated by the methods of the invention can have altered substrate specificities, substrate binding specificities, substrate cleavage patterns, thermal stability, pH/activity profile, pH/stability profile (such as increased stability at low, e.g. pH ⁇ 6 or pH ⁇ 5, or high, e.g.
- the invention provides for altering any property of interest.
- the alteration may result in a variant which, as compared to a parent phospholipase, has altered pH and temperature activity profile.
- the phospholipases of the invention are used in various oil processing steps, such as in oil extraction, e.g., in the removal of
- compositions e.g., comprising enzymes of the invention
- processes for the treatment of oils e.g. crude oils
- oils e.g
- phospholipase enzymes of the invention can be used in place of PLA, e.g., phospholipase A2, in any vegetable oil processing step.
- suitable enzymes for use in the methods provided herein include, one or more phospholipase A (PLA) enzymes, phospholipase C (PLC),
- Phosphatidyl-Inositol specific phospholipase C PI-PLC enzymes, or a combination thereof.
- the PLA enzymes include phospholipase Al (PLA1) and/or phospholipase A2 (PLA2).
- crude oil refers to (also called a non-degummed oil) a pressed or extracted oil or a mixture thereof from, e.g. vegetable sources, including but not limited to acai oil, almond oil, babassu oil, blackcurrent seed oil, borage seed oil, canola oil, cashew oil, castor oil, coconut oil, coriander oil, corn oil, cottonseed oil, crambe oil, flax seed oil, grape seed oil, hazelnut oil, hempseed oil, jatropha oil, jojoba oil, linseed oil, macadamia nut oil, mango kernel oil, meadowfoam oil, mustard oil, neat's foot oil, olive oil, palm oil, palm kernel oil, palm olein, peanut oil, pecan oil, pine nut oil, pistachio oil, poppy seed oil, rapeseed oil, rice bran oil, safflower oil, sasanqua oil, sesame oil, shea
- the total phosphatide content in a crude oil may vary from 0.5-3% w/w corresponding to a phosphorus content in the range of 200-1200 ppm or 250-1200 ppm.
- degummed oil refers to an oil obtained after removal of NHPs, hydratable phospholipids, and lecithins (known collectively as “gums”) from the oil to produce a degummed oil or fat product that can be used for food production and/or nonfood applications.
- gums lecithins
- the degummed oil has the phospholipids content of less than about 200 ppm phosphorus, less than about 150 ppm phosphorus, less than about 100 ppm phosphorus, less than about 50 ppm phosphorus, less than about 40 ppm phosphorus, less than about 30 ppm phosphorus, less than about 20 ppm phosphorus, less than about 15 ppm phosphorus, less than about 10 ppm phosphorus, less than about 7 ppm phosphorus, less than about 5 ppm phosphorus, less than about 3 ppm phosphorus or less than about 1 ppm phosphorus.
- non hydratable phospholipids refers to phosphatidic acid and the salts of phosphatidic acid, for example, calcium, magnesium and iron salts of phosphatidic acid; and calcium, magnesium and iron salts of - ethanolamine.
- water-degummed oil refers to an oil obtained after water degumming process.
- water-degummed oil is obtained by mixing 1-3% w/w of hot water with warm (60-90 °C) crude oil for 30-60 minutes.
- the water-degumming step removes the phosphatides and mucilaginous gums which become insoluble in the oil when hydrated.
- the hydrated phosphatides and gums can be separated from the oil by settling, filtering or centrifuging.
- the invention provides isolated, synthetic and recombinant nucleic acids (e.g., the exemplary SEQ ID NO: 5 and nucleic acids encoding SEQ ID NO: 6 comprising (and having) one or more amino acid residue changes (e.g., mutations) as set forth in Tables 12 to 15, including expression cassettes such as expression vectors, encoding the polypeptides and phospholipases of the invention.
- the invention also includes methods for discovering new phospholipase sequences using the nucleic acids of the invention. Also provided are methods for modifying the nucleic acids of the invention by, e.g., synthetic ligation reassembly, optimized directed evolution system and/or saturation mutagenesis.
- nucleic acids of the invention can be made, isolated and/or manipulated by, e.g., cloning and expression of cDNA libraries, amplification of message or genomic DNA by PCR, and the like.
- homologous genes can be modified by manipulating a template nucleic acid, as described herein.
- the invention can be practiced in conjunction with any method or protocol or device known in the art, which are well described in the scientific and patent literature.
- gene sequences of the invention comprise the segment of DNA involved in producing a polypeptide chain, including, inter alia, regions preceding and following the coding region, such as leader and trailer, promoters and enhancers, as well as, where applicable, intervening sequences (introns) between individual coding segments (exons).
- nucleic acids or nucleic acid sequences of the invention can comprise an oligonucleotide, nucleotide, polynucleotide, or to a fragment of any of these, to DNA or RNA (e.g., mRNA, rRNA, tRNA, iRNA) of genomic or synthetic origin which may be single-stranded or double- stranded and may represent a sense or antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material, natural or synthetic in origin, including, e.g., iRNA, ribonucleoproteins (e.g., double stranded iRNAs, e.g., iRNPs).
- DNA or RNA e.g., mRNA, rRNA, tRNA, iRNA
- PNA peptide nucleic acid
- nucleic acids or nucleic acid sequences of the invention also encompass nucleic-acid-like structures with synthetic backbones, see e.g., Mata (1997) Toxicol. Appl. Pharmacol. 144: 189-197; Strauss-Soukup (1997) Biochemistry 36:8692-8698; Mull (1996) Antisense Nucleic Acid Drug Dev 6:153-156.
- RNA, iRNA, antisense nucleic acid, cDNA, genomic DNA, vectors, viruses or hybrids thereof may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/ generated recombinantly. Recombinant polypeptides generated from these nucleic acids can be individually isolated or cloned and tested for a desired activity. Any recombinant expression system can be used, including bacterial, mammalian, yeast, insect or plant cell expression systems.
- these nucleic acids can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22: 1859; U.S. Patent No. 4,458,066.
- nucleic acids such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS TN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY:
- Another useful means of obtaining and manipulating nucleic acids used to practice the methods of the invention is to clone from genomic samples, and, if desired, screen and re-clone inserts isolated or amplified from, e.g., genomic clones or cDNA clones.
- Sources of nucleic acid used in the methods of the invention include genomic or cDNA libraries contained in, e.g., mammalian artificial chromosomes (MACs), see, e.g., U.S. Patent Nos. 5,721,118; 6,025,155; human artificial chromosomes, see, e.g., Rosenfeld (1997) Nat. Genet.
- MACs mammalian artificial chromosomes
- yeast artificial chromosomes YAC
- bacterial artificial chromosomes BAC
- PI artificial chromosomes see, e.g., Woon (1998) Genomics 50:306-316
- Pl-derived vectors see, e.g., Kern (1997) Biotechniques 23:120- 124; cosmids, recombinant viruses, phages or plasmids.
- a nucleic acid encoding a polypeptide of the invention is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof.
- the invention provides fusion proteins and nucleic acids encoding them.
- a polypeptide of the invention can be fused to a heterologous peptide or polypeptide, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification.
- Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, e.g., producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, to identify and isolate antibodies and antibody-expressing B cells, and the like.
- Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine- tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).
- metal chelating peptides such as polyhistidine tracts and histidine- tryptophan modules that allow purification on immobilized metals
- protein A domains that allow purification on immobilized immunoglobulin
- the domain utilized in the FLAGS extension/affinity purification system Immunex Corp, Seattle WA.
- the inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between a purification domain and the motif-comprising peptide or polypeptide to facilitate purification.
- an expression vector can include an epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34: 1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-414).
- the histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein.
- Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.
- the invention provides nucleic acid (e.g., DNA) sequences of the invention operatively linked to expression (e.g., transcriptional or translational) control
- RNA synthesis/expression control sequence can be in an expression vector.
- exemplary bacterial promoters include lacl, lacZ, T3, T7, gpt, lambda PR, PL and trp.
- exemplary eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein I.
- Promoters suitable for expressing a polypeptide in bacteria include the E. coli lac or trp promoters, the lacl promoter, the lacZ promoter, the T3 promoter, the T7 promoter, the gpt promoter, the lambda PR promoter, the lambda PL promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter.
- Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses may also be used.
- the invention provides expression vectors and cloning vehicles comprising nucleic acids of the invention, e.g., sequences encoding the phospholipases of the invention.
- Expression vectors and cloning vehicles of the invention can comprise viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g., vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), Pl-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as Bacillus, Aspergillus and yeast).
- Vectors of the invention can include chromosomal, non- chromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art, and are commercially available. Exemplary vectors are include: bacterial: pQE vectors (Qiagen, San Diego, CA), pBluescript plasmids
- expression cassette comprises a nucleotide sequence which is capable of affecting expression of a structural gene (i.e., a protein coding sequence, such as a phospholipase of the invention) in a host compatible with such sequences.
- Expression cassettes can include at least a promoter operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used, e.g., enhancers.
- "operably linked” refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence.
- expression cassettes include plasmids, expression vectors, recombinant viruses, any form of recombinant "naked DNA" vector, and the like.
- vectors of this invention comprise a nucleic acid which can infect, transfect, transiently or permanently transduce a cell.
- a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid.
- the vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.).
- Vectors of this invention include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated.
- Vectors thus include, but are not limited to RNA, autonomous self -replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Patent No.
- the invention provides plasmids, which can be designated by a lower case “p" preceded and/or followed by capital letters and/or numbers.
- a "starting" plasmid is either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures.
- equivalent plasmids to those described herein are known in the art and will be apparent to the ordinarily skilled artisan.
- an expression vector may comprise a promoter, a ribosome-binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression.
- Mammalian expression vectors can comprise an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences.
- DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required non- transcribed genetic elements.
- the expression vectors contain one or more selectable marker genes to permit selection of host cells containing the vector.
- selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in E. coli, and the S. cerevisiae TRPl gene.
- Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers.
- CAT chloramphenicol transferase
- Enhancers are ds-acting elements of DNA, usually from about 10 to about 300 bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers.
- a DNA sequence may be inserted into a vector by a variety of procedures.
- the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases.
- blunt ends in both the insert and the vector may be ligated.
- a variety of cloning techniques are known in the art, e.g., as described in Ausubel and Sambrook. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the vector may be in the form of a plasmid, a viral particle, or a phage.
- Other vectors include chromosomal, non-chromosomal and synthetic DNA sequences, derivatives of SV40; bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies.
- a variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by, e.g., Sambrook.
- Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), GEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pDIO, psiX174 pBluescript II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7.
- Particular eukaryotic vectors include pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia).
- any other vector may be used as long as it is replicable and viable in the host cell.
- the invention also provides a transformed cell comprising a nucleic acid sequence of the invention, e.g., a sequence encoding a phospholipase of the invention, a vector of the invention.
- the host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, such as bacterial cells, fungal cells, yeast cells, mammalian cells, insect cells, or plant cells.
- Enzymes of the invention can be expressed in any host cell, e.g., any bacterial cell, any yeast cell, e.g., Pichia pastoris, Saccharomyces cerevisiae or Schizosaccharomyces pombe.
- Exemplary bacterial cells include any species within the genera Escherichia, Bacillus, Streptomyces, Salmonella, Pseudomonas and Staphylococcus, including, e.g., Escherichia coli, Lactococcus lactis, Bacillus subtilis, Bacillus cereus, Salmonella typhimurium,
- Exemplary fungal cells include any species of Aspergillus.
- Exemplary yeast cells include any species of Pichia, Saccharomyces,
- Schizosaccharomyces or Schwanniomyces, including Pichia pastoris, Saccharomyces cerevisiae, or Schizosaccharomyces pombe.
- Exemplary insect cells include any species of Spodoptera or Drosophila, including Drosophila S2 and Spodoptera Sf9.
- Exemplary animal cells include CHO, COS or Bowes melanoma or any mouse or human cell line. The selection of an appropriate host is within the abilities of those skilled in the art.
- the vector may be introduced into the host cells using any of a variety of techniques, including transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Particular methods include calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)). Where appropriate, the engineered host cells can be cultured in
- the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.
- Cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification.
- Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art.
- the expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.
- HPLC high performance liquid chromatography
- mammalian cell culture systems can also be employed to express recombinant protein.
- mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines.
- the constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
- the polypeptides produced by host cells containing the vector may be glycosylated or may be non-glycosylated.
- Polypeptides of the invention may or may not also include an initial methionine amino acid residue.
- Cell-free translation systems can also be employed to produce a polypeptide of the invention.
- Cell-free translation systems can use mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof.
- the DNA construct may be linearized prior to conducting an in vitro transcription reaction.
- the transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.
- the expression vectors can contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- An exemplary PI-PLC enzyme (having a sequence as set forth in SEQ ID NO: 6 comprising (and having) one or more amino acid residue changes (e.g., mutations) as set forth in Tables 12 to 15) has been over-expressed in active form in a variety of host systems including gram negative bacteria, such as E. coli, gram positive bacteria, such as any Bacillus sp.(e.g., Bacillus subtilis, Bacillus cereus), yeast host cells (including, e.g., Pichia pastoris, Saccharomyces sp., such as S. cerevisiae and S. pombe) and Lactococcus lactis, or mammalian, fungi, plant or insect cells.
- gram negative bacteria such as E. coli
- gram positive bacteria such as any Bacillus sp.(e.g., Bacillus subtilis, Bacillus cereus)
- yeast host cells including, e.g., Pichia pastoris, Sac
- the active enzyme is expressed from a variety of constructs in each host system.
- These nucleic acid expression constructs can comprise nucleotides encoding the full-length open reading frame (composed of the signal sequence, the pro-sequence, and the mature protein coding sequence) or they can comprise a subset of these genetic elements either alone or in combination with heterologous genetic elements that serve as the signal sequence and/or the pro-sequence for the mature open reading frame.
- Each of these systems can serve as a commercial production host for the expression of PLC for use in the previously described enzymatic oil degumming processes.
- nucleic acids encoding the polypeptides of the invention, or modified nucleic acids can be reproduced by, e.g., amplification.
- the invention provides amplification primer sequence pairs for amplifying nucleic acids encoding polypeptides with a phospholipase activity.
- the primer pairs are capable of amplifying nucleic acid sequences of the invention.
- One of skill in the art can design amplification primer sequence pairs for any part of or the full length of these sequences.
- the invention provides an amplification primer sequence pair for amplifying a nucleic acid encoding a polypeptide having a phospholipase activity, wherein the primer pair is capable of amplifying a nucleic acid comprising a sequence of the invention, or fragments or subsequences thereof.
- One or each member of the amplification primer sequence pair can comprise an oligonucleotide comprising at least about 10 to 50 consecutive bases of the sequence, or about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 consecutive bases of the sequence.
- the invention provides amplification primer pairs, wherein the primer pair comprises a first member having a sequence as set forth by about the first (the 5') 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues of a nucleic acid of the invention, and a second member having a sequence as set forth by about the first (the 5') 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 residues of the complementary strand of the first member.
- the invention provides phospholipases generated by amplification, e.g., polymerase chain reaction (PCR), using an amplification primer pair of the invention.
- PCR polymerase chain reaction
- the invention provides methods of making a phospholipase by amplification, e.g., polymerase chain reaction (PCR), using an amplification primer pair of the invention.
- amplification primer pair amplifies a nucleic acid from a library, e.g., a gene library, such as an environmental library.
- Amplification reactions can also be used to quantify the amount of nucleic acid in a sample (such as the amount of message in a cell sample), label the nucleic acid (e.g., to apply it to an array or a blot), detect the nucleic acid, or quantify the amount of a specific nucleic acid in a sample.
- message isolated from a cell or a cDNA library are amplified.
- the skilled artisan can select and design suitable oligonucleotide amplification primers.
- Amplification methods are also well known in the art, and include, e.g.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- the invention provides isolated and recombinant nucleic acids comprising sequences having at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, or complete (100%) sequence identity to an exemplary nucleic acid of the invention (e.g., SEQ ID NO:5 and encoding one or more mutations as set forth in Tables 12 to 15, as discussed in Example 3, or an enzymatically active fragment thereof, and nucleic acids encoding SEQ ID NO:5 and encoding one
- the invention provides polypeptides comprising sequences having at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, or complete (100%) sequence identity to an exemplary polypeptide of the invention. The extent of sequence identity
- sequence identity may be determined using any computer program and associated parameters, including those described herein, such as BLAST 2.2.2. or FASTA version 3.0t78, with the default parameters.
- sequence identify can be over a region of at least about 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400 consecutive residues, or the full length of the nucleic acid or polypeptide.
- the extent of sequence identity (homology) may be determined using any computer program and associated parameters, including those described herein, such as BLAST 2.2.2. or FASTA version 3.0t78, with the default parameters.
- Homologous sequences also include RNA sequences in which uridines replace the thymines in the nucleic acid sequences.
- the homologous sequences may be obtained using any of the procedures described herein or may result from the correction of a sequencing error.
- the nucleic acid sequences as set forth herein can be represented in the traditional single character format (see, e.g., Stryer, Lubert. Biochemistry, 3rd Ed., W. H Freeman & Co., New York) or in any other format which records the identity of the nucleotides in a sequence.
- sequence comparison programs identified herein are used in this aspect of the invention. Protein and/or nucleic acid sequence identities (homologies) may be evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are not limited to,
- sequence comparison refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or designated region as measured using any number of sequence comparison algorithms or by manual alignment and visual inspection.
- sequence comparison one sequence can act as a reference sequence to which test sequences are compared.
- test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
- sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- a “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous residues.
- contiguous residues ranging anywhere from 20 to the full length of an exemplary sequence of the invention are compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
- subsequences ranging from about 20 to 600, about 50 to 200, and about 100 to 150 are compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
- Methods of alignment of sequence for comparison are well-known in the art.
- Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith &
- Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences.
- a number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (Gibbs, 1995).
- BLAST, BLAST 2.0 and BLAST 2.2.2 algorithms are also used to practice the invention. They are described, e.g., in Altschul (1977) Nuc. Acids Res. 25:3389- 3402; Altschul (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul (1990) supra).
- HSPs high scoring sequence pairs
- initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them.
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative- scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
- W wordlength
- E expectation
- B BLOSUM62 scoring matrix
- BLAST Basic Local Alignment Search Tool
- five specific BLAST programs can be used to perform the following task: (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database; (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database; (3) BLASTX compares the six- frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and, (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.
- the BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database.
- High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art.
- the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., Science 256:1443-1445, 1992; Henikoff and Henikoff, Proteins 17:49-61, 1993).
- the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation).
- the NCBI BLAST 2.2.2 programs is used, default options to blastp. There are about 38 setting options in the BLAST 2.2.2 program. In this exemplary aspect of the invention, all default values are used except for the default filtering setting (i.e., all parameters set to default except filtering which is set to OFF); in its place a "-F F" setting is used, which disables filtering. Use of default filtering often results in Karlin-Altschul violations due to short length of sequence.
- NCBI BLAST 2.2.2 program setting is set forth in Example 1, below. Note that the "-W" option defaults to 0. This means that, if not set, the word size defaults to 3 for proteins and 11 for nucleotides.
- the invention provides isolated, synthetic or recombinant nucleic acids that hybridize under stringent conditions to an exemplary sequence of the invention, e.g., a sequence as set forth in SEQ ID NO: 5 and having one or more mutations as set forth in Tables 12 to 15, as described in Example 3, below, or a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO: 6 and encoding one or more mutations as set forth in Tables 12 to 15, or an enzymatically active fragment thereof.
- an exemplary sequence of the invention e.g., a sequence as set forth in SEQ ID NO: 5 and having one or more mutations as set forth in Tables 12 to 15, as described in Example 3, below, or a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO: 6 and encoding one or more mutations as set forth in Tables 12 to 15, or an enzymatically active fragment thereof.
- the stringent conditions can be highly stringent conditions, medium stringent conditions, low stringent conditions, including the high and reduced stringency conditions described herein.
- nucleic acids of the invention as defined by their ability to hybridize under stringent conditions can be between about five residues and the full length of the molecule, e.g., an exemplary nucleic acid of the invention.
- they can be at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 90, 100, 150, 200, 250, 300, 350, 400 or more residues in length. Nucleic acids shorter than full length are also included.
- nucleic acids are useful as, e.g., hybridization probes, labeling probes, PCR oligonucleotide probes, iRNA (single or double stranded), antisense or sequences encoding antibody binding peptides (epitopes), motifs, active sites, binding domains, regulatory domains and the like.
- nucleic acids of the invention are defined by their ability to hybridize under high stringency comprises conditions of about 50% formamide at about 37°C to 42°C. In one aspect, nucleic acids of the invention are defined by their ability to hybridize under reduced stringency comprising conditions in about 35% to 25% formamide at about 30°C to 35 °C. Alternatively, nucleic acids of the invention are defined by their ability to hybridize under high stringency comprising conditions at 42 °C in 50% formamide, 5X SSPE, 0.3% SDS, and a repetitive sequence blocking nucleic acid, such as cot-1 or salmon sperm DNA (e.g., 200 ug/ml sheared and denatured salmon sperm DNA). In one aspect, nucleic acids of the invention are defined by their ability to hybridize under reduced stringency conditions comprising 35% formamide at a reduced temperature of 35 °C.
- the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be “moderate” conditions above 25% formamide and “low” conditions below 25% formamide.
- “moderate” hybridization conditions is when the above hybridization is conducted at 30% formamide.
- a specific example of “low stringency” hybridization conditions is when the above hybridization is conducted at 10% formamide.
- the temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly.
- Nucleic acids of the invention are also defined by their ability to hybridize under high, medium, and low stringency conditions as set forth in Ausubel and Sambrook. Variations on the above ranges and conditions can be used to practice the invention and are well known in the art.
- Oligonucleotides probes and methods for using them
- the invention also provides nucleic acid probes for identifying and/or isolating a nucleic acid encoding a polypeptide having a phospholipase activity.
- the probe comprises or consists of a nucleic acid of the invention, e.g., a nucleic acid having a sequence as set forth in SEQ ID NO: 5 and having one or more base changes (mutations) as set forth in Tables 12 to 15, as described in Example 3, below, or a nucleic acid that encodes a polypeptide comprising a sequence as set forth in SEQ ID NO: 6 and encoding one or more amino acid residue changes (mutations) as set forth in Tables 12 to 15, or an enzymatically active fragment thereof.
- a probe of the invention can be at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or 150, or more, or about 10 to 50, about 20 to 60 about 30 to 70, consecutive bases of a nucleic acid sequence of the invention.
- hybridization comprises the process by which a nucleic acid strand joins with a complementary strand through base pairing.
- Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations.
- Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. For example, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature, altering the time of hybridization, as described in detail, below.
- nucleic acids of the invention are defined by their ability to hybridize under various stringency conditions (e.g., high, medium, and low), as set forth herein.
- the probes can be used in arrays of the invention, see discussion below, including, e.g., capillary arrays.
- the probes of the invention can also be used to isolate and/or identify other phospholipase-encoding nucleic acids or polypeptides having a
- the probes of the invention can be used to determine whether a biological sample, such as a soil sample, contains an organism having a nucleic acid sequence of the invention.
- a biological sample potentially harboring the organism from which the nucleic acid was isolated is obtained and nucleic acids are obtained from the sample.
- the nucleic acids are contacted with the probe under conditions which permit the probe to specifically hybridize to any complementary sequences present in the sample.
- conditions which permit the probe to specifically hybridize to complementary sequences may be determined by placing the probe in contact with complementary sequences from samples known to contain the complementary sequence, as well as control sequences which do not contain the complementary sequence.
- Hybridization conditions such as the salt concentration of the hybridization buffer, the formamide concentration of the hybridization buffer, or the hybridization temperature, may be varied to identify conditions which allow the probe to hybridize specifically to complementary nucleic acids (see discussion on specific hybridization conditions).
- Hybridization may be detected by labeling the probe with a detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.
- detectable agent such as a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.
- Many methods for using the labeled probes to detect the presence of complementary nucleic acids in a sample are familiar to those skilled in the art. These include Southern Blots, Northern Blots, colony hybridization procedures, and dot blots. Protocols for each of these procedures are provided in Ausubel and Sambrook.
- more than one probe may be used in an amplification reaction to determine whether the sample contains an organism containing a nucleic acid sequence of the invention (e.g., an organism from which the nucleic acid was isolated).
- the probes comprise oligonucleotides.
- the amplification reaction may comprise a PCR reaction. PCR protocols are described in Ausubel and Sambrook (see discussion on amplification reactions). In such procedures, the nucleic acids in the sample are contacted with the probes, the amplification reaction is performed, and any resulting amplification product is detected.
- the amplification product may be detected by performing gel electrophoresis on the reaction products and staining the gel with an intercalator such as ethidium bromide.
- an intercalator such as ethidium bromide.
- one or more of the probes may be labeled with a radioactive isotope and the presence of a radioactive amplification product may be detected by autoradiography after gel electrophoresis.
- Probes derived from sequences near the 3' or 5' ends of a nucleic acid sequence of the invention can also be used in chromosome walking procedures to identify clones containing additional, e.g., genomic sequences. Such methods allow the isolation of genes which encode additional proteins of interest from the host organism.
- nucleic acid sequences of the invention are used as probes to identify and isolate related nucleic acids.
- the so-identified related nucleic acids may be cDNAs or genomic DNAs from organisms other than the one from which the nucleic acid of the invention was first isolated.
- a nucleic acid sample is contacted with the probe under conditions which permit the probe to specifically hybridize to related sequences. Hybridization of the probe to nucleic acids from the related organism is then detected using any of the methods described above.
- nucleic acid hybridization reactions the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions.
- a nucleic acid is immobilized, for example, on a filter. Hybridization may be carried out under conditions of low stringency, moderate stringency or high stringency.
- a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45°C in a solution consisting of 0.9 M NaCl, 50 mM NaH 2 P04, pH 7.0, 5.0 mM Na 2 EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid.
- Approximately 2 x 10 7 cpm (specific activity 4 to 9 x 10 8 cpm/ug) of 32 P end-labeled oligonucleotide probe can be added to the solution.
- the membrane is washed for 30 minutes at room temperature (RT) in IX SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na2EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh IX SET at Tm- 10°C for the oligonucleotide probe.
- the membrane can be exposed to auto-radiographic film for detection of hybridization signals.
- nucleic acids having different levels of homology to the probe can be identified and isolated.
- Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes.
- the melting temperature, Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly complementary probe.
- Very stringent conditions are selected to be equal to or about 5°C lower than the Tm for a particular probe.
- the melting temperature of the probe may be calculated using the following exemplary formulas.
- Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 ⁇ g/ml denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 ⁇ g/ml denatured fragmented salmon sperm DNA, 50% formamide.
- Formulas for SSC and Denhardt's and other solutions are listed, e.g., in Sambrook.
- Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the probe.
- hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto.
- the hybridization may be carried out at 15-25°C below the Tm.
- the hybridization may be conducted at 5-10°C below the Tm.
- hybridizations in 6X SSC are conducted at approximately 68°C.
- hybridizations in 50% formamide containing solutions are conducted at approximately 42°C. All of the foregoing hybridizations would be considered to be under conditions of high stringency.
- the stringency used to wash the filters can also be varied depending on the nature of the nucleic acids being hybridized, the length of the nucleic acids being hybridized, the degree of complementarity, the nucleotide sequence composition (e.g., GC v. AT content), and the nucleic acid type (e.g., RNA v. DNA). Examples of progressively higher stringency condition washes that can be used to practice this invention are: 2X SSC, 0.1% SDS at room temperature for 15 minutes (low stringency); 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour
- Nucleic acids which have hybridized to the probe can be identified by:
- the hybridization temperature may be decreased in increments of 5°C from 68°C to 42°C in a hybridization buffer having a Na+ concentration of approximately 1M.
- the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization.
- These conditions are considered to be "moderate” conditions above 50°C and "low” conditions below 50°C.
- An example of “moderate” hybridization conditions is when the above hybridization is conducted at 55°C.
- An example of "low stringency” hybridization conditions is when the above hybridization is conducted at 45°C.
- the hybridization is carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C.
- concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe.
- the filter may be washed with 6X SSC, 0.5% SDS at 50°C.
- “moderate” conditions are above 25% formamide and “low” conditions are below 25% formamide.
- “moderate” hybridization conditions is when the above hybridization is conducted at 30% formamide.
- “low stringency" hybridization conditions is when the above hybridization is conducted at 10% formamide.
- probes and methods of the invention can be used to isolate nucleic acids having a sequence with at least about 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, or at least 50% homology to a nucleic acid sequence of the invention comprising at least about 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. Homology may be measured using an alignment algorithm, as discussed herein.
- the homologous polynucleotides may have a coding sequence which is a naturally occurring allelic variant of one of the coding sequences described herein.
- allelic variants may have a substitution, deletion or addition of one or more nucleotides when compared to nucleic acids of the invention.
- probes and methods of the invention may be used to isolate nucleic acids which encode polypeptides having at least about 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, or at least 50% sequence identity (homology) to a polypeptide of the invention comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using a sequence alignment algorithm (e.g., such as the FASTA version 3.0t78 algorithm with the default parameters, or a BLAST 2.2.2 program with exemplary settings as set forth herein).
- a sequence alignment algorithm e.g., such as the FASTA version 3.0t78 algorithm with the default parameters, or a BLAST 2.2.2 program with exemplary settings as set forth herein.
- the invention further provides nucleic acids complementary to (e.g., antisense sequences to) the nucleic acids of the invention, e.g., phospholipase-encoding nucleic acids.
- Antisense sequences are capable of inhibiting the transport, splicing or transcription of phospholipase-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA (mRNA, a transcript). The transcription or function of targeted nucleic acid can be inhibited, for example, by hybridization and/or cleavage.
- One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind phospholipase gene or message, in either case preventing or inhibiting the production or function of phospholipase enzyme. The association can be though sequence specific hybridization.
- Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of phospholipase message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes.
- the oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the
- Inhibition of phospholipase expression can have a variety of industrial applications. For example, inhibition of phospholipase expression can slow or prevent spoilage. Spoilage can occur when lipids or polypeptides, e.g., structural lipids or polypeptides, are enzymatically degraded. This can lead to the deterioration, or rot, of fruits and vegetables.
- use of compositions of the invention that inhibit the expression and/or activity of phospholipase e.g., antibodies, antisense oligonucleotides, ribozymes and RNAi, are used to slow or prevent spoilage.
- the invention provides methods and compositions comprising application onto a plant or plant product (e.g., a fruit, seed, root, leaf, etc.) antibodies, antisense oligonucleotides, ribozymes and RNAi of the invention to slow or prevent spoilage.
- a plant or plant product e.g., a fruit, seed, root, leaf, etc.
- antisense oligonucleotides, ribozymes and RNAi of the invention to slow or prevent spoilage.
- RNAi RNAi of the invention to slow or prevent spoilage.
- These compositions also can be expressed by the plant (e.g., a transgenic plant) or another organism (e.g., a bacterium or other microorganism transformed with a phospholipase gene of the invention).
- compositions of the invention for the inhibition of phospholipase expression can be used as pharmaceutical compositions.
- phospholipase expression e.g., antisense, iRNA, ribozymes, antibodies
- the invention provides antisense oligonucleotides capable of binding
- phospholipase message which can inhibit phospholipase activity by targeting mRNA.
- Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such phospholipase oligonucleotides using the novel reagents of the invention.
- gene walking/ RNA mapping protocols to screen for effective antisense oligonucleotides are well known in the art, see, e.g., Ho (2000) Methods Enzymol. 314: 168-183, describing an RNA mapping assay, which is based on standard molecular techniques to provide an easy and reliable method for potent antisense sequence selection. See also Smith (2000) Eur. J. Pharm. Sci.
- Naturally occurring nucleic acids are used as antisense oligonucleotides.
- the antisense oligonucleotides can be of any length; for example, in alternative aspects, the antisense oligonucleotides are between about 5 to 100, about 10 to 80, about 15 to 60, about 18 to 40. The optimal length can be determined by routine screening.
- the antisense oligonucleotides can be present at any concentration. The optimal
- PNAs peptide nucleic acids
- N-(2-aminoethyl) glycine units can be used.
- oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) Toxicol Appl. .Pharmacol. 144: 189-197;
- Antisense Therapeutics ed. Agrawal (Humana Press, Totowa, N.J., 1996).
- Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described above.
- Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense phospholipase sequences of the invention (see, e.g., Gold (1995) J. of Biol. Chem. 270:13581-13584).
- the invention provides for with ribozymes capable of binding phospholipase message which can inhibit phospholipase enzyme activity by targeting mRNA.
- ribozymes capable of binding phospholipase message which can inhibit phospholipase enzyme activity by targeting mRNA.
- Strategies for designing ribozymes and selecting the phospholipase-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such ribozymes using the novel reagents of the invention.
- Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA.
- the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.
- a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide.
- antisense technology where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule
- This potential advantage reflects the ability of the ribozyme to act enzymatically.
- a single ribozyme molecule is able to cleave many molecules of target RNA.
- a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.
- the enzymatic ribozyme RNA molecule can be formed in a hammerhead motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) Aids Research and Human
- an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate binding site which imparts an RNA cleaving activity to the molecule.
- RNA interference provides an RNA inhibitory molecule, a so-called "RNAi" molecule, comprising a phospholipase sequence of the invention.
- the RNAi molecule comprises a double- stranded RNA (dsRNA) molecule.
- the RNAi can inhibit expression of a phospholipase gene.
- the RNAi is about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more duplex nucleotides in length.
- the RNAi can enter a cell and cause the degradation of a single-stranded RNA (ssRNA) of similar or identical sequences, including endogenous mRNAs.
- ssRNA single-stranded RNA
- RNAi RNA interference
- dsRNA double-stranded RNA
- short interfering RNA short interfering RNA
- the invention provides methods to selectively degrade RNA using the RNAi's of the invention. The process may be practiced in vitro, ex vivo or in vivo.
- the RNAi molecules of the invention can be used to generate a loss-of-function mutation in a cell, an organ or an animal.
- Methods for making and using RNAi molecules for selectively degrade RNA are well known in the art, see, e.g., U.S. Patent No. 6,506,559; 6,511,824 ; 6,515,109; 6,489,127.
- the invention provides methods of generating variants of the nucleic acids of the invention, e.g., those encoding a phospholipase enzyme.
- the invention provides methods for modifying an enzyme of the invention, e.g., by mutation of its coding sequence by random or stochastic methods, or, non-stochastic, or "directed evolution," such as Gene Site Saturation MutagenesisTM (GSSM), to alter the enzymes pH range of activity or range of optimal activity, temperature range of activity or range of optimal activity, specificity, activity (kinetics); the enzyme's use of glycosylation, phosphorylation or metals (e.g., Ca, Mg, Zn, Fe, Na), e.g., to impact pH/temperature stability.
- GSSM Gene Site Saturation MutagenesisTM
- the invention provides methods for modifying an enzyme of the invention, e.g., by mutation of its coding sequence, e.g., by GSSM, to increase its resistance to protease activity.
- the invention provides methods for modifying an enzyme of the invention, e.g., by mutation of its coding sequence, e.g., by GSSM, to modify the enzyme's use of metal chelators specific for Ca, Mg, Na that would not chelate Zn.
- the invention provides methods for modifying an enzyme of the invention, e.g., by mutation of its coding sequence, e.g., by GSSM, that would have a desired combination of activities, e.g., PI, PA and PC/PE specific PLCs.
- GSSM Gene Site Saturation Mutagenesis
- GSSM Gene Site Saturation Mutagenesis
- GSSM Gene Site Saturation Mutagenesis
- GSSM comprises a method that uses degenerate oligonucleotide primers to introduce point mutations into a polynucleotide, as described in detail, below.
- optimal directed evolution system or “optimized directed evolution” comprises a method for reassembling fragments of related nucleic acid sequences, e.g., related genes, and explained in detail, below.
- synthetic ligation reassembly or “SLR” comprises a method of ligating oligonucleotide fragments in a non-stochastic fashion, and explained in detail, below.
- the invention provides "variants" of exemplary nucleic acids and polypeptides of the invention, including e.g., SEQ ID NO:8, encoded e.g., by SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9.
- variants of polynucleotides or polypeptides of the invention are nucleic acids or polypeptides that have been modified at one or more base pairs, codons, introns, exons, or amino acid residues (respectively) yet still retain the biological activity of a
- Variants can be produced by any number of means included methods such as, for example, error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, GSSM and any combination thereof.
- Techniques for producing variant phospholipases having activity at a pH or temperature for example, that is different from a wild-type phospholipase, are included herein.
- phospholipase enzymes having an altered or different activity or an altered or different stability from that of a phospholipase encoded by the template nucleic acid.
- methods also can be repeated or used in various combinations, e.g., to generate variations in gene/ message expression, message translation or message stability.
- the genetic composition of a cell is altered by, e.g., modification of a homologous gene ex vivo, followed by its reinsertion into the cell.
- a nucleic acid of the invention can be altered by any means. For example, random or stochastic methods, or, non-stochastic, or "directed evolution," methods. Methods for random mutation of genes are well known in the art, see, e.g., U.S. Patent No. 5,830,696.
- mutagens can be used to randomly mutate a gene. Mutagens include, e.g., ultraviolet light or gamma irradiation, or a chemical mutagen, e.g., mitomycin, nitrous acid, photoactivated psoralens, alone or in combination, to induce DNA breaks amenable to repair by recombination.
- Other chemical mutagens include, for example, sodium bisulfite, nitrous acid, hydroxylamine, hydrazine or formic acid.
- Other mutagens are analogues of nucleotide precursors, e.g., nitrosoguanidine, 5-bromouracil, 2-aminopurine, or acridine. These agents can be added to a PCR reaction in place of the nucleotide precursor thereby mutating the sequence.
- Intercalating agents such as proflavine, acriflavine, quinacrine and the like can also be used.
- nucleic acids e.g., genes
- Stochastic fragmentation
- GSSM synthetic ligation reassembly
- SLR synthetic ligation reassembly
- recombination recursive sequence recombination
- phosphothioate-modified DNA mutagenesis uracil-containing template mutagenesis
- gapped duplex mutagenesis point mismatch repair mutagenesis
- repair-deficient host strain mutagenesis chemical mutagenesis
- radiogenic mutagenesis deletion mutagenesis
- restriction-selection mutagenesis restriction-purification mutagenesis
- artificial gene synthesis ensemble mutagenesis, chimeric nucleic acid multimer creation, and/or a combination of these and other methods.
- Mutational methods of generating diversity include, for example, site- directed mutagenesis (Ling et al. (1997) "Approaches to DNA mutagenesis: an overview” Anal Biochem. 254(2): 157-178; Dale et al. (1996) “Oligonucleotide-directed random mutagenesis using the phosphorothioate method” Methods Mol. Biol. 57:369-374; Smith (1985) "In vitro mutagenesis” Ann. Rev. Genet. 19:423-462; Botstein & Shortle (1985) "Strategies and applications of in vitro mutagenesis” Science 229:1193-1201; Carter (1986) "Site-directed mutagenesis” Biochem. J.
- Additional protocols used in the methods of the invention include point mismatch repair (Kramer (1984) "Point Mismatch Repair” Cell 38:879-887), mutagenesis using repair-deficient host strains (Carter et al. (1985) "Improved oligonucleotide site- directed mutagenesis using M13 vectors” Nucl. Acids Res. 13: 4431-4443; and Carter (1987) "Improved oligonucleotide-directed mutagenesis using M13 vectors” Methods in Enzymol. 154: 382-403), deletion mutagenesis (Eghtedarzadeh (1986) "Use of oligonucleotides to generate large deletions" Nucl. Acids Res.
- Non-stochastic, or "directed evolution,” methods include, e.g., saturation mutagenesis (e.g., GSSM), synthetic ligation reassembly (SLR), or a combination thereof are used to modify the nucleic acids of the invention to generate phospholipases with new or altered properties (e.g., activity under highly acidic or alkaline conditions, high temperatures, and the like).
- Polypeptides encoded by the modified nucleic acids can be screened for an activity before testing for a phospholipase or other activity. Any testing modality or protocol can be used, e.g., using a capillary array platform. See, e.g., U.S. Patent Nos. 6,280,926; 5,939,250.
- non-stochastic gene modification a "directed evolution process” is used to generate phospholipases with new or altered properties. Variations of this method have been termed “gene site mutagenesis,” “site-saturation mutagenesis,” “Gene Site Saturation Mutagenesis” or simply “GSSM.” It can be used in combination with other mutagenization processes. See, e.g., U.S. Patent Nos. 6,171,820; 6,238,884.
- GSSM comprises providing a template polynucleotide and a plurality of oligonucleotides, wherein each oligonucleotide comprises a sequence homologous to the template polynucleotide, thereby targeting a specific sequence of the template polynucleotide, and a sequence that is a variant of the homologous gene;
- progeny polynucleotides comprising non-stochastic sequence variations by replicating the template polynucleotide with the oligonucleotides, thereby generating polynucleotides comprising homologous gene sequence variations.
- codon primers containing a degenerate N,N,G/T sequence are used to introduce point mutations into a polynucleotide, so as to generate a set of progeny polypeptides in which a full range of single amino acid substitutions is represented at each amino acid position, e.g., an amino acid residue in an enzyme active site or ligand binding site targeted to be modified.
- These oligonucleotides can comprise a contiguous first homologous sequence, a degenerate N,N,G/T sequence, and, optionally, a second homologous sequence.
- the downstream progeny translational products from the use of such oligonucleotides include all possible amino acid changes at each amino acid site along the polypeptide, because the degeneracy of the N,N,G/T sequence includes codons for all 20 amino acids.
- one such degenerate oligonucleotide (comprised of, e.g., one degenerate N,N,G/T cassette) is used for subjecting each original codon in a parental polynucleotide template to a full range of codon substitutions.
- at least two degenerate cassettes are used - either in the same
- oligonucleotide or not, for subjecting at least two original codons in a parental polynucleotide template to a full range of codon substitutions.
- more than one N,N,G/T sequence can be contained in one oligonucleotide to introduce amino acid mutations at more than one site.
- This plurality of N,N,G/T sequences can be directly contiguous, or separated by one or more additional nucleotide sequence(s).
- oligonucleotides serviceable for introducing additions and deletions can be used either alone or in combination with the codons containing an N,N,G/T sequence, to introduce any combination or permutation of amino acid additions, deletions, and/or substitutions.
- simultaneous mutagenesis of two or more contiguous amino acid positions is done using an oligonucleotide that contains contiguous N,N,G/T triplets, i.e. a degenerate (N,N,G/T)n sequence.
- degenerate cassettes having less degeneracy than the N,N,G/T sequence are used.
- degenerate triplets allows for systematic and easy generation of a full range of possible natural amino acids (for a total of 20 amino acids) into each and every amino acid position in a polypeptide (in alternative aspects, the methods also include generation of less than all possible substitutions per amino acid residue, or codon, position). For example, for a 100 amino acid polypeptide, 2000 distinct species (i.e. 20 possible amino acids per position X 100 amino acid positions) can be generated.
- an oligonucleotide or set of oligonucleotides containing a degenerate N,N,G/T triplet 32 individual sequences can code for all 20 possible natural amino acids.
- Nondegenerate oligonucleotides can optionally be used in combination with degenerate primers disclosed; for example, nondegenerate oligonucleotides can be used to generate specific point mutations in a working polynucleotide. This provides one means to generate specific silent point mutations, point mutations leading to corresponding amino acid changes, and point mutations that cause the generation of stop codons and the corresponding expression of polypeptide fragments.
- each saturation mutagenesis reaction vessel contains polynucleotides encoding at least 20 progeny polypeptide (e.g., phospholipase) molecules such that all 20 natural amino acids are represented at the one specific amino acid position corresponding to the codon position mutagenized in the parental polynucleotide (other aspects use less than all 20 natural combinations).
- the 32-fold degenerate progeny polypeptides generated from each saturation mutagenesis reaction vessel can be subjected to clonal amplification (e.g. cloned into a suitable host, e.g., E. coli host, using, e.g., an expression vector) and subjected to expression screening.
- an individual progeny polypeptide is identified by screening to display a favorable change in property (when compared to the parental polypeptide, such as increased phospholipase activity under alkaline or acidic conditions), it can be sequenced to identify the correspondingly favorable amino acid substitution contained therein.
- favorable amino acid changes may be identified at more than one amino acid position.
- One or more new progeny molecules can be generated that contain a combination of all or part of these favorable amino acid substitutions. For example, if 2 specific favorable amino acid changes are identified in each of 3 amino acid positions in a polypeptide, the
- permutations include 3 possibilities at each position (no change from the original amino acid, and each of two favorable changes) and 3 positions. Thus, there are 3 x 3 x 3 or 27 total possibilities, including 7 that were previously examined - 6 single point mutations (i.e. 2 at each of three positions) and no change at any position.
- site-saturation mutagenesis can be used together with another stochastic or non-stochastic means to vary sequence, e.g., synthetic ligation reassembly (see below), shuffling, chimerization, recombination and other mutagenizing processes and mutagenizing agents.
- This invention provides for the use of any mutagenizing process(es), including saturation mutagenesis, in an iterative manner.
- the invention provides a non-stochastic gene modification system termed "synthetic ligation reassembly,” or simply “SLR,” a “directed evolution process,” to generate phospholipases with new or altered properties.
- SLR is a method of ligating oligonucleotide fragments together non-stochastically. This method differs from stochastic oligonucleotide shuffling in that the nucleic acid building blocks are not shuffled, concatenated or chimerized randomly, but rather are assembled non- stochastically. See, e.g., U.S. Patent Application Serial No.
- SLR comprises the following steps: (a) providing a template polynucleotide, wherein the template polynucleotide comprises sequence encoding a homologous gene; (b) providing a plurality of building block
- polynucleotides wherein the building block polynucleotides are designed to cross-over reassemble with the template polynucleotide at a predetermined sequence, and a building block polynucleotide comprises a sequence that is a variant of the homologous gene and a sequence homologous to the template polynucleotide flanking the variant sequence; (c) combining a building block polynucleotide with a template polynucleotide such that the building block polynucleotide cross-over reassembles with the template polynucleotide to generate polynucleotides comprising homologous gene sequence variations.
- SLR does not depend on the presence of high levels of homology between polynucleotides to be rearranged.
- this method can be used to non-stochastically generate libraries (or sets) of progeny molecules comprised of over 10 100 different chimeras.
- SLR can be used to generate libraries comprised of over 10 1000 different progeny chimeras.
- aspects of the present invention include non-stochastic methods of producing a set of finalized chimeric nucleic acid molecule shaving an overall assembly order that is chosen by design. This method includes the steps of generating by design a plurality of specific nucleic acid building blocks having serviceable mutually compatible ligatable ends, and assembling these nucleic acid building blocks, such that a designed overall assembly order is achieved.
- the mutually compatible ligatable ends of the nucleic acid building blocks to be assembled are considered to be "serviceable" for this type of ordered assembly if they enable the building blocks to be coupled in predetermined orders.
- the overall assembly order in which the nucleic acid building blocks can be coupled is specified by the design of the ligatable ends. If more than one assembly step is to be used, then the overall assembly order in which the nucleic acid building blocks can be coupled is also specified by the sequential order of the assembly step(s).
- the annealed building pieces are treated with an enzyme, such as a ligase (e.g. T4 DNA ligase), to achieve covalent bonding of the building pieces.
- a ligase e.g. T4 DNA ligase
- the design of the oligonucleotide building blocks is obtained by analyzing a set of progenitor nucleic acid sequence templates that serve as a basis for producing a progeny set of finalized chimeric polynucleotides.
- These parental oligonucleotide templates thus serve as a source of sequence information that aids in the design of the nucleic acid building blocks that are to be mutagenized, e.g., chimerized or shuffled.
- the sequences of a plurality of parental nucleic acid templates are aligned in order to select one or more demarcation points.
- the demarcation points can be located at an area of homology, and are comprised of one or more nucleotides. These demarcation points are preferably shared by at least two of the progenitor templates.
- the demarcation points can thereby be used to delineate the boundaries of oligonucleotide building blocks to be generated in order to rearrange the parental polynucleotides.
- the demarcation points identified and selected in the progenitor molecules serve as potential chimerization points in the assembly of the final chimeric progeny molecules.
- a demarcation point can be an area of homology
- a demarcation point can be an area of homology that is shared by at least half of the parental polynucleotide sequences, or, it can be an area of homology that is shared by at least two thirds of the parental polynucleotide sequences.
- a serviceable demarcation points is an area of homology that is shared by at least three fourths of the parental polynucleotide sequences, or, it can be shared by at almost all of the parental polynucleotide sequences.
- a demarcation point is an area of homology that is shared by all of the parental polynucleotide sequences.
- a ligation reassembly process is performed exhaustively in order to generate an exhaustive library of progeny chimeric polynucleotides.
- all possible ordered combinations of the nucleic acid building blocks are represented in the set of finalized chimeric nucleic acid molecules.
- the assembly order i.e. the order of assembly of each building block in the 5' to 3 sequence of each finalized chimeric nucleic acid
- the assembly order is by design (or non- stochastic) as described above. Because of the non- stochastic nature of this invention, the possibility of unwanted side products is greatly reduced.
- the ligation reassembly method is performed systematically.
- the method is performed in order to generate a
- this invention provides that, through the selective and judicious use of specific nucleic acid building blocks, coupled with the selective and judicious use of sequentially stepped assembly reactions, a design can be achieved where specific sets of progeny products are made in each of several reaction vessels. This allows a systematic examination and screening procedure to be performed. Thus, these methods allow a potentially very large number of progeny molecules to be examined systematically in smaller groups.
- the progeny molecules generated preferably comprise a library of finalized chimeric nucleic acid molecules having an overall assembly order that is chosen by design.
- the saturation mutagenesis and optimized directed evolution methods also can be used to generate different progeny molecular species.
- the invention provides freedom of choice and control regarding the selection of demarcation points, the size and number of the nucleic acid building blocks, and the size and design of the couplings. It is appreciated, furthermore, that the requirement for intermolecular homology is highly relaxed for the operability of this invention. In fact, demarcation points can even be chosen in areas of little or no intermolecular homology. For example, because of codon wobble, i.e. the degeneracy of codons, nucleotide substitutions can be introduced into nucleic acid building blocks without altering the amino acid originally encoded in the corresponding progenitor template. Alternatively, a codon can be altered such that the coding for an originally amino acid is altered.
- This invention provides that such substitutions can be introduced into the nucleic acid building block in order to increase the incidence of intermolecularly homologous demarcation points and thus to allow an increased number of couplings to be achieved among the building blocks, which in turn allows a greater number of progeny chimeric molecules to be generated.
- the synthetic nature of the step in which the building blocks are generated allows the design and introduction of nucleotides (e.g., one or more nucleotides, which may be, for example, codons or introns or regulatory sequences) that can later be optionally removed in an in vitro process (e.g. by mutagenesis) or in an in vivo process (e.g. by utilizing the gene splicing ability of a host organism).
- nucleotides e.g., one or more nucleotides, which may be, for example, codons or introns or regulatory sequences
- a nucleic acid building block is used to introduce an intron.
- functional introns are introduced into a man-made gene manufactured according to the methods described herein.
- the artificially introduced intron(s) can be functional in a host cells for gene splicing much in the way that naturally-occurring introns serve functionally in gene splicing.
- the invention provides a non-stochastic gene modification system termed "optimized directed evolution system" to generate phospholipases with new or altered properties.
- Optimized directed evolution is directed to the use of repeated cycles of reductive reassortment, recombination and selection that allow for the directed molecular evolution of nucleic acids through recombination.
- Optimized directed evolution allows generation of a large population of evolved chimeric sequences, wherein the generated population is significantly enriched for sequences that have a predetermined number of crossover events.
- a crossover event is a point in a chimeric sequence where a shift in sequence occurs from one parental variant to another parental variant. Such a point is normally at the juncture of where oligonucleotides from two parents are ligated together to form a single sequence. This method allows calculation of the correct concentrations of oligonucleotide sequences so that the final chimeric population of sequences is enriched for the chosen number of crossover events. This provides more control over choosing chimeric variants having a predetermined number of crossover events.
- this method provides a convenient means for exploring a tremendous amount of the possible protein variant space in comparison to other systems.
- Previously if one generated, for example, 10 chimeric molecules during a reaction, it would be extremely difficult to test such a high number of chimeric variants for a particular activity.
- a significant portion of the progeny population would have a very high number of crossover events which resulted in proteins that were less likely to have increased levels of a particular activity.
- the population of chimerics molecules can be enriched for those variants that have a particular number of crossover events.
- each of the molecules chosen for further analysis most likely has, for example, only three crossover events.
- the boundaries on the functional variety between the chimeric molecules is reduced. This provides a more manageable number of variables when calculating which oligonucleotide from the original parental polynucleotides might be responsible for affecting a particular trait.
- One method for creating a chimeric progeny polynucleotide sequence is to create oligonucleotides corresponding to fragments or portions of each parental sequence.
- Each oligonucleotide preferably includes a unique region of overlap so that mixing the oligonucleotides together results in a new variant that has each oligonucleotide fragment assembled in the correct order. Additional information can also be found in USSN 09/332,835.
- the number of oligonucleotides generated for each parental variant bears a relationship to the total number of resulting crossovers in the chimeric molecule that is ultimately created.
- three parental nucleotide sequence variants might be provided to undergo a ligation reaction in order to find a chimeric variant having, for example, greater activity at high temperature.
- oligonucleotide sequences can be generated corresponding to each portions of each parental variant. Accordingly, during the ligation reassembly process there could be up to 50 crossover events within each of the chimeric sequences. The probability that each of the generated chimeric polynucleotides will contain oligonucleotides from each parental variant in alternating order is very low. If each oligonucleotide fragment is present in the ligation reaction in the same molar quantity it is likely that in some positions
- oligonucleotides from the same parental polynucleotide will ligate next to one another and thus not result in a crossover event. If the concentration of each oligonucleotide from each parent is kept constant during any ligation step in this example, there is a 1/3 chance (assuming 3 parents) that an oligonucleotide from the same parental variant will ligate within the chimeric sequence and produce no crossover. Accordingly, a probability density function (PDF) can be determined to predict the population of crossover events that are likely to occur during each step in a ligation reaction given a set number of parental variants, a number of oligonucleotides corresponding to each variant, and the concentrations of each variant during each step in the ligation reaction.
- PDF probability density function
- This system allows generation of a large population of evolved chimeric sequences, wherein the generated population is significantly enriched for sequences that have a predetermined number of crossover events.
- a crossover event is a point in a chimeric sequence where a shift in sequence occurs from one parental variant to another parental variant. Such a point is normally at the juncture of where oligonucleotides from two parents are ligated together to form a single sequence.
- the method allows calculation of the correct concentrations of oligonucleotide sequences so that the final chimeric population of sequences is enriched for the chosen number of crossover events. This provides more control over choosing chimeric variants having a predetermined number of crossover events.
- the population of chimerics molecules can be enriched for those variants that have a particular number of crossover events.
- each of the molecules chosen for further analysis most likely has, for example, only three crossover events.
- the resulting progeny population can be skewed to have a predetermined number of crossover events, the boundaries on the functional variety between the chimeric molecules is reduced. This provides a more manageable number of variables when calculating which oligonucleotide from the original parental polynucleotides might be responsible for affecting a particular trait.
- the method creates a chimeric progeny polynucleotide sequence by creating oligonucleotides corresponding to fragments or portions of each parental sequence.
- Each oligonucleotide preferably includes a unique region of overlap so that mixing the oligonucleotides together results in a new variant that has each oligonucleotide fragment assembled in the correct order. See also USSN 09/332,835.
- the number of oligonucleotides generated for each parental variant bears a relationship to the total number of resulting crossovers in the chimeric molecule that is ultimately created.
- three parental nucleotide sequence variants might be provided to undergo a ligation reaction in order to find a chimeric variant having, for example, greater activity at high temperature.
- oligonucleotide sequences can be generated corresponding to each portions of each parental variant. Accordingly, during the ligation reassembly process there could be up to 50 crossover events within each of the chimeric sequences. The probability that each of the generated chimeric polynucleotides will contain oligonucleotides from each parental variant in alternating order is very low. If each oligonucleotide fragment is present in the ligation reaction in the same molar quantity it is likely that in some positions
- oligonucleotides from the same parental polynucleotide will ligate next to one another and thus not result in a crossover event. If the concentration of each oligonucleotide from each parent is kept constant during any ligation step in this example, there is a 1/3 chance (assuming 3 parents) that a oligonucleotide from the same parental variant will ligate within the chimeric sequence and produce no crossover.
- a probability density function can be determined to predict the population of crossover events that are likely to occur during each step in a ligation reaction given a set number of parental variants, a number of oligonucleotides corresponding to each variant, and the concentrations of each variant during each step in the ligation reaction.
- PDF probability density function
- a target number of crossover events can be predetermined, and the system then programmed to calculate the starting quantities of each parental oligonucleotide during each step in the ligation reaction to result in a probability density function that centers on the predetermined number of crossover events.
- Embodiments of the invention include a system and software that receive a desired crossover probability density function (PDF), the number of parent genes to be reassembled, and the number of fragments in the reassembly as inputs.
- PDF crossover probability density function
- the output of this program is a "fragment PDF" that can be used to determine a recipe for producing reassembled genes, and the estimated crossover PDF of those genes.
- the processing described herein is preferably performed in MATLAB ® (The Mathworks, Natick, Massachusetts) a programming language and development environment for technical computing.
- these processes can be iteratively repeated.
- a nucleic acid (or, the nucleic acid) responsible for an altered phospholipase phenotype is identified, re-isolated, again modified, re-tested for activity.
- This process can be iteratively repeated until a desired phenotype is engineered.
- an entire biochemical anabolic or catabolic pathway can be engineered into a cell, including phospholipase activity.
- a particular oligonucleotide has no affect at all on the desired trait (e.g., a new phospholipase phenotype)
- it can be removed as a variable by synthesizing larger parental oligonucleotides that include the sequence to be removed. Since incorporating the sequence within a larger sequence prevents any crossover events, there will no longer be any variation of this sequence in the progeny polynucleotides. This iterative practice of determining which oligonucleotides are most related to the desired trait, and which are unrelated, allows more efficient exploration all of the possible protein variants that might be provide a particular trait or activity.
- In vivo shuffling of molecules is use in methods of the invention that provide variants of polypeptides of the invention, e.g., antibodies, phospholipase enzymes, and the like.
- In vivo shuffling can be performed utilizing the natural property of cells to recombine multimers. While recombination in vivo has provided the major natural route to molecular diversity, genetic recombination remains a relatively complex process that involves 1) the recognition of homologies; 2) strand cleavage, strand invasion, and metabolic steps leading to the production of recombinant chiasma; and finally 3) the resolution of chiasma into discrete recombined molecules. The formation of the chiasma requires the recognition of homologous sequences.
- the invention provides a method for producing a hybrid polynucleotide from at least a first polynucleotide and a second polynucleotide.
- the invention can be used to produce a hybrid polynucleotide by introducing at least a first polynucleotide and a second polynucleotide which share at least one region of partial sequence homology into a suitable host cell.
- the regions of partial sequence homology promote processes which result in sequence reorganization producing a hybrid polynucleotide.
- hybrid polynucleotide is any nucleotide sequence which results from the method of the present invention and contains sequence from at least two original polynucleotide sequences.
- hybrid polynucleotides can result from intermolecular recombination events which promote sequence integration between DNA molecules.
- hybrid polynucleotides can result from intramolecular reductive reassortment processes which utilize repeated sequences to alter a nucleotide sequence within a DNA molecule.
- the invention also provides methods of making sequence variants of the nucleic acid and phospholipase sequences of the invention or isolating phospholipase enzyme, e.g., phospholipase, sequence variants using the nucleic acids and polypeptides of the invention.
- the invention provides for variants of a phospholipase gene of the invention, which can be altered by any means, including, e.g., random or stochastic methods, or, non-stochastic, or "directed evolution," methods, as described above.
- the isolated variants may be naturally occurring. Variant can also be created in vitro. Variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, Exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures. Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids which encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the sequence obtained from the natural isolate are generated and characterized. These nucleotide differences can result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates.
- variants may be created using error prone PCR.
- error prone PCR PCR is performed under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product.
- Error prone PCR is described, e.g., in Leung, D.W., et al., Technique, 1:11-15, 1989) and Caldwell, R. C. & Joyce G.F., PCR Methods Applic, 2:28-33, 1992.
- nucleic acids to be mutagenized are mixed with PCR primers, reaction buffer, MgC12, MnC12, Taq polymerase and an appropriate concentration of dNTPs for achieving a high rate of point mutation along the entire length of the PCR product.
- the reaction may be performed using 20 fmoles of nucleic acid to be mutagenized, 30 pmole of each PCR primer, a reaction buffer comprising 50 mM KCl, lOmM Tris HCl (pH 8.3) and 0.01% gelatin, 7 mM MgC12, 0.5 mM MnCl 2 , 5 units of Taq polymerase, 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP, and 1 mM dTTP.
- PCR may be performed for 30 cycles of 94° C for 1 min, 45° C for 1 min, and 72° C for 1 min. However, it will be appreciated that these parameters may be varied as appropriate.
- the mutagenized nucleic acids are cloned into an appropriate vector and the activities of the polypeptides encoded by the mutagenized nucleic acids is evaluated.
- Variants may also be created using oligonucleotide directed mutagenesis to generate site-specific mutations in any cloned DNA of interest.
- Oligonucleotide mutagenesis is described, e.g., in Reidhaar- Olson (1988) Science 241:53-57. Briefly, in such procedures a plurality of double stranded oligonucleotides bearing one or more mutations to be introduced into the cloned DNA are synthesized and inserted into the cloned DNA to be mutagenized. Clones containing the mutagenized DNA are recovered and the activities of the polypeptides they encode are assessed.
- Assembly PCR involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction. Assembly PCR is described in, e.g., U.S. Patent No. 5,965,408.
- Still another method of generating variants is sexual PCR mutagenesis.
- sexual PCR mutagenesis forced homologous recombination occurs between DNA molecules of different but highly related DNA sequence in vitro, as a result of random fragmentation of the DNA molecule based on sequence homology, followed by fixation of the crossover by primer extension in a PCR reaction.
- Sexual PCR mutagenesis is described, e.g., in Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751. Briefly, in such procedures a plurality of nucleic acids to be recombined are digested with DNase to generate fragments having an average size of 50-200 nucleotides.
- Fragments of the desired average size are purified and resuspended in a PCR mixture.
- PCR is conducted under conditions which facilitate recombination between the nucleic acid fragments.
- PCR may be performed by resuspending the purified fragments at a
- oligonucleotides may be included in the PCR reactions.
- the Klenow fragment of DNA polymerase I may be used in a first set of PCR reactions and Taq polymerase may be used in a subsequent set of PCR reactions. Recombinant sequences are isolated and the activities of the polypeptides they encode are assessed.
- Variants may also be created by in vivo mutagenesis.
- random mutations in a sequence of interest are generated by propagating the sequence of interest in a bacterial strain, such as an E. coli strain, which carries mutations in one or more of the DNA repair pathways.
- a bacterial strain such as an E. coli strain
- Such "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA.
- Mutator strains suitable for use for in vivo mutagenesis are described, e.g., in PCT Publication No. WO 91/16427.
- cassette mutagenesis a small region of a double stranded DNA molecule is replaced with a synthetic oligonucleotide "cassette" that differs from the native sequence.
- the oligonucleotide often contains completely and/or partially randomized native sequence.
- Recursive ensemble mutagenesis may also be used to generate variants.
- Recursive ensemble mutagenesis is an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. Recursive ensemble mutagenesis is described, e.g., in Arkin (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815.
- variants are created using exponential ensemble mutagenesis.
- Exponential ensemble mutagenesis is a process for generating
- Exponential ensemble mutagenesis is described, e.g., in Delegrave (1993) Biotechnology Res. 11:1548-1552. Random and site-directed mutagenesis are described, e.g., in Arnold (1993) Current Opinion in Biotechnology 4:450-455.
- the variants are created using shuffling procedures wherein portions of a plurality of nucleic acids which encode distinct polypeptides are fused together to create chimeric nucleic acid sequences which encode chimeric polypeptides as described in, e.g., U.S. Patent Nos. 5,965,408; 5,939,250.
- the invention also provides variants of polypeptides of the invention comprising sequences in which one or more of the amino acid residues (e.g., of an exemplary polypeptide of the invention) are substituted with a conserved or non-conserved amino acid residue (e.g., a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.
- Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics.
- polypeptides of the invention include those with conservative substitutions of sequences of the invention, including but not limited to the following replacements: replacements of an aliphatic amino acid such as Alanine, Valine, Leucine and Isoleucine with another aliphatic amino acid; replacement of a Serine with a
- Threonine or vice versa replacement of an acidic residue such as Aspartic acid and Glutamic acid with another acidic residue; replacement of a residue bearing an amide group, such as Asparagine and Glutamine, with another residue bearing an amide group; exchange of a basic residue such as Lysine and Arginine with another basic residue; and replacement of an aromatic residue such as Phenylalanine, Tyrosine with another aromatic residue.
- an acidic residue such as Aspartic acid and Glutamic acid
- replacement of a residue bearing an amide group such as Asparagine and Glutamine, with another residue bearing an amide group
- exchange of a basic residue such as Lysine and Arginine with another basic residue
- an aromatic residue such as Phenylalanine, Tyrosine with another aromatic residue.
- Other variants are those in which one or more of the amino acid residues of the polypeptides of the invention includes a substituent group.
- variants within the scope of the invention are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide, for example, polyethylene glycol.
- additional variants within the scope of the invention are those in which additional amino acids are fused to the polypeptide, such as a leader sequence, a secretory sequence, a proprotein sequence or a sequence which facilitates purification, enrichment, or stabilization of the polypeptide.
- the variants, fragments, derivatives and analogs of the polypeptides of the invention retain the same biological function or activity as the exemplary polypeptides, e.g., a phospholipase activity, as described herein.
- the variant, fragment, derivative, or analog includes a proprotein, such that the variant, fragment, derivative, or analog can be activated by cleavage of the proprotein portion to produce an active polypeptide.
- the invention provides methods for modifying phospholipase-encoding nucleic acids to modify codon usage.
- the invention provides methods for modifying codons in a nucleic acid encoding a phospholipase to increase or decrease its expression in a host cell.
- the invention also provides nucleic acids encoding a phospholipase modified to increase its expression in a host cell, phospholipase enzymes so modified, and methods of making the modified phospholipase enzymes.
- the method comprises identifying a "non-preferred” or a "less preferred” codon in phospholipase- encoding nucleic acid and replacing one or more of these non-preferred or less preferred codons with a "preferred codon” encoding the same amino acid as the replaced codon and at least one non-preferred or less preferred codon in the nucleic acid has been replaced by a preferred codon encoding the same amino acid.
- a preferred codon is a codon over- represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell.
- Host cells for expressing the nucleic acids, expression cassettes and vectors of the invention include bacteria, yeast, fungi, plant cells, insect cells and mammalian cells. Thus, the invention provides methods for optimizing codon usage in all of these cells, codon-altered nucleic acids and polypeptides made by the codon-altered nucleic acids.
- Exemplary host cells include gram negative bacteria, such as Escherichia coli; gram positive bacteria, such as any Bacillus (e.g., B. cereus) or Streptomyces, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris, Bacillus subtilis.
- Exemplary host cells also include eukaryotic organisms, e.g., various yeast, such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger, and mammalian cells and cell lines and insect cells and cell lines.
- yeast such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger, and mammalian cells and cell lines and insect cells and cell lines.
- the codons of a nucleic acid encoding a phospholipase isolated from a bacterial cell are modified such that the nucleic acid is optimally expressed in a bacterial cell different from the bacteria from which the phospholipase was derived, a yeast, a fungi, a plant cell, an insect cell or a mammalian cell.
- Methods for optimizing codons are well known in the art, see, e.g., U.S. Patent No. 5,795,737; Baca (2000) Int. J. Parasitol. 30:113-118; Hale (1998) Protein Expr. Purif. 12:185-188; Narum (2001) Infect. Immun. 69:7250-7253.
- the invention provides transgenic non-human animals comprising a nucleic acid, a polypeptide, an expression cassette or vector or a transfected or transformed cell of the invention.
- the transgenic non-human animals can be, e.g., goats, rabbits, sheep, pigs, cows, rats and mice, comprising the nucleic acids of the invention. These animals can be used, e.g., as in vivo models to study phospholipase activity, or, as models to screen for modulators of phospholipase activity in vivo.
- the coding sequences for the polypeptides to be expressed in the transgenic non-human animals can be designed to be constitutive, or, under the control of tissue-specific, developmental- specific or inducible transcriptional regulatory factors.
- Transgenic non-human animals can be designed and generated using any method known in the art; see, e.g., U.S. Patent Nos. 6,211,428; 6,187,992; 6,156,952; 6,118,044; 6,111,166; 6,107,541; 5,959,171; 5,922,854; 5,892,070; 5,880,327; 5,891,698; 5,639,940; 5,573,933; 5,387,742; 5,087,571, describing making and using transformed cells and eggs and transgenic mice, rats, rabbits, sheep, pigs and cows. See also, e.g., Pollock (1999) J. Immunol. Methods 231:147-157, describing the production of recombinant proteins in the milk of transgenic dairy animals; Baguisi (1999) Nat.
- U.S. Patent No. 6,211,4208 describes making and using transgenic non-human mammals which express in their brains a nucleic acid construct comprising a DNA sequence.
- U.S. Patent No. 5,387,742 describes injecting cloned recombinant or synthetic DNA sequences into fertilized mouse eggs, implanting the injected eggs in pseudo-pregnant females, and growing to term transgenic mice whose cells express proteins related to the pathology of Alzheimer's disease.
- U.S. Patent No. 6,187,992 describes making and using a transgenic mouse whose genome comprises a disruption of the gene encoding amyloid precursor protein (APP).
- APP amyloid precursor protein
- the transgenic or modified animals of the invention can also be used to practice the methods of the invention.
- the transgenic or modified animals of the invention comprise a "knockout animal,” e.g., a “knockout mouse,” engineered not to express or to be unable to express a phospholipase.
- the invention provides transgenic plants and seeds comprising a nucleic acid, a polypeptide (e.g., a phospholipase), an expression cassette or vector or a transfected or transformed cell of the invention.
- the invention also provides plant products, e.g., oils, seeds, leaves, extracts and the like, comprising a nucleic acid and/or a polypeptide (e.g., a phospholipase) of the invention.
- the transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot).
- the invention also provides methods of making and using these transgenic plants and seeds.
- the transgenic plant or plant cell expressing a polypeptide of the invention may be constructed in accordance with any method known in the art. See, for example, U.S. Patent No. 6,309,872.
- Nucleic acids and expression constructs of the invention can be introduced into a plant cell by any means.
- nucleic acids or expression constructs can be introduced into the genome of a desired plant host, or, the nucleic acids or expression constructs can be episomes.
- Introduction into the genome of a desired plant can be such that the host' s phospholipase production is regulated by endogenous transcriptional or translational control elements.
- the invention also provides "knockout plants” where insertion of gene sequence by, e.g., homologous recombination, has disrupted the expression of the endogenous gene. Means to generate "knockout" plants are well-known in the art, see, e.g., Strepp (1998) Proc Natl. Acad. Sci. USA 95:4368-4373; Miao (1995) Plant J 7:359-365. See discussion on transgenic plants, below.
- nucleic acids of the invention can be used to confer desired traits on essentially any plant, e.g., on oil-seed containing plants, such as rice, soybeans, rapeseed, sunflower seeds, sesame and peanuts.
- Nucleic acids of the invention can be used to manipulate metabolic pathways of a plant in order to optimize or alter host's expression of phospholipase. The can change phospholipase activity in a plant.
- a phospholipase of the invention can be used in production of a transgenic plant to produce a compound not naturally produced by that plant. This can lower production costs or create a novel product.
- the first step in production of a transgenic plant involves making an expression construct for expression in a plant cell.
- These techniques are well known in the art. They can include selecting and cloning a promoter, a coding sequence for facilitating efficient binding of ribosomes to mRNA and selecting the appropriate gene terminator sequences.
- a constitutive promoter is CaMV35S, from the cauliflower mosaic virus, which generally results in a high degree of expression in plants. Other promoters are more specific and respond to cues in the plant's internal or external environment.
- An exemplary light-inducible promoter is the promoter from the cab gene, encoding the major chlorophyll a/b binding protein.
- the nucleic acid is modified to achieve greater expression in a plant cell.
- a sequence of the invention is likely to have a higher percentage of A- T nucleotide pairs compared to that seen in a plant, some of which prefer G-C nucleotide pairs. Therefore, A-T nucleotides in the coding sequence can be substituted with G-C nucleotides without significantly changing the amino acid sequence to enhance production of the gene product in plant cells.
- Selectable marker gene can be added to the gene construct in order to identify plant cells or tissues that have successfully integrated the transgene. This may be necessary because achieving incorporation and expression of genes in plant cells is a rare event, occurring in just a few percent of the targeted tissues or cells.
- Selectable marker genes encode proteins that provide resistance to agents that are normally toxic to plants, such as antibiotics or herbicides. Only plant cells that have integrated the selectable marker gene will survive when grown on a medium containing the appropriate antibiotic or herbicide. As for other inserted genes, marker genes also require promoter and termination sequences for proper function.
- making transgenic plants or seeds comprises incorporating sequences of the invention and, optionally, marker genes into a target expression construct (e.g., a plasmid), along with positioning of the promoter and the terminator sequences.
- a target expression construct e.g., a plasmid
- This can involve transferring the modified gene into the plant through a suitable method.
- a construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. For example, see, e.g., Christou (1997) Plant Mol. Biol. 35:197-203; Pawlowski (1996) Mol. Biotechnol.
- protoplasts can be immobilized and injected with nucleic acids, e.g., an expression construct.
- nucleic acids e.g., an expression construct.
- plant regeneration from protoplasts is not easy with cereals, plant regeneration is possible in legumes using somatic embryogenesis from protoplast derived callus.
- Organized tissues can be transformed with naked DNA using gene gun technique, where DNA is coated on tungsten microprojectiles, shot 1/lOOth the size of cells, which carry the DNA deep into cells and organelles. Transformed tissue is then induced to regenerate, usually by somatic embryogenesis. This technique has been successful in several cereal species including maize and rice.
- Nucleic acids can also be introduced in to plant cells using recombinant viruses.
- Plant cells can be transformed using viral vectors, such as, e.g., tobacco mosaic virus derived vectors (Rouwendal (1997) Plant Mol. Biol. 33:989- 999), see Porta (1996) "Use of viral replicons for the expression of genes in plants," Mol. Biotechnol. 5:209-221.
- nucleic acids e.g., an expression construct
- suitable T-DNA flanking regions can be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector.
- the virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.
- Agrobacterium tumefaciens-medi&ted transformation techniques including disarming and use of binary vectors, are well described in the scientific literature. See, e.g., Horsch (1984) Science 233:496-498;
- the DNA in an A. tumefaciens cell is contained in the bacterial chromosome as well as in another structure known as a Ti (tumor-inducing) plasmid.
- the Ti plasmid contains a stretch of DNA termed T-DNA (-20 kb long) that is transferred to the plant cell in the infection process and a series of vir (virulence) genes that direct the infection process.
- tumefaciens can only infect a plant through wounds: when a plant root or stem is wounded it gives off certain chemical signals, in response to which, the vir genes of A. tumefaciens become activated and direct a series of events necessary for the transfer of the T-DNA from the Ti plasmid to the plant's chromosome. The T-DNA then enters the plant cell through the wound.
- the T-DNA waits until the plant DNA is being replicated or transcribed, then inserts itself into the exposed plant DNA.
- A. tumefaciens as a transgene vector, the tumor-inducing section of T-DNA have to be removed, while retaining the T-DNA border regions and the vir genes. The transgene is then inserted between the T-DNA border regions, where it is transferred to the plant cell and becomes integrated into the plant's chromosomes.
- the invention provides for the transformation of monocotyledonous plants using the nucleic acids of the invention, including important cereals, see Hiei (1997) Plant Mol. Biol. 35:205-218. See also, e.g., Horsch, Science (1984) 233:496; Fraley (1983) Proc. Natl. Acad. Sci USA 80:4803; Thykjaer (1997) supra; Park (1996) Plant Mol. Biol. 32: 1135-1148, discussing T-DNA integration into genomic DNA. See also D'Halluin, U.S. Patent No. 5,712,135, describing a process for the stable integration of a DNA comprising a gene that is functional in a cell of a cereal, or other monocotyledonous plant.
- the third step can involve selection and regeneration of whole plants capable of transmitting the incorporated target gene to the next generation.
- Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker that has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture, pp. 124-176, MacMillilan Publishing Company, New York, 1983; and Binding, Regeneration of Plants, Plant Protoplasts, pp. 21-73, CRC Press, Boca Raton, 1985.
- Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee (1987) Ann. Rev. of Plant Phys. 38:467-486. To obtain whole plants from transgenic tissues such as immature embryos, they can be grown under controlled environmental conditions in a series of media containing nutrients and hormones, a process known as tissue culture. Once whole plants are generated and produce seed, evaluation of the progeny begins.
- the expression cassette After the expression cassette is stably incorporated in transgenic plants, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed. Since transgenic expression of the nucleic acids of the invention leads to phenotypic changes, plants comprising the recombinant nucleic acids of the invention can be sexually crossed with a second plant to obtain a final product. Thus, the seed of the invention can be derived from a cross between two transgenic plants of the invention, or a cross between a plant of the invention and another plant.
- the desired effects can be enhanced when both parental plants express the polypeptides (e.g., a phospholipase) of the invention.
- the desired effects can be passed to future plant generations by standard propagation means.
- Transgenic plants of the invention can be dicotyledonous or monocotyledonous.
- monocot transgenic plants of the invention are grasses, such as meadow grass (blue grass, Poa), forage grass such as festuca, lolium, temperate grass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).
- dicot transgenic plants of the invention are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism Arabidopsis thaliana.
- the transgenic plants and seeds of the invention include a broad range of plants, including, but not limited to, species from the genera Anacardium, Arachis, Asparagus, Atropa, Avena, Brassica, Citrus, Citrullus, Capsicum, Carthamus, Cocos, Coffea, Cucumis, Cucurbita, Daucus, Elaeis, Fragaria, Glycine, Gossypium, Helianthus, Heterocallis, Hordeum, Hyoscyamus, Lactuca, Linum, Lolium, Lupinus, Lycopersicon, Malus, Manihot, Majorana, Medicago, Nicotiana, Olea, Oryza, Panieum, Pannisetum, Persea, Phaseolus, Pistachia, Pisum, Pyrus, Prunus, Raphanus, Ricinus, Secale, Senecio, Sinapis, Solanum, Sorghum, Theobromus, Trigonella,
- the nucleic acids of the invention are expressed in plants (e.g., as transgenic plants), such as oil-seed containing plants, e.g., rice, soybeans, rapeseed, sunflower seeds, sesame and peanuts.
- the nucleic acids of the invention can be expressed in plants which contain fiber cells, including, e.g. , cotton, silk cotton tree (Kapok, Ceiba pentandra), desert willow, creosote bush, winterfat, balsa, ramie, kenaf, hemp, roselle, jute, sisal abaca and flax.
- the transgenic plants of the invention can be members of the genus Gossypium, including members of any Gossypium species, such as G. arboreum;. G. herbaceum, G. barbadense, and G.
- the invention also provides for transgenic plants to be used for producing large amounts of the polypeptides (e.g., a phospholipase or antibody) of the invention.
- a polypeptide or antibody e.g., a phospholipase or antibody
- transgenic plants of the invention can screen for plants of the invention by detecting the increase or decrease of transgene mRNA or protein in transgenic plants.
- Means for detecting and quantitation of mRNAs or proteins are well known in the art.
- the invention provides isolated, synthetic or recombinant polypeptides having a sequence identity (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, or complete (100%) sequence identity) to an exemplary sequence of the invention, e.g., SEQ ID NO:6 having one or more sequence changes (e.g., mutations) as set forth in Tables 12 to 15, as discussed in Example 3, below, or an enzymatically active fragment thereof.
- sequence identity
- the identity can be over the full length of the polypeptide, or, the identity can be over a subsequence thereof, e.g., a region of at least about 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700 or more residues.
- Polypeptides of the invention can also be shorter than the full length of exemplary polypeptides.
- the invention provides polypeptides (peptides, fragments) ranging in size between about 5 and the full length of a polypeptide, e.g., an enzyme, such as a phospholipase, e.g., phospholipase; exemplary sizes being of about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400 or more residues, e.g., contiguous residues of the exemplary phospholipases.
- Peptides of the invention can be useful as, e.g., labeling probes, antigens, toleragens, motifs, phospholipase active sites, binding domains, regulatory domains, and the like.
- the invention provides polypeptides having sequences as set forth in SEQ ID NO:6 comprising (and having) one or more amino acid residue changes (e.g., mutations) as set forth in Tables 12 to 15, and subsequences thereof, e.g., their active sites ("catalytic domains") having a phospholipase activity, e.g., a phospholipase C (PLC) activity, e.g., a PI-PLC activity.
- the polypeptide has a phospholipase activity but lacks neutral oil (triglyceride) hydrolysis activity.
- the polypeptide has a phospholipase activity but lacks any activity that affects a neutral oil (triglyceride) fraction.
- the invention provides a degumming process comprising use of a polypeptide of the invention having a phospholipase activity, but not a lipase activity.
- amino acid or “amino acid sequence” as used herein refer to an oligopeptide, peptide, polypeptide, or protein sequence, or to a fragment, portion, or subunit of any of these, and to naturally occurring or synthetic molecules.
- polypeptide and protein refer to amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids.
- polypeptide also includes peptides and polypeptide fragments, motifs and the like. The term also includes glycosylated polypeptides.
- the peptides and polypeptides of the invention also include all "mimetic” and “peptidomimetic” forms, as described in further detail, below.
- isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
- Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
- an isolated material or composition can also be a "purified" composition, i.e., it does not require absolute purity; rather, it is intended as a relative definition.
- Individual nucleic acids obtained from a library can be conventionally purified to electrophoretic homogeneity.
- the invention provides nucleic acids which have been purified from genomic DNA or from other sequences in a library or other environment by at least one, two, three, four, five or more orders of magnitude.
- Polypeptides and peptides of the invention can be isolated from natural sources, be synthetic, or be recombinantly generated polypeptides. Peptides and proteins can be recombinantly expressed in vitro or in vivo.
- the peptides and polypeptides of the invention can be made and isolated using any method known in the art. Polypeptide and peptides of the invention can also be synthesized, whole or in part, using chemical methods well known in the art. See e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser.
- peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.
- the peptides and polypeptides of the invention can also be glycosylated.
- the glycosylation can be added post-translationally either chemically or by cellular biosynthetic mechanisms, wherein the later incorporates the use of known glycosylation motifs, which can be native to the sequence or can be added as a peptide or added in the nucleic acid coding sequence.
- the glycosylation can be O-linked or N-linked.
- the peptides and polypeptides of the invention include all “mimetic” and “peptidomimetic” forms.
- the terms “mimetic” and “peptidomimetic” refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics of the polypeptides of the invention.
- the mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids.
- the mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic 's structure and/or activity.
- a mimetic composition is within the scope of the invention if it has a phospholipase activity.
- Polypeptide mimetic compositions of the invention can contain any combination of non-natural structural components.
- mimetic compositions of the invention include one or all of the following three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non- natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.
- a polypeptide of the invention can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds.
- Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, ⁇ , ⁇ '-dicyclohexylcarbodiimide (DCC) or N,N'-di-isopropylcarbodiimide (DIC).
- glutaraldehyde N-hydroxysuccinimide esters
- bifunctional maleimides ⁇ , ⁇ '-dicyclohexylcarbodiimide (DCC) or N,N'-di-isopropylcarbodiimide (DIC).
- DCC ⁇ , ⁇ '-dicyclohexylcarbodiimide
- DIC N,N'-di-isopropylcarbodiimide
- a polypeptide of the invention can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues.
- Non-natural residues are well described in the scientific and patent literature; a few exemplary non-natural compositions useful as mimetics of natural amino acid residues and guidelines are described below.
- Mimetics of aromatic amino acids can be generated by replacing by, e.g., D- or L- naphylalanine; D- or L- phenylglycine; D- or L- 2 thieneylalanine; D- or L-l, -2, 3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)-alanine; D- or L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)-phenylglycine; D-(trifluoromethyl)-phenylglycine; D- (trifluoromethyl)-phenylalanine; D-p-fluoro-phenylalanine; D- or L-p-biphenyl- phenylalanine; K- or L-p-methoxy-bipheny
- Aromatic rings of a non-natural amino acid include, e.g., thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.
- Mimetics of acidic amino acids can be generated by substitution by, e.g., non- carboxylate amino acids while maintaining a negative charge; (phosphono)alanine;
- Carboxyl side groups e.g., aspartyl or glutamyl
- Carboxyl side groups can also be selectively modified by reaction with carbodiimides (R'-N-C-N-R') such as, e.g., 1- cyclohexyl-3(2-morpholinyl-(4-ethyl) carbodiimide or l-ethyl-3(4-azonia- 4,4- dimetholpentyl) carbodiimide.
- Aspartyl or glutamyl can also be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
- Mimetics of basic amino acids can be generated by substitution with, e.g., (in addition to lysine and arginine) the amino acids ornithine, citrulline, or (guanidino)-acetic acid, or (guanidino)alkyl-acetic acid, where alkyl is defined above.
- Nitrile derivative e.g., containing the CN-moiety in place of COOH
- Asparaginyl and glutaminyl residues can be deaminated to the corresponding aspartyl or glutamyl residues.
- Arginine residue mimetics can be generated by reacting arginyl with, e.g., one or more
- Tyrosine residue mimetics can be generated by reacting tyrosyl with, e.g., aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitromethane can be used to form O- acetyl tyrosyl species and 3-nitro derivatives, respectively.
- Cysteine residue mimetics can be generated by reacting cysteinyl residues with, e.g., alpha-haloacetates such as 2- chloroacetic acid or chloroacetamide and corresponding amines; to give carboxymethyl or carboxyamidomethyl derivatives.
- alpha-haloacetates such as 2- chloroacetic acid or chloroacetamide and corresponding amines
- Cysteine residue mimetics can also be generated by reacting cysteinyl residues with, e.g., bromo-trifluoroacetone, alpha-bromo-beta-(5- imidozoyl) propionic acid; chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide; methyl 2-pyridyl disulfide; p-chloromercuribenzoate; 2-chloromercuri-4 nitrophenol; or, chloro-7-nitrobenzo-oxa-1,3-diazole.
- cysteinyl residues e.g., bromo-trifluoroacetone, alpha-bromo-beta-(5- imidozoyl) propionic acid
- chloroacetyl phosphate N-alkylmaleimides
- 3-nitro-2-pyridyl disulfide methyl 2-pyridyl disulfide
- Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysinyl with, e.g., succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino-containing residue mimetics can also be generated by reaction with imidoesters, such as methyl
- Mimetics of methionine can be generated by reaction with, e.g., methionine sulfoxide.
- Mimetics of proline include, e.g., pipecolic acid, thiazolidine carboxylic acid, 3- or 4- hydroxy proline, dehydroproline, 3- or 4-methylproline, or 3,3,- dimethylproline.
- Histidine residue mimetics can be generated by reacting histidyl with, e.g., diethylprocarbonate or para-bromophenacyl bromide.
- Other mimetics include, e.g., those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha-amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine; methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C-terminal carboxyl groups.
- a residue, e.g., an amino acid, of a polypeptide of the invention can also be replaced by an amino acid (or peptidomimetic residue) of the opposite chirality.
- any amino acid naturally occurring in the L-configuration (which can also be referred to as the R or S, depending upon the structure of the chemical entity) can be replaced with the amino acid of the same chemical structural type or a peptidomimetic, but of the opposite chirality, referred to as the D- amino acid, but also can be referred to as the R- or S- form.
- the invention also provides methods for modifying the polypeptides of the invention by either natural processes, such as post-translational processing (e.g., phosphorylation, acylation, etc), or by chemical modification techniques, and the resulting modified polypeptides. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also a given polypeptide may have many types of modifications.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, cross-linking cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma- carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pegylation, proteolytic processing,
- Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art since the early 1960's (Merrifield, R. B., J. Am. Chem. Soc, 85:2149-2154, 1963) (See also Stewart, J. M. and Young, J. D., Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, 111., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research
- FMOC peptide synthesizer By repeating such a process step, i.e., inverting and inserting the rod's and pin's tips into appropriate solutions, amino acids are built into desired peptides.
- a number of available FMOC peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431 ATM automated peptide synthesizer. Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.
- polypeptides having a phospholipase activity polypeptides having a phospholipase activity, nucleic acids encoding them, antibodies that bind them, peptides representing the enzyme's antigenic sites (epitopes) and active sites, regulatory and binding domains, and methods for making and using them.
- polypeptides of the invention have a phospholipase activity, or any combination of phospholipase activities, as described herein (e.g., a phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme activity, etc.).
- the phospholipases of the invention have activities that have been modified from those of the exemplary phospholipases described herein.
- phospholipase encompasses enzymes having any phospholipase activity, for example, cleaving a glycerolphosphate ester linkage
- the phospholipase activity of the invention can generate a water extractable phosphorylated base and a diglyceride.
- a phospholipase activity hydrolysis of glycerolphosphate ester linkages at high temperatures, low temperatures, alkaline pHs and at acidic pHs, cleaving a glycerolphosphate ester to generate a water extractable phosphorylated base and a diglyceride, cutting ester bonds of glycerin and phosphoric acid in phospholipids, and other activities, such as the ability to bind to and hydrolyze a substrate, such as an oil, e.g. a crude oil or a vegetable oil, substrate also including plant and animal phosphatidylcholines,
- the phospholipase activity can comprise a phospholipase C (PLC) activity; a PI-PLC activity, a
- phospholipase A (PLA) activity such as a phospholipase Al or phospholipase A2 activity
- a phospholipase B (PLB) activity such as a phospholipase Bl or phospholipase B2 activity, including lysophospholipase (LPL) activity and/or lysophospholipase- transacylase (LPTA) activity
- a phospholipase D (PLD) activity such as a phospholipase Dl or a phospholipase D2 activity
- a patatin activity or any combination thereof such as a phospholipase Al or phospholipase A2 activity
- the phospholipase activity can comprise hydrolysis of a glycoprotein, e.g., as a glycoprotein found in a potato tuber or any plant of the genus Solatium, e.g., Solatium tuberosum.
- the phospholipase activity can comprise a patatin enzymatic activity, such as a patatin esterase activity (see, e.g., Jimenez (2002)
- the phospholipase activity can comprise a lipid acyl hydrolase (LAH) activity.
- LAH lipid acyl hydrolase
- the PLC phospholipases of the invention utilize (e.g., catalyze hydrolysis of) a variety of phospholipid substrates including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and/or phosphatidic acid (PA) or a combination thereof.
- these enzymes can have varying degrees of activity on the lysophospholipid forms of these phospholipids.
- PLC enzymes of the invention may show a preference for
- the phosphatidylinositol PLC phospholipases of the invention utilize a variety of phospholipid substrates including phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid, or a combination thereof.
- these enzymes can have varying degrees of activity on the lysophospholipid forms of these phospholipids.
- phosphatidylinositol PLC enzymes of the invention may show a preference for phosphatidylinositol as a substrate.
- the phospholipase activity can comprise being specific for one or more specific substrates, e.g., an enzyme of the invention can have a specificity of action for PE and PC; PE an PI; PE and PS; PS and PC; PS and PI; PI and PC; PS, PI and PC; PE, PI and PC; PC, PE and PS; PE, PS and PI; or, PE, PS, PI and PC, or any combination thereof.
- an enzyme of the invention can have a specificity of action for PE and PC; PE an PI; PE and PS; PS and PC; PS and PI; PI and PC; PS, PI and PC; PC, PE and PS; PE, PS and PI; or, PE, PS, PI and PC, or any combination thereof.
- a phospholipase of the invention can have multifunctional activity, e.g., a combination of one or more of the enzyme activities described herein.
- a polypeptide of the invention is enzymatically active, but lacks a lipase activity or lacks any enzymatic activity that affects a neutral oil (triglyceride) fraction. It may be desirable to use such a polypeptide in a particular process, e.g., in a degumming process where it is important that the neutral oil fraction not be harmed (diminished, degraded, e.g., hydrolyzed).
- the invention provides a degumming process comprising use of a polypeptide of the invention having a phospholipase activity, but not a lipase activity.
- polypeptides of the invention having patatin enzyme activity can utilize a variety of phospholipid substrates including phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid, or a combination thereof.
- these enzymes can have varying degrees of activity on the lysophospholipid forms of these phospholipids.
- patatins of the invention are based on a conservation of amino acid sequence similarity.
- these enzymes display a diverse set of biochemical properties and may perform reactions characteristic of PLA1, PLA2, PLC, or PLD enzyme classes.
- polypeptides of the invention having PLD having PLD
- phospholipases of the invention can utilize a variety of phospholipid substrates including phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,
- these enzymes can have varying degrees of activity on the lysophospholipid forms of these phospholipids. In one aspect, these enzymes are useful for carrying out transesterification reactions to produce structured phospholipids.
- polypeptides of the invention have an activity comprising cleavage of a glycerolphosphate ester linkage, the ability to hydrolyze phosphate ester bonds, including patatin, lipid acyl hydrolase (LAH), phospholipase A, B, C and/or phospholipase D activity, or any combination thereof.
- a glycerolphosphate ester linkage including patatin, lipid acyl hydrolase (LAH), phospholipase A, B, C and/or phospholipase D activity, or any combination thereof.
- 1 enzyme unit is the quantity of an enzyme needed to cause a reaction to process 1 micromole of substance per minute under specified conditions.
- the invention provides polypeptides with and without signal sequences, and the signal sequences themselves (e.g., isolated signal sequence peptides).
- the invention includes fragments or subsequences of enzymes of the invention, e.g., peptides or polypeptides comprising or consisting of catalytic domains ("active sites"), binding sites, regulatory domains, epitopes, signal sequences, prepro domains, and the like.
- the invention also includes immobilized phospholipases, anti- phospholipase antibodies and fragments thereof.
- the invention includes
- heterocomplexes e.g., fusion proteins, heterodimers, etc., comprising the phospholipases of the invention.
- Determining peptides representing the enzyme's antigenic sites (epitopes), active sites, binding sites, signal sequences, and the like can be done by routine screening protocols.
- enzymes and processes of the invention can be used to achieve a more complete degumming of high phosphorus oils, in particular, rice, soybean, corn, canola, and sunflower oils.
- high phosphorus oils in particular, rice, soybean, corn, canola, and sunflower oils.
- phosphatidylinositol is converted to diacylglycerol and phosphoinositol.
- diacylglycerol partitions to the aqueous phase (improving oil yield) and the
- enzymes of the invention have phosphatidylinositol-specific phospholipase C (PI-PLC) activity, phosphatidylcholine-specific phospholipase C activity, phosphatidic acid phosphatase activity, phospholipase A activity and/or patatin- related phospholipase activity.
- PI-PLC phosphatidylinositol-specific phospholipase C
- phosphatidylcholine-specific phospholipase C activity phosphatidic acid phosphatase activity
- phospholipase A activity phospholipase A activity
- patatin- related phospholipase activity phosphatidylinositol-specific phospholipase C
- the invention provides methods wherein these enzymes (including phosphatidylinositol- specific phospholipase C (PIPLC), phosphatidylcholine-specific phospholipase C, and/or phospholipase D (in conjunction with a phosphatase), phosphatidic acid phosphatase, phospholipase A, patatin-related phospholipases of the invention) are used alone or in combination in the degumming of oils, e.g., vegetable oils, e.g., high phosphorus oils, such as soybean, corn, canola, rice bran and sunflower oils.
- oils e.g., vegetable oils, e.g., high phosphorus oils, such as soybean, corn, canola, rice bran and sunflower oils.
- the diacylglycerol partitions to the aqueous phase (improving oil yield) and the phosphoinositol partitions to the aqueous phase where it is removed as a component of the heavy phase during centrifugation.
- An enzyme of the invention e.g., a PI-PLC of the invention, can be incorporated into either a chemical or physical oil refining process.
- the invention provides compositions, e.g., solutions, comprising sodium citrate at neutral pH to hydrate non-hydratables.
- the invention provides sodium citrate solutions in a pH range of between about 4 to 9, or, 5 to 8, or, 6 to 7, that can be used to hydrate non-hydratable phospholipids (including enzymes of the invention) in high phosphorus oils.
- the hydration of non-hydratable phospholipids is by chelating the calcium and magnesium associated with the phospholipids, thereby allowing the formerly insoluble phospholipid salts to more readily partition in the aqueous phase.
- a phospholipase of the invention e.g., a
- phospholipase-specific phosphohydrolase of the invention or another phospholipase, will convert the phospholipid to diacylglycerol and a phosphate-ester.
- calcium and magnesium metal content are lowered upon addition of acid and caustic (see discussion on caustic processes).
- the enzymes of the invention are highly selective catalysts. As with other enzymes, they catalyze reactions with extraordinar stereo-, regio-, and chemo- selectivities that are unparalleled in conventional synthetic chemistry. Moreover, the enzymes of the invention are remarkably versatile. They can be tailored to function in organic solvents, operate at extreme pHs (for example, high pHs and low pHs) extreme temperatures (for example, high temperatures and low temperatures), extreme salinity levels (for example, high salinity and low salinity), and catalyze reactions with compounds that are structurally unrelated to their natural, physiological substrates. Enzymes of the invention can be designed to be reactive toward a wide range of natural and unnatural substrates, thus enabling the modification of virtually any organic lead compound.
- Enzymes of the invention can also be designed to be highly enantio- and regio-selective. The high degree of functional group specificity exhibited by these enzymes enables one to keep track of each reaction in a synthetic sequence leading to a new active compound. Enzymes of the invention can also be designed to catalyze many diverse reactions unrelated to their native physiological function in nature.
- the present invention exploits the unique catalytic properties of enzymes.
- biocatalysts i.e., purified or crude enzymes, non-living or living cells
- the present invention uses selected biocatalysts, i.e., the enzymes of the invention, and reaction conditions that are specific for functional groups that are present in many starting compounds.
- Each biocatalyst is specific for one functional group, or several related functional groups, and can react with many starting compounds containing this functional group.
- the biocatalytic reactions produce a population of derivatives from a single starting compound. These derivatives can be subjected to another round of biocatalytic reactions to produce a second population of derivative compounds. Thousands of variations of the original compound can be produced with each iteration of biocatalytic derivatization.
- the invention provides methods for identifying a single active PLC enzyme within a library, where the library is characterized by the series of biocatalytic reactions used to produce it, a so-called "biosynthetic history".
- One embodiment comprises screening the library for biological activities and tracing the biosynthetic history identifies the specific reaction sequence producing the active compound. The reaction sequence cah be repeated and the structure of the synthesized compound determined.
- an immobilization technology is not required; compounds can be synthesized and tested free in solution using virtually any type of screening assay.
- the high degree of specificity of enzyme reactions on functional groups allows for the "tracking" of specific enzymatic reactions that make up the biocatalytically produced library.
- the invention also provides methods of discovering new phospholipases using the nucleic acids, polypeptides and antibodies of the invention.
- lambda phage libraries are screened for expression-based discovery of phospholipases.
- Use of lambda phage libraries in screening allows detection of toxic clones; improved access to substrate; reduced need for engineering a host, by-passing the potential for any bias resulting from mass excision of the library; and, faster growth at low clone densities.
- Screening of lambda phage libraries can be in liquid phase or in solid phase. Screening in liquid phase gives greater flexibility in assay conditions; additional substrate flexibility; higher sensitivity for weak clones; and ease of automation over solid phase screening.
- procedural steps are performed using robotic automation; e.g., enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility (see discussion of arrays, below).
- robotic automation e.g., enabling the execution of many thousands of biocatalytic reactions and screening assays per day as well as ensuring a high level of accuracy and reproducibility (see discussion of arrays, below).
- a library of derivative compounds can be produced in a matter of weeks.
- the invention provides phospholipase signal sequences (e.g., signal peptides (SPs)), e.g., peptides comprising signal sequences and/or chimeric polypeptides, where the peptides or chimerics have a signal sequence as described herein.
- SPs signal peptides
- the invention provides nucleic acids encoding these signal sequences (SPs, e.g., a peptide having a sequence comprising/ consisting of amino terminal residues of a polypeptide of the invention).
- the invention provides a signal sequence comprising a peptide comprising/ consisting of a sequence as set forth in residues 1 to 20, 1 to 21, 1 to 22, 1 to 23, 1 to 24, 1 to 25, 1 to 26, 1 to 27, 1 to 28, 1 to 28, 1 to 30, 1 to 31, 1 to 32 or 1 to 33 of a polypeptide of the invention, e.g., a polypeptide comprising a sequence as set forth in SEQ ID NO: 6 and having one or more mutations as set forth in Tables 12 to 15, or an enzymatically active fragment thereof. Any of these peptides can be part of a chimeric protein, e.g., a recombinant protein.
- a signal sequence peptide can be matched with another enzyme of the invention (e.g., a phospholipase of the invention from which is was not derived), or, with another phospholipase, or with any polypeptide, as discussed further, below.
- another enzyme of the invention e.g., a phospholipase of the invention from which is was not derived
- another phospholipase or with any polypeptide, as discussed further, below.
- Exemplary signal sequences include residues 1 to 37 of SEQ ID NO:4 and residues 1 to 23 of SEQ ID NO:6.
- phospholipases of the invention do not have signal sequences.
- the invention provides the phospholipases of the invention lacking all or part of a signal sequence.
- the invention provides a nucleic acid sequence encoding a signal sequence from one phospholipase operably linked to a nucleic acid sequence of a different phospholipase or, optionally, a signal sequence from a non- phospholipase protein may be desired.
- Phospholipase prepro domains binding domains and catalytic domains
- the invention provides prepro domains, binding domains (e.g., substrate binding domain) and catalytic domains (CDs).
- the SP domains, binding domains, prepro domains and/or CDs of the invention can be isolated, synthetic or recombinant peptides or can be part of a fusion protein, e.g., as a heterologous domain in a chimeric protein.
- the invention provides nucleic acids encoding these catalytic domains (CDs) (e.g., "active sites"), prepro domains, binding domains and signal sequences (SPs, e.g., a peptide having a sequence comprising/ consisting of amino terminal residues of a polypeptide of the invention).
- CDs catalytic domains
- SPs signal sequences
- the phospholipase signal sequences (SPs) , binding domains, catalytic domains (CDs) and/or prepro sequences of the invention can be isolated peptides, or, sequences joined to another phospholipase or a non- phospholipase polypeptide, e.g., as a fusion (chimeric) protein.
- polypeptides comprising phospholipase signal sequences SPs and/or prepro of the invention comprise sequences heterologous to phospholipases of the invention (e.g., a fusion protein comprising an SP and/or prepro of the invention and sequences from another phospholipase or a non- phospholipase protein).
- the invention provides phospholipases of the invention with heterologous CDs, SPs and/or prepro sequences, e.g., sequences with a yeast signal sequence.
- a phospholipase of the invention can comprise a heterologous CD, SP and/or prepro in a vector, e.g., a pPIC series vector (Invitrogen, Carlsbad, CA).
- SPs, CDs, and/or prepro sequences of the invention are identified following identification of novel phospholipase polypeptides.
- the pathways by which proteins are sorted and transported to their proper cellular location are often referred to as protein targeting pathways.
- One of the most important elements in all of these targeting systems is a short amino acid sequence at the amino terminus of a newly synthesized polypeptide called the signal sequence. This signal sequence directs a protein to its appropriate location in the cell and is removed during transport or when the protein reaches its final destination.
- Most lysosomal, membrane, or secreted proteins have an amino-terminal signal sequence that marks them for translocation into the lumen of the endoplasmic reticulum.
- the signal sequences can vary in length from 13 to 45 or more amino acid residues.
- Various methods of recognition of signal sequences are known to those of skill in the art.
- novel hydrolase signal peptides are identified by a method referred to as SignalP.
- SignalP uses a combined neural network which recognizes both signal peptides and their cleavage sites.
- a phospholipase of the invention may not have SPs and/or prepro sequences, and/or catalytic domains (CDs).
- the invention provides phospholipases lacking all or part of an SP, a CD and/or a prepro domain.
- the invention provides a nucleic acid sequence encoding a signal sequence (SP), a CD and/or prepro from one phospholipase operably linked to a nucleic acid sequence of a different phospholipase or, optionally, a signal sequence (SPs), a CD and/or prepro domain from a non-phospholipase protein may be desired.
- the invention also provides isolated, synthetic or recombinant polypeptides comprising signal sequences (SPs), prepro domain and/or catalytic domains (CDs) of the invention and heterologous sequences.
- the heterologous sequences are sequences not naturally associated (e.g., to a phospholipase) with an SP, prepro domain and/or CD.
- the sequence to which the SP, prepro domain and/or CD are not naturally associated can be on the SP's, prepro domain and/or CD's amino terminal end, carboxy terminal end, and/or on both ends of the SP and/or CD.
- the invention provides an isolated, synthetic or recombinant polypeptide comprising (or consisting of) a polypeptide comprising a signal sequence (SP), prepro domain and/or catalytic domain (CD) of the invention with the proviso that it is not associated with any sequence to which it is naturally associated (e.g., phospholipase sequence).
- SP signal sequence
- CD catalytic domain
- the invention provides isolated, synthetic or recombinant nucleic acids encoding these polypeptides.
- the isolated, synthetic or recombinant nucleic acid of the invention comprises coding sequence for a signal sequence (SP), prepro domain and/or catalytic domain (CD) of the invention and a heterologous sequence (i.e., a sequence not naturally associated with the a signal sequence (SP), prepro domain and/or catalytic domain (CD) of the invention).
- the heterologous sequence can be on the 3' terminal end, 5' terminal end, and/or on both ends of the SP, prepro domain and/or CD coding sequence.
- the polypeptides of the invention include phospholipases in an active or inactive form.
- the polypeptides of the invention include proproteins before "maturation” or processing of prepro sequences, e.g., by a proprotein-processing enzyme, such as a proprotein convertase to generate an "active" mature protein.
- the polypeptides of the invention include phospholipases inactive for other reasons, e.g., before
- activation by a post-translational processing event, e.g., an endo- or exo-peptidase or proteinase action, a phosphorylation event, an amidation, a glycosylation, a de- glycosylation, a sulfation, a dimerization event, and/or the like.
- Methods for identifying "prepro" domain sequences, CDs, binding domains and signal sequences are routine and well known in the art, see, e.g., Van de Ven (1993) Crit. Rev. Oncog. 4(2): 115-136; yeast two-hybrid screenings for identifying protein-protein interactions, described e.g., by Miller (2004) Methods Mol. Biol.
- the protein is purified from the extracellular space and the N-terminal protein sequence is determined and compared to the unprocessed form.
- polypeptides of the invention can be formulated as a protein preparation into any liquid, solid, semi-solid or gel form.
- a protein preparation of the invention can comprise a formulation comprising a non-aqueous liquid composition, a cast solid, a powder, a lyophilized powder, a granular form, a particulate form, a compressed tablet, a pellet, a pill, a gel form, a hydrogel, a paste, an aerosol, a spray, a lotion or a slurry formulation.
- the polypeptides of the invention include all active forms, including active subsequences, e.g., catalytic domains (CDs) or active sites, of an enzyme of the invention.
- the invention provides catalytic domains or active sites as set forth below.
- the invention provides a peptide or polypeptide comprising or consisting of an active site domain as predicted through use of a database such as Pfam (which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein families, The Pfam protein families database, A. Bateman, E. Birney, L. Cerruti, R. Durbin, L. Etwiller, S.R. Eddy, S. Griffiths -Jones, K.L. Howe, M. Marshall, and E.L.L. Sonnhammer, Nucleic Acids Research, 30(l):276-280, 2002) or equivalent.
- Pfam which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein families
- the invention provides fusion of N-terminal or C-terminal subsequences of enzymes of the invention (e.g., signal sequences, prepro sequences) with other polypeptides, active proteins or protein fragments.
- enzymes of the invention e.g., signal sequences, prepro sequences
- the production of an enzyme of the invention may also be accomplished by expressing the enzyme as an inactive fusion protein that is later activated by a proteolytic cleavage event (using either an endogenous or exogenous protease activity, e.g. trypsin) that results in the separation of the fusion protein partner and the mature enzyme, e.g., phospholipase C enzyme.
- the fusion protein of the invention is expressed from a hybrid nucleotide construct that encodes a single open reading frame containing the following elements: the nucleotide sequence for the fusion protein, a linker sequence (defined as a nucleotide sequence that encodes a flexible amino acid sequence that joins two less flexible protein domains), protease cleavage recognition site, and the mature enzyme (e.g., any enzyme of the invention, e.g., a phospholipase) sequence.
- the linker sequence defined as a nucleotide sequence that encodes a flexible amino acid sequence that joins two less flexible protein domains
- protease cleavage recognition site e.g., any enzyme of the invention, e.g., a phospholipase
- the fusion protein can comprise a pectate lyase sequence, a xylanase sequence, a phosphatidic acid phosphatase sequence, or another sequence, e.g., a sequence that has previously been shown to be over-expressed in a host system of interest.
- any host system can be used (see discussion, above), for example, any bacteria, e.g., a gram positive bacteria, such as Bacillus, or a gram negative bacteria, such as E. coli, or any yeast, e.g., Pichia pastoris.
- the arrangement of the nucleotide sequences in the chimeric nucleotide construction can be determined based on the protein expression levels achieved with each fusion construct. Proceeding from the 5' end of the nucleotide construct to the 3' prime end of the construct, in one aspect, the nucleotide sequences is assembled as follows: Signal sequence/fusion protein/linker
- sequence/protease cleavage recognition site/ mature enzyme e.g., any enzyme of the invention, e.g., a phospholipase
- Signal sequence/pro sequence/mature enzyme/linker sequence/fusion protein e.g., any enzyme of the invention, e.g., a phospholipase
- the expression of enzyme e.g., any enzyme of the invention, e.g., a phospholipase
- as an inactive fusion protein may improve the overall expression of the enzyme's sequence, may reduce any potential toxicity associated with the overproduction of active enzyme and/or may increase the shelf life of enzyme prior to use because enzyme would be inactive until the fusion protein e.g. pectate lyase is separated from the enzyme, e.g., phospholipase protein.
- the invention provides specific formulations for the activation of phospholipase of the invention expressed as a fusion protein.
- the activation of the phospholipase activity initially expressed as an inactive fusion protein is accomplished using a proteolytic activity or potentially a proteolytic activity in combination with an amino-terminal or carboxyl-terminal peptidase. This activation event may be accomplished in a variety of ways and at variety of points in the manufacturing/storage process prior to application in oil degumming.
- Exemplary processes of the invention include: Cleavage by an endogenous activity expressed by the manufacturing host upon secretion of the fusion construct into the fermentation media; Cleavage by an endogenous protease activity that is activated or comes in contact with intracellularly expressed fusion construct upon rupture of the host cells; Passage of the crude or purified fusion construct over a column of immobilized protease activity to accomplish cleavage and enzyme (e.g., phospholipase of the invention, e.g., a phospholipase C) activation prior to enzyme formulation; Treatment of the crude or purified fusion construct with a soluble source of proteolytic activity; Activation of a phospholipase (e.g., a phospholipase of the invention, e.g., a phospholipase C) at the oil refinery using either a soluble or insoluble source of proteolytic activity immediately prior to use in the process; and/or, Activation of the phospholipa
- the peptides and polypeptides of the invention can also be glycosylated, for example, in one aspect, comprising at least one glycosylation site, e.g., an N-linked or O-linked glycosylation.
- the polypeptide can be glycosylated after being expressed in a P. pastoris or a S. pombe.
- the glycosylation can be added post-translationally either chemically or by cellular biosynthetic mechanisms, wherein the later incorporates the use of known glycosylation motifs, which can be native to the sequence or can be added as a peptide or added in the nucleic acid coding sequence.
- the invention provides isolated, synthetic or recombinant polypeptides (e.g., enzymes, antibodies) having a phospholipase activity, or any combination of phospholipase activities, and nucleic acids encoding them. Any of the many polypeptides (e.g., enzymes, antibodies) having a phospholipase activity, or any combination of phospholipase activities, and nucleic acids encoding them. Any of the many polypeptides (e.g., enzymes, antibodies) having a phospholipase activity, or any combination of phospholipase activities, and nucleic acids encoding them. Any of the many polypeptides (e.g., enzymes, antibodies) having a phospholipase activity, or any combination of phospholipase activities, and nucleic acids encoding them. Any of the many polypeptides (e.g., enzymes, antibodies) having a phospholipase activity, or any combination of phospholipa
- phospholipase activity assays known in the art can be used to determine if a polypeptide has a phospholipase activity and is within the scope of the invention. Routine protocols for determining phospholipase A, B, D and C, patatin and lipid acyl hydrolase activities, or lipase activity, are well known in the art.
- Exemplary activity assays include turbidity assays, methylumbelliferyl phosphocholine (fluorescent) assays, Amplex red (fluorescent) phospholipase assays, thin layer chromatography assays (TLC), cytolytic assays and p-nitrophenylphosphorylcholine assays.
- turbidity assays methylumbelliferyl phosphocholine (fluorescent) assays
- Amplex red (fluorescent) phospholipase assays assays
- TLC thin layer chromatography assays
- cytolytic assays cytolytic assays
- p-nitrophenylphosphorylcholine assays p-nitrophenylphosphorylcholine assays.
- the phospholipase activity can comprise a lipid acyl hydrolase (LAH) activity.
- LAH lipid acyl hydrolase
- Methylumbelliferyl (fluorescent) phosphocholine assays to determine phospholipase activity are described, e.g., in Goode (1997) "Evidence for cell surface and internal phospholipase activity in ascidian eggs,” Develop. Growth Differ. 39:655-660; Diaz (1999) "Direct fluorescence-based lipase activity assay," BioTechniques 27:696- 700.
- Amplex Red (fluorescent) Phospholipase Assays to determine phospholipase activity are available as kits, e.g., the detection of phosphatidylcholine- specific phospholipase using an Amplex Red phosphatidylcholine-specific phospholipase assay kit from Molecular Probes Inc. (Eugene, OR), according to manufacturer's instructions. Fluorescence is measured in a fluorescence microplate reader using excitation at 560 + 10 nm and fluorescence detection at 590 + 10 nm. The assay is sensitive at very low enzyme concentrations.
- Thin layer chromatography assays to determine phospholipase activity are described, e.g., in Reynolds (1991) Methods in Enzymol. 197:3-13; Taguchi (1975) "Phospholipase from Clostridium novyi type A.I,” Biochim. Biophys. Acta 409:75-85.
- Thin layer chromatography is a widely used technique for detection of phospholipase activity.
- Various modifications of this method have been used to extract the phospholipids from the aqueous assay mixtures. In some PLC assays the hydrolysis is stopped by addition of chloroform/methanol (2:1) to the reaction mixture.
- the unreacted starting material and the diacylglycerol are extracted into the organic phase and may be fractionated by TLC, while the head group product remains in the aqueous phase.
- radiolabeled substrates can be used (see, e.g., Reynolds (1991) Methods in Enzymol. 197:3-13).
- the ratios of products and reactants can be used to calculate the actual number of moles of substrate hydrolyzed per unit time. If all the components are extracted equally, any losses in the extraction will affect all components equally.
- This assay is based on enzymatic hydrolysis of the substrate analog p-nitrophenylphosphorylcholine to liberate a yellow chromogenic compound p-nitrophenol, detectable at 405 nm.
- This substrate is convenient for high- throughput screening.
- a cytolytic assay can detect phospholipases with cytolytic activity based on lysis of erythrocytes. Toxic phospholipases can interact with eukaryotic cell membranes and hydrolyze phosphatidylcholine and sphingomyelin, leading to cell lysis. See, e.g., Titball (1993) Microbiol. Rev. 57:347-366.
- the invention provides hybrid phospholipases and fusion proteins, including peptide libraries, comprising sequences of the invention.
- the peptide libraries of the invention can be used to isolate peptide modulators (e.g., activators or inhibitors) of targets, such as phospholipase substrates, receptors, enzymes.
- the peptide libraries of the invention can be used to identify formal binding partners of targets, such as ligands, e.g., cytokines, hormones and the like.
- the invention provides chimeric proteins comprising a signal sequence (SP) and/or catalytic domain (CD) of the invention and a heterologous sequence (see above).
- SP signal sequence
- CD catalytic domain
- the invention also provides methods for generating "improved" and hybrid phospholipases using the nucleic acids and polypeptides of the invention.
- the invention provides methods for generating enzymes that have activity, e.g., phospholipase activity (such as, e.g., phospholipase A, B, C or D activity, patatin esterase activity, cleavage of a glycerolphosphate ester linkage, cleavage of an ester linkage in a phospholipid in a vegetable oil) at extreme alkaline pHs and/or acidic pHs, high and low temperatures, osmotic conditions and the like.
- the invention provides methods for generating hybrid enzymes (e.g., hybrid phospholipases).
- the methods of the invention produce new hybrid polypeptides by utilizing cellular processes that integrate the sequence of a first polynucleotide such that resulting hybrid polynucleotides encode polypeptides demonstrating activities derived from the first biologically active polypeptides.
- the first polynucleotides can be an exemplary nucleic acid sequence encoding an exemplary phospholipase of the invention.
- the first nucleic acid can encode an enzyme from one organism that functions effectively under a particular environmental condition, e.g. high salinity. It can be "integrated" with an enzyme encoded by a second polynucleotide from a different organism that functions effectively under a different environmental condition, such as extremely high temperatures.
- a hybrid polynucleotide containing sequences from the first and second original polynucleotides may encode an enzyme that exhibits characteristics of both enzymes encoded by the original polynucleotides.
- the enzyme encoded by the hybrid polynucleotide may function effectively under environmental conditions shared by each of the enzymes encoded by the first and second polynucleotides, e.g., high salinity and extreme temperatures.
- a hybrid polypeptide resulting from this method of the invention may exhibit specialized enzyme activity not displayed in the original enzymes.
- the resulting hybrid polypeptide encoded by a hybrid polynucleotide can be screened for specialized activities obtained from each of the original enzymes, i.e. the type of bond on which the phospholipase acts and the temperature at which the phospholipase functions.
- the phospholipase may be screened to ascertain those chemical functionalities which distinguish the hybrid phospholipase from the original phospholipases, such as: (a) amide (peptide bonds), i.e., phospholipases; (b) ester bonds, i.e., phospholipases and lipases; (c) acetals, i.e., glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.
- amide (peptide bonds) i.e., phospholipases
- ester bonds i.e., phospholipases and lipases
- acetals i.e., glycosidases and, for example, the temperature, pH or salt concentration at which the hybrid polypeptide functions.
- Sources of the polynucleotides to be "integrated” with nucleic acids of the invention may be isolated from individual organisms ("isolates”), collections of organisms that have been grown in defined media (“enrichment cultures”), or, uncultivated organisms ("environmental samples”).
- isolated cultures collections of organisms that have been grown in defined media
- uncultivated organisms uncultivated organisms
- the use of a culture-independent approach to derive polynucleotides encoding novel bioactivities from environmental samples is most preferable since it allows one to access untapped resources of biodiversity.
- “Environmental libraries” are generated from environmental samples and represent the collective genomes of naturally occurring organisms archived in cloning vectors that can be propagated in suitable prokaryotic hosts.
- the libraries are not limited to the small fraction of prokaryotes that can be grown in pure culture. Additionally, a normalization of the environmental DNA present in these samples could allow more equal representation of the DNA from all of the species present in the original sample. This can dramatically increase the efficiency of finding interesting genes from minor constituents of the sample that may be under-represented by several orders of magnitude compared to the dominant species.
- gene libraries generated from one or more uncultivated microorganisms are screened for an activity of interest.
- Potential pathways encoding bioactive molecules of interest are first captured in prokaryotic cells in the form of gene expression libraries.
- Polynucleotides encoding activities of interest are isolated from such libraries and introduced into a host cell. The host cell is grown under conditions that promote recombination and/or reductive reassortment creating potentially active biomolecules with novel or enhanced activities.
- the microorganisms from which hybrid polynucleotides may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
- Polynucleotides may be isolated from environmental samples. Nucleic acid may be recovered without culturing of an organism or recovered from one or more cultured organisms.
- such microorganisms may be extremophiles, such as hyperthermophiles, psychrophiles, psychrotrophs, halophiles, barophiles and acidophiles.
- polynucleotides encoding phospholipase enzymes isolated from extremophilic microorganisms are used to make hybrid enzymes.
- Such enzymes may function at temperatures above 100°C in, e.g., terrestrial hot springs and deep sea thermal vents, at temperatures below 0°C in, e.g., arctic waters, in the saturated salt environment of, e.g., the Dead Sea, at pH values around 0 in, e.g., coal deposits and geothermal sulfur-rich springs, or at pH values greater than 11 in, e.g., sewage sludge.
- phospholipases cloned and expressed from extremophilic organisms can show high activity throughout a wide range of temperatures and pHs.
- Polynucleotides selected and isolated as described herein, including at least one nucleic acid of the invention, are introduced into a suitable host cell.
- a suitable host cell is any cell that is capable of promoting recombination and/or reductive reassortment.
- the selected polynucleotides can be in a vector that includes appropriate control sequences.
- the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or preferably, the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis et al., 1986).
- Exemplary appropriate hosts may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, such as bacterial cells, fungal cells, yeast cells, mammalian cells, insect cells, or plant cells.
- Exemplary bacterial cells include any species within the genera Escherichia, Bacillus, Streptomyces,
- Salmonella Pseudomonas and Staphylococcus, including, e.g., Escherichia coli, Lactococcus lactis, Bacillus subtilis, Bacillus cereus, Salmonella typhimurium,
- Exemplary fungal cells include any species of Aspergillus.
- Exemplary yeast cells include any species of Pichia, Saccharomyces,
- Schizosaccharomyces, or Schwanniomyces including Pichia pastoris, Saccharomyces cerevisiae, or Schizosaccharomyces pombe.
- Exemplary insect cells include any species of Spodoptera or Drosophila, including Drosophila S2 and Spodoptera Sf9.
- Exemplary animal cells include CHO, COS or Bowes melanoma or any mouse or human cell line. The selection of an appropriate host is within the abilities of those skilled in the art. The selection of an appropriate host for recombination and/or reductive reassortment or just for expression of recombinant protein is deemed to be within the scope of those skilled in the art from the teachings herein.
- Mammalian cell culture systems that can be employed for recombination and/or reductive reassortment or just for expression of recombinant protein include, e.g., the COS-7 lines of monkey kidney fibroblasts, described in "SV40- transformed simian cells support the replication of early SV40 mutants" (Gluzman, 1981), the C127, 3T3, CHO, HeLa and BHK cell lines.
- Mammalian expression vectors can comprise an origin of replication, a suitable promoter and enhancer, and necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites,
- DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required non- transcribed genetic elements.
- Host cells containing the polynucleotides of interest can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the clones which are identified as having the specified enzyme activity may then be sequenced to identify the
- polynucleotide sequence encoding an enzyme having the enhanced activity.
- the nucleic acids and methods of the present invention can be used to generate novel polynucleotides for biochemical pathways, e.g., pathways from one or more operons or gene clusters or portions thereof.
- biochemical pathways e.g., pathways from one or more operons or gene clusters or portions thereof.
- bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
- the genes are clustered, in structures referred to as "gene clusters,” on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
- a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Gene cluster DNA can be isolated from different organisms and ligated into vectors, particularly vectors containing expression regulatory sequences which can control and regulate the production of a detectable protein or protein-related array activity from the ligated gene clusters.
- vectors which have an exceptionally large capacity for exogenous DNA introduction are particularly appropriate for use with such gene clusters and are described by way of example herein to include the f-factor (or fertility factor) of E. coli.
- This f-factor of E. coli is a plasmid which affects high-frequency transfer of itself during conjugation and is ideal to achieve and stably propagate large DNA fragments, such as gene clusters from mixed microbial samples.
- “Fosmids,” cosmids or bacterial artificial chromosome (BAC) vectors can be used as cloning vectors. These are derived from E. coli f-factor which is able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library.” Cosmid vectors were originally designed to clone and propagate large segments of genomic DNA. Cloning into cosmid vectors is described in detail in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press (1989).
- the invention relates to a method for producing a biologically active hybrid polypeptide using a nucleic acid of the invention and screening the polypeptide for an activity (e.g., enhanced activity) by:
- a first polynucleotide e.g., a nucleic acid of the invention
- In vivo reassortment can be focused on "inter-molecular" processes collectively referred to as "recombination.” In bacteria it is generally viewed as a “RecA- dependent” phenomenon.
- the invention can rely on recombination processes of a host cell to recombine and re-assort sequences, or the cells' ability to mediate reductive processes to decrease the complexity of quasi-repeated sequences in the cell by deletion. This process of "reductive reassortment” occurs by an "intra-molecular", RecA- independent process.
- novel polynucleotides are generated by the process of reductive reassortment.
- the method involves the generation of constructs containing consecutive sequences (original encoding sequences), their insertion into an appropriate vector, and their subsequent introduction into an appropriate host cell.
- the reassortment of the individual molecular identities occurs by combinatorial processes between the consecutive sequences in the construct possessing regions of homology, or between quasi-repeated units.
- the reassortment process recombines and/or reduces the complexity and extent of the repeated sequences, and results in the production of novel molecular species.
- Various treatments may be applied to enhance the rate of reassortment. These could include treatment with ultra-violet light, or DNA damaging chemicals, and/or the use of host cell lines displaying enhanced levels of "genetic instability".
- the reassortment process may involve homologous recombination or the natural property of quasi-repeated sequences to direct their own evolution.
- Quadsi-repeated sequences play a role in genetic instability.
- Quasi-repeats are repeats that are not restricted to their original unit structure. Quasi- repeated units can be presented as an array of sequences in a construct; consecutive units of similar sequences. Once ligated, the junctions between the consecutive sequences become essentially invisible and the quasi-repetitive nature of the resulting construct is now continuous at the molecular level. The deletion process the cell performs to reduce the complexity of the resulting construct operates between the quasi -repeated sequences.
- the quasi-repeated units provide a practically limitless repertoire of templates upon which slippage events can occur.
- the constructs containing the quasi-repeats thus effectively provide sufficient molecular elasticity that deletion (and potentially insertion) events can occur virtually anywhere within the quasi-repetitive units.
- the quasi- repeated sequences are all ligated in the same orientation, for instance head to tail or vice versa, the cell cannot distinguish individual units. Consequently, the reductive process can occur throughout the sequences.
- the units are presented head to head, rather than head to tail, the inversion delineates the endpoints of the adjacent unit so that deletion formation will favor the loss of discrete units.
- the sequences to be reassorted are in the same orientation.
- Random orientation of quasi-repeated sequences will result in the loss of reassortment efficiency, while consistent orientation of the sequences will offer the highest efficiency. However, while having fewer of the contiguous sequences in the same orientation decreases the efficiency, it may still provide sufficient elasticity for the effective recovery of novel molecules. Constructs can be made with the quasi-repeated sequences in the same orientation to allow higher efficiency.
- Sequences can be assembled in a head to tail orientation using any of a variety of methods, including the following: a) Primers that include a poly-A head and poly-T tail which when made single- stranded would provide orientation can be utilized. This is accomplished by having the first few bases of the primers made from RNA and hence easily removed RNase H. b) Primers that include unique restriction cleavage sites can be utilized. Multiple sites, a battery of unique sequences, and repeated synthesis and ligation steps would be required, c) The inner few bases of the primer could be thiolated and an exonuclease used to produce properly tailed molecules.
- the recovery of the re-assorted sequences relies on the identification of cloning vectors with a reduced repetitive index (RI).
- the re-assorted encoding sequences can then be recovered by amplification.
- the products are re-cloned and expressed.
- the recovery of cloning vectors with reduced RI can be affected by: 1) The use of vectors only stably maintained when the construct is reduced in complexity. 2) The physical recovery of shortened vectors by physical procedures. In this case, the cloning vector would be recovered using standard plasmid isolation procedures and size fractionated on either an agarose gel, or column with a low molecular weight cut off utilizing standard procedures. 3) The recovery of vectors containing interrupted genes which can be selected when insert size decreases. 4) The use of direct selection techniques with an expression vector and the appropriate selection.
- Encoding sequences may demonstrate a high degree of homology and encode quite diverse protein products. These types of sequences are particularly useful in the present invention as quasi-repeats.
- nucleic acid sequences are derived from three (3) species, including a nucleic acid of the invention. Each sequence encodes a protein with a distinct set of properties, including an enzyme of the invention. Each of the sequences differs by a single or a few base pairs at a unique position in the sequence.
- the quasi-repeated sequences are separately or collectively amplified and ligated into random assemblies such that all possible permutations and combinations are available in the population of ligated molecules.
- the number of quasi-repeat units can be controlled by the assembly conditions.
- the average number of quasi-repeated units in a construct is defined as the repetitive index (RI).
- the constructs may, or may not be size fractionated on an agarose gel according to published protocols, inserted into a cloning vector, and transfected into an appropriate host cell.
- the cells are then propagated and "reductive reassortment" is effected.
- the rate of the reductive reassortment process may be stimulated by the introduction of DNA damage if desired.
- the reduction in RI is mediated by deletion formation between repeated sequences by an "intra-molecular” mechanism, or mediated by recombination- like events through “inter-molecular” mechanisms is immaterial. The end result is a reassortment of the molecules into all possible combinations.
- the method comprises the additional step of screening the library members of the shuffled pool to identify individual shuffled library members having the ability to bind or otherwise interact, or catalyze a particular reaction (e.g., such as catalytic domain of an enzyme) with a predetermined macromolecule, such as for example a proteinaceous receptor, an oligosaccharide, virion, or other
- polypeptides e.g., phospholipases
- phospholipases that are identified from such libraries can be used for various purposes, e.g., the industrial processes described herein and/or can be subjected to one or more additional cycles of shuffling and/or selection.
- polynucleotides generated by the method of the invention can be subjected to agents or processes which promote the introduction of mutations into the original polynucleotides.
- the introduction of such mutations would increase the diversity of resulting hybrid polynucleotides and polypeptides encoded therefrom.
- the agents or processes which promote mutagenesis can include, but are not limited to: (+)-CC-1065, or a synthetic analog such as (+)-CC-1065-(N3-Adenine (See Sun and Hurley, (1992); an N-acetylated or deacetylated 4'-fluro-4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See , for example, van de Poll et al. (1992)); or a N-acetylated or deacetylated 4-aminobiphenyl adduct capable of inhibiting DNA synthesis (See also, van de Poll et al. (1992), pp.
- trivalent chromium a trivalent chromium salt, a polycyclic aromatic hydrocarbon (PAH) DNA adduct capable of inhibiting DNA replication, such as 7-bromomethyl-benz[a] anthracene ("BMA”), tris(2,3-dibromopropyl)phosphate (“Tris- BP”), 1,2-dibromo-3-chloropropane (“DBCP”), 2-bromoacrolein (2BA), benzo[a]pyrene- 7,8-dihydrodiol-9-10-epoxide (“BPDE”), a platinum(II) halogen salt, N-hydroxy-2- amino-3-methylimidazo[4,5-f]-quinoline (“N-hydroxy-IQ”), and N-hydroxy-2-amino-1- methyl-6-phenylimidazo[4,5-f]-pyridine (“N-hydroxy-PhIP”).
- BMA 7-bromomethyl-benz[a] anthracene
- Especially preferred means for slowing or halting PCR amplification consist of UV light (+)-CC-1065 and (+)- CC-1065-(N3-Adenine).
- Particularly encompassed means are DNA adducts or polynucleotides comprising the DNA adducts from the polynucleotides or
- polynucleotides pool which can be released or removed by a process including heating the solution comprising the polynucleotides prior to further processing.
- a variety of apparatus and methodologies can be used to in conjunction with the polypeptides and nucleic acids of the invention, e.g., to screen polypeptides for phospholipase activity, to screen compounds as potential modulators of activity (e.g., potentiation or inhibition of enzyme activity), for antibodies that bind to a polypeptide of the invention, for nucleic acids that hybridize to a nucleic acid of the invention, and the like.
- the phospholipase enzymes, fragments thereof and nucleic acids that encode the enzymes and fragments can be affixed to a solid support. This is often economical and efficient in the use of the phospholipases in industrial processes. For example, a consortium or cocktail of phospholipase enzymes (or active fragments thereof), which are used in a specific chemical reaction, can be attached to a solid support and dunked into a process vat. The enzymatic reaction can occur. Then, the solid support can be taken out of the vat, along with the enzymes affixed thereto, for repeated use.
- an isolated nucleic acid of the invention is affixed to a solid support.
- the solid support is selected from the group of a gel, a resin, a polymer, a ceramic, a glass, a microelectrode and any combination thereof.
- solid supports useful in this invention include gels.
- Some examples of gels include Sepharose, gelatin, glutar aldehyde, chitosan-treated
- glutaraldehyde albumin-glutaraldehyde, chitosan-Xanthan, toyopearl gel (polymer gel), alginate, alginate-polylysine, carrageenan, agarose, glyoxyl agarose, magnetic agarose, dextran-agarose, poly(Carbamoyl Sulfonate) hydrogel, BSA-PEG hydrogel,
- PVA phosphorylated polyvinyl alcohol
- MVA monoaminoethyl-N-aminoethyl
- amino amino, or any combination thereof.
- resins or polymers include cellulose, acrylamide, nylon, rayon, polyester, anion-exchange resin, AMBERLITETM XAD-7, AMBERLITETM XAD- 8, AMBERLITETM IRA-94, AMBERLITETM IRC-50, polyvinyl, polyacrylic, polymethacrylate, or any combination thereof.
- Another type of solid support useful in the present invention is ceramic. Some examples include non-porous ceramic, porous ceramic, Si0 2 , AI2O 3 . Another type of solid support useful in the present invention is glass. Some examples include non- porous glass, porous glass, aminopropyl glass or any combination thereof. Another type of solid support that can be used is a microelectrode. An example is a polyethyleneimine- coated magnetite. Graphitic particles can be used as a solid support. Other exemplary solid supports used to practice the invention comprise diatomaceous earth products and silicates. Some examples include CELITE ® KENITE ® , DIACTIV ® , PRIMISIL ® , DIAFIL ® diatomites and MICRO-CEL ® , CALFLO ® ,
- SILASORBTM and CELKATE ® synthetic calcium and magnesium silicates.
- Another example of a solid support is a cell, such as a red blood cell.
- Capillary arrays such as the GIGAMATRIXTM, Diversa Corporation, San Diego, CA, can be used to in the methods of the invention.
- Nucleic acids or polypeptides of the invention can be immobilized to or applied to an array, including capillary arrays.
- Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention.
- Capillary arrays provide another system for holding and screening samples.
- a sample screening apparatus can include a plurality of capillaries formed into an array of adjacent capillaries, wherein each capillary comprises at least one wall defining a lumen for retaining a sample.
- the apparatus can further include interstitial material disposed between adjacent capillaries in the array, and one or more reference indicia formed within of the interstitial material.
- a capillary for screening a sample wherein the capillary is adapted for being bound in an array of capillaries, can include a first wall defining a lumen for retaining the sample, and a second wall formed of a filtering material, for filtering excitation energy provided to the lumen to excite the sample.
- a polypeptide or nucleic acid e.g., a ligand
- a first component into at least a portion of a capillary of a capillary array.
- Each capillary of the capillary array can comprise at least one wall defining a lumen for retaining the first component.
- An air bubble can be introduced into the capillary behind the first component.
- a second component can be introduced into the capillary, wherein the second component is separated from the first component by the air bubble.
- a sample of interest can be introduced as a first liquid labeled with a detectable particle into a capillary of a capillary array, wherein each capillary of the capillary array comprises at least one wall defining a lumen for retaining the first liquid and the detectable particle, and wherein the at least one wall is coated with a binding material for binding the detectable particle to the at least one wall.
- the method can further include removing the first liquid from the capillary tube, wherein the bound detectable particle is maintained within the capillary, and introducing a second liquid into the capillary tube.
- the capillary array can include a plurality of individual capillaries comprising at least one outer wall defining a lumen.
- the outer wall of the capillary can be one or more walls fused together.
- the wall can define a lumen that is cylindrical, square, hexagonal or any other geometric shape so long as the walls form a lumen for retention of a liquid or sample.
- the capillaries of the capillary array can be held together in close proximity to form a planar structure.
- the capillaries can be bound together, by being fused (e.g., where the capillaries are made of glass), glued, bonded, or clamped side-by-side.
- the capillary array can be formed of any number of individual capillaries, for example, a range from 100 to 4,000,000 capillaries.
- a capillary array can form a microtiter plate having about 100,000 or more individual capillaries bound together.
- Nucleic acids or polypeptides of the invention can be immobilized to or applied to an array.
- Arrays can be used to screen for or monitor libraries of compositions (e.g., small molecules, antibodies, nucleic acids, etc.) for their ability to bind to or modulate the activity of a nucleic acid or a polypeptide of the invention.
- a monitored parameter is transcript expression of a phospholipase gene.
- One or more, or, all the transcripts of a cell can be measured by hybridization of a sample comprising transcripts of the cell, or, nucleic acids representative of or complementary to transcripts of a cell, by hybridization to immobilized nucleic acids on an array, or "biochip.”
- array By using an “array” of nucleic acids on a microchip, some or all of the transcripts of a cell can be simultaneously quantified.
- arrays comprising genomic nucleic acid can also be used to determine the genotype of a newly engineered strain made by the methods of the invention.
- Polypeptide arrays can also be used to simultaneously quantify a plurality of proteins.
- the invention provides "arrays” or “microarrays” or
- biochips or “chips” comprising a plurality of target elements, wherein each target element can comprise a defined amount of one or more polypeptides (including antibodies) or nucleic acids immobilized onto a defined area of a substrate surface, and at least one nucleic acid and/or polypeptide is a nucleic acid and/or polypeptide of this invention.
- the present invention can be practiced with, or can comprise, any known "array,” also referred to as a "microarray” or “nucleic acid array” or “polypeptide array” or “antibody array” or “biochip,” or variation thereof.
- Arrays are generically a plurality of “spots” or “target elements,” each target element comprising a defined amount of one or more biological molecules, e.g., oligonucleotides, immobilized onto a defined area of a substrate surface for specific binding to a sample molecule, e.g., mRNA transcripts.
- any known array and/or method of making and using arrays can be incorporated in whole or in part, or variations thereof, as described, for example, in U.S. Patent Nos. 6,277,628; 6,277,489; 6,261,776; 6,258,606; 6,054,270 ; 6,048,695; 6,045,996; 6,022,963; 6,013,440; 5,965,452; 5,959,098; 5,856,174; 5,830,645; 5,770,456; 5,632,957; 5,556,752; 5,143,854; 5,807,522; 5,800,992; 5,744,305; 5,700,637; 5,556,752; 5,434,049; see also, e.g., WO 99/51773; WO 99/09217; WO 97/46313; WO 96/17958; see also, e.g., Johnston (1998) Curr. Biol. 8:R171
- the invention provides isolated, synthetic or recombinant antibodies that specifically bind to a phospholipase of the invention. These antibodies can be used to isolate, identify or quantify the phospholipases of the invention or related polypeptides. These antibodies can be used to inhibit the activity of an enzyme of the invention. These antibodies can be used to isolated polypeptides related to those of the invention, e.g., related phospholipase enzymes.
- an “antibody” of this invention can include a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or
- immunoglobulin genes capable of specifically binding an antigen or epitope, see, e.g. Fundamental Immunology, Third Edition, W.E. Paul, ed., Raven
- antibody includes antigen-binding portions, i.e., "antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a
- F(ab')2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains;
- the antibodies can be used in immunoprecipitation, staining (e.g., FACS), immunoaffinity columns, and the like.
- nucleic acid sequences encoding for specific antigens can be generated by immunization followed by isolation of polypeptide or nucleic acid, amplification or cloning and immobilization of polypeptide onto an array of the invention.
- the methods of the invention can be used to modify the structure of an antibody produced by a cell to be modified, e.g., an antibody's affinity can be increased or decreased.
- the ability to make or modify antibodies can be a phenotype engineered into a cell by the methods of the invention.
- Antibodies also can be generated in vitro, e.g., using recombinant antibody binding site expressing phage display libraries, in addition to the traditional in vivo methods using animals. See, e.g., Hoogenboom (1997) Trends Biotechnol. 15:62-70; Katz (1997) Annu. Rev. Biophys. Biomol. Struct. 26:27-45.
- the polypeptides can be used to generate antibodies which bind specifically to the polypeptides of the invention.
- the resulting antibodies may be used in immunoaffinity chromatography procedures to isolate or purify the polypeptide or to determine whether the polypeptide is present in a biological sample.
- a protein preparation such as an extract, or a biological sample is contacted with an antibody capable of specifically binding to one of the polypeptides of the invention.
- the antibody is attached to a solid support, such as a bead or other column matrix.
- the protein preparation is placed in contact with the antibody under conditions in which the antibody specifically binds to one of the polypeptides of the invention. After a wash to remove non-specifically bound proteins, the specifically bound polypeptides are eluted.
- binding may be determined using any of a variety of procedures familiar to those skilled in the art. For example, binding may be determined by labeling the antibody with a detectable label such as a fluorescent agent, an enzymatic label, or a radioisotope. Alternatively, binding of the antibody to the sample may be detected using a secondary antibody having such a detectable label thereon. Particular assays include ELISA assays, sandwich assays, radioimmunoassays, and Western Blots.
- Polyclonal antibodies generated against the polypeptides of the invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, for example, a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies which may bind to the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from cells expressing that polypeptide.
- any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique, the trioma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (see, e.g., Cole (1985) in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Techniques described for the production of single chain antibodies (see, e.g., U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to the polypeptides of the invention. Alternatively, transgenic mice may be used to express humanized antibodies to these polypeptides or fragments thereof.
- Antibodies generated against the polypeptides of the invention may be used in screening for similar polypeptides from other organisms and samples. In such techniques, polypeptides from the organism are contacted with the antibody and those polypeptides which specifically bind the antibody are detected. Any of the procedures described above may be used to detect antibody binding.
- kits comprising the compositions, e.g., nucleic acids, expression cassettes, vectors, cells, polypeptides (e.g., a kit having at least one phospholipase of the invention) and/or antibodies (e.g., a kit having at least one antibody of the invention.
- the kits can contain enzymes for the processing (the making of) biofuels, detergents, or for treating or processing foods, feeds, biomass, food or feed additives or nutritional supplements, and the like.
- the kits also can contain instructional material teaching the methodologies and industrial uses of the invention, as described herein.
- the invention provides many industrial uses and medical applications using polypeptides of the invention, e.g., a phospholipase and other enzymes of the invention, e.g., phospholipases A, B, C and D, patatins, including converting a non-hydratable phospholipid to a hydratable form, making biofuels and processing biomass, oil degumming, processing of oils from plants, fish, algae and the like, to name just a few applications.
- polypeptides of the invention e.g., a phospholipase and other enzymes of the invention, e.g., phospholipases A, B, C and D, patatins, including converting a non-hydratable phospholipid to a hydratable form, making biofuels and processing biomass, oil degumming, processing of oils from plants, fish, algae and the like, to name just a few applications.
- an enzymes can be added in a specific order, e.g., phospholipases with differing specificities are added in a specific order, for example, an enzyme with PC- and PE-hydrolyzing activity is added first (or two enzymes are added, one with PC-hydrolyzing activity and the other with PE-hydrolyzing activity), then an enzyme with PI-hydrolyzing activity (e.g., PLC or PI-PLC activity) is added, or any combination thereof.
- phospholipases with differing specificities are added in a specific order, for example, an enzyme with PC- and PE-hydrolyzing activity is added first (or two enzymes are added, one with PC-hydrolyzing activity and the other with PE-hydrolyzing activity), then an enzyme with PI-hydrolyzing activity (e.g., PLC or PI-PLC activity) is added, or any combination thereof.
- PI-hydrolyzing activity e.g., PLC or PI-PLC activity
- any or all of the methods of the invention can be used on a "process scale", e.g., an oil processes or refining on a scale from about 15,000; 25,000; 50,000; 75,000; or 100,000 lbs of refined oil/day up to about 1, 2, 3, 4, 5 or 6 or more million lbs refined oil/day.
- a “process scale” e.g., an oil processes or refining on a scale from about 15,000; 25,000; 50,000; 75,000; or 100,000 lbs of refined oil/day up to about 1, 2, 3, 4, 5 or 6 or more million lbs refined oil/day.
- phospholipases and methods of the invention can be used for the processing of fats and oils as described, e.g., in JP Patent Application
- Phospholipases of the invention can be used to process plant oils and
- phospholipids such as those derived from or isolated from rice bran, soy, canola, palm, cottonseed, corn, palm kernel, coconut, peanut, sesame, sunflower.
- Phospholipases of the invention can be used to process essential oils, e.g., those from fruit seed oils, e.g., grapeseed, apricot, borage, etc.
- Phospholipases of the invention can be used to process oils and phospholipids in different forms, including crude forms, degummed, gums, wash water, clay, silica, soapstock, and the like.
- the phospholipids of the invention can be used to process high phosphorus oils, fish oils, animal oils, plant oils, algae oils and the like.
- any time a phospholipase C can be used an alternative comprises use of a phospholipase D of the invention and a phosphatase (e.g., using a PLD/ phosphatase combination to improve yield in a high phosphorus oil, such as a soy bean oil).
- Phospholipases of the invention can be used to process and make various soaps.
- the phospholipids obtained by the methods provided herein include a variety of phospholipids, including, but not limited to phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS),
- PC phosphatidylcholine
- PE phosphatidylethanolamine
- PS phosphatidylserine
- PI phosphatidylinositol
- PA phosphatidic acid
- LPC lysophosphatidylcholine
- LPE lysophosphatidylethanolamine
- LPS lysophosphatidylserine
- lysophosphatidylinositol LPI
- LP A lysophosphatidic acid
- C choline
- E ethanolamine
- S serine
- I inositol
- the invention provides processes using enzyme(s) of the invention to make 1,3- diacylglycerol (1,3 DAG).
- a phospholipase C or phospholipase D plus a phosphatase generates 1,2-diacylglycerol; this improves oil yield during edible oil refining.
- a caustic neutralization step for example as a caustic refining aid
- 1,2-diacylglyceride (1,2-DAG) undergoes acyl migration and is converted to 1,3-DAG.
- 1,3-DAG possesses increased health benefits and therefore the use of PLC as a caustic refining aid produces an oil with increased nutritional value.
- the invention provides processes using enzyme(s) of the invention to make and process edible oils, including generation of edible oils with increased amounts of 1,3- DAG.
- Diacylglycerols are naturally occurring compounds found in many edible oils.
- a base e.g., the oil degumming process
- a base causes the isomerization of 1,2-DAG, produced by PLC, into 1,3-DAG which provides a nutritional health benefit over 1,2-DAG, e.g., the 1,3-DAG is burned as energy instead of being stored as fat (as is 1,2-DAG).
- the methods of the invention By adding the PLC at the front end of caustic refining process (and the acid and caustic subsequently), the methods of the invention generate an elevated level of 1,3-DAG (decreasing 1,2-DAG). Nutritionally, 1,3-DAG is better for you than 1,2-DAG.
- the invention comprises an oil degumming process using a PLC of the invention, whereby the final degummed oil product contains not less than 0.5%, 1.0%, 2.0% or 3.0% or more 1,3-DAG.
- the invention provides a process for making (through interesterification) a refined oil (e.g., a diacylglycerol oil), including edible oils, containing increased levels of 1,3-diacylglycerol (1,3-DAG), where a phospholipase, such as an enzyme of the invention, is "front-loaded” or added before addition of acid or caustic.
- a refined oil e.g., a diacylglycerol oil
- 1,3-DAG 1,3-diacylglycerol
- the generation by enzymatic hydrolysis of a DAG from a triglyceride generates by interesterification 1,3 DAG from 1,2 DAG.
- the 1,3 DAG-comprising edible oil shows different metabolic effects compared to conventional edible oils.
- the invention provides a process using an enzyme of the invention for making a food, e.g., a baked good, having increased levels of 1,3-DAG diacylglycerol and baked goods comprising diacylglycerol oils.
- a food e.g., a baked good
- the baked goods are cookies, cakes and similar baked goods.
- combination of enzymes that can be used in the methods of the invention, including the processing of edible oils include (where one, several or all of the enzymes in the combination comprise an enzyme of the instant invention):
- the enzymes of the invention can be used in various vegetable oil processing steps, such as in vegetable oil extraction, particularly, in the removal of "phospholipid gums" in a process called "oil degumming".
- processes of the invention can be used on a "process scale", e.g., on a scale from about 15,000; 25,000; 50,000; 75,000; or 100,000 lbs of refined oil/day up to about 1, 2, 3, 4, 5 or 6 or more million lbs refined oil/day.
- the invention provides oil degumming processes comprising use of a phospholipase of the invention, e.g., a PLC, e.g. a PI-PLC of the invention.
- the process further comprises addition of another phospholipase (which can also be a phospholipase of the invention), e.g., another PLC, a PLA, a PLB, a PLB or a patatin of the invention, or an enzyme (which can also be an enzyme of the invention) having a lysophospholipase-transacylase (LPT A) activity or lysophospholipase (LPL) activity and lysophospholipase-transacylase (LPT A), or a combination thereof, and/or a patatin- like phospholipase (which can also be an enzyme of the invention).
- LPT A lysophospholipase-transacylase
- LPL lysophospholipase
- LPL
- all enzymes are added together, or, alternatively, the enzymes are added in a specific order, e.g., PLC addition is followed by PLA and/or patatin addition; or, an enzyme or enzymes of the invention having PC and PE activity added first, then PI PLC added second.
- this process provides a yield improvement as a result of the phospholipase (e.g., PLC of the invention) treatment. In one aspect, this process provides an additional decrease of the phosphorus content of the oil as a result of the phospholipase (e.g., PLA of the invention) treatment.
- PLC phospholipase
- PLA phospholipase
- the invention provides processes comprising use of a phospholipase of the invention, e.g., a PLC or a PI-PLC of the invention, to reduce gum mass and increase neutral oil (triglyceride) gain through reduced oil entrapment.
- the invention provides processes comprising use of a phospholipase of the invention, e.g., a PLC of the invention, e.g., a PI-PLC of the invention, for increasing neutral oils and diacylglycerol (DAG) production to contribute to the oil phase.
- processes of the invention may comprise one or more other enzymes such as a protease, an amylase, a lipase, a cutinase, another phospholipase
- a carbohydrase including, e.g., an enzyme of the invention, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a lactase, and/or a peroxidase, or polypeptides with equivalent activity, or a combination thereof.
- the phospholipases of the invention can be used in various vegetable oil processing steps, such as in vegetable oil extraction, particularly, in the removal of "phospholipid gums" in a process called “oil degumming,” as described above.
- the invention provides methods for processing vegetable oils from various sources, such as rice bran, soybeans, rapeseed, peanuts and other nuts, sesame, sunflower, palm and corn.
- the methods can used in conjunction with processes based on extraction with as hexane, with subsequent refining of the crude extracts to edible oils, including use of the methods and enzymes of the invention.
- the first step in the refining sequence is the so-called “degumming" process, which serves to separate phosphatides by the addition of water.
- the material precipitated by degumming is separated and further processed to mixtures of lecithins.
- the commercial lecithins such as soybean lecithin and sunflower lecithin, are semi-solid or very viscous materials. They consist of a mixture of polar lipids, mainly phospholipids, and oil, mainly triglycerides.
- the phospholipases of the invention can be used in any "degumming" procedure, including water degumming, ALCON oil degumming (e.g., for soybeans), safinco degumming, "super degumming," UF degumming, TOP degumming, uni-degumming, dry degumming and ENZYMAXTM degumming. See, e.g., U.S. Patent Nos. 6,355,693; 6,162,623; 6,103,505; 6,001,640; 5,558,781; 5,264,367.
- Various "degumming" procedures incorporated by the methods of the invention are described in Bockisch, M.
- the phospholipases of the invention can be used in the industrial application of enzymatic degumming of triglyceride oils as described, e.g., in EP 513 709.
- phospholipases of the invention are used to treat vegetable oils, e.g., crude oils, such as rice bran, soy, canola, flower and the like. In one aspect, this improves the efficiency of the degumming process.
- the invention provides methods for enzymatic degumming under conditions of low water, e.g., in the range of between about 0.1 % to 20 % water, or, 0.5% to 10% water. In one aspect, this results in the improved separation of a heavy phase from the oil phase during centrifugation. The improved separation of these phases can result in more efficient removal of phospholipids from the oil, including both hydratable and nonhydratable oils. In one aspect, this can produce a gum fraction that contains less entrained neutral oil (triglycerides), thereby improving the overall yield of oil during the degumming process.
- phospholipases of the invention e.g., a polypeptide having PLC activity, e.g., a PI-PLC activity
- oils e.g., vegetable oils, including crude oils, such as rice bran, soy, canola, flower and the like
- phospholipases of the invention are used for diacylglycerol (DAG) production and to contribute to the oil phase.
- DAG diacylglycerol
- the phospholipases of the invention can be used in the industrial application of enzymatic degumming as described, e.g., in CA 1102795, which describes a method of isolating polar lipids from cereal lipids by the addition of at least 50% by weight of water. This method is a modified degumming in the sense that it utilizes the principle of adding water to a crude oil mixture.
- the invention provides enzymatic processes comprising use of phospholipases of the invention (e.g., a PLC, e.g., a PI-PLC) comprising hydrolysis of hydrated phospholipids in oil at a temperature of about 20°C to 40°C, at an alkaline pH, e.g., a pH of about pH 8 to pH 10, using a reaction time of about 3 to 10 minutes. This can result in less than 10 ppm final oil phosphorus levels.
- phospholipases of the invention e.g., a PLC, e.g., a PI-PLC
- the invention also provides enzymatic processes comprising use of phospholipases of the invention (e.g., a PI-PLC) comprising hydrolysis of hydratable and non-hydratable phospholipids in oil at a temperature of about 50°C to 60°C, at a pH slightly below neutral, e.g., of about pH 5 to pH 6.5, using a reaction time of about 30 to 60 minutes. This can result in less than 10 ppm final oil phosphorus levels.
- phospholipases of the invention e.g., a PI-PLC
- hydrolysis of hydratable and non-hydratable phospholipids in oil at a temperature of about 50°C to 60°C, at a pH slightly below neutral, e.g., of about pH 5 to pH 6.5, using a reaction time of about 30 to 60 minutes. This can result in less than 10 ppm final oil phosphorus levels.
- the invention provides enzymatic processes that utilize a phospholipase C enzyme to hydrolyze a glyceryl phosphoester bond and thereby enable the return of the diacylglyceride portion of phospholipids back to the oil, e.g., a vegetable, fish or algae oil (a "phospholipase C (PLC) caustic refining aid”); and, reduce the phospholipid content in a degumming step to levels low enough for high phosphorus oils to be physically refined (a "phospholipase C (PLC) degumming aid").
- PLC phospholipase C
- the two approaches can generate different values and have different target applications.
- a number of distinct steps compose the degumming process preceding the core bleaching and deodorization refining processes. These steps include heating, mixing, holding, separating and drying.
- the non hydratable phospholipids are then reacted and/or removed from the lipids.
- the method comprises a) mixing an aqueous acid with an edible oil to obtain an acidic mixture having pH of less than about 4; and b) mixing a base with the acidic mixture to obtain a reacted mixture having pH of about 6-9, wherein the mixing in steps a) and/or b) creates an emulsion that comprises an aqueous phase in average droplet size between about 15 ⁇ m to about 45 ⁇ m in size.
- mixing in steps a) and/or b) creates an emulsion that comprises at least about 60% of an aqueous phase by volume in droplet size between about 15 ⁇ m to about 45 ⁇ m in size, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the methods provided herein allow the non hydratable phospholipids within a lipid matrix to migrate to an oil-water interface.
- the mixing in steps a) and/or b) creates an emulsion that comprises an aqueous phase in average droplet size between about 15-40 ⁇ m, 15-35 ⁇ m, 17-40 ⁇ m, 20-40 ⁇ m, 20-30 ⁇ m, 25-30 ⁇ m, 25-40 ⁇ m, or 25-35 ⁇ m.
- the mixing in step a) creates an emulsion that comprises an aqueous phase in average droplet size between about 15-40 ⁇ m, 15-35 ⁇ m, 17-40 ⁇ m, 20-40 ⁇ m, 20-30 ⁇ m, 25-30 ⁇ m, 25-40 ⁇ m, or 25-35 ⁇ m.
- the mixing in step b) creates an emulsion that comprises an aqueous phase in average droplet size between about 15-40 ⁇ m, 15-35 ⁇ m, 17-40 ⁇ m, 20-40 ⁇ m, 20-30 ⁇ m, 25-30 ⁇ m, 25-40 ⁇ m, or 25- 35 ⁇ m.
- the average droplet size is about 15 ⁇ m, 17 ⁇ m, 19 ⁇ m, 20 ⁇ m, 22 ⁇ m, 25 ⁇ m, 27 ⁇ m, 30 ⁇ m, 35 ⁇ m, or 40 ⁇ m. In certain embodiments, the average droplet size is about 20 ⁇ m.
- the mixing in steps a) and/or b) creates an emulsion that comprises at least about 60% of the aqueous phase by volume in droplet size between about 20 ⁇ m to about 40 ⁇ m in size, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing steps creates an emulsion that comprises about 60-95%, 60-90%, 60-80%, 70-95%, 80-95% of the aqueous phase by volume in droplet size between about 20-40 ⁇ m, 20-35 ⁇ m, 25-40 ⁇ m, 30-40 ⁇ m, 35-40 ⁇ m, or 25-45 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in steps a) and/or b) creates an emulsion that comprises at least about 60, 70, 80, 90,93, 95, 96, 97, 98, or 99% of the aqueous phase by volume in droplet size between about 15-45 ⁇ m, 20- 40 ⁇ m, 20-45 ⁇ m, 25-40 ⁇ m, 20-35 ⁇ m, 30-40 ⁇ m, 35-40 ⁇ m, or 25-45 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in step a) creates an emulsion that comprises at least about 60, 70, 80, 90,93, 95, 96, 97, 98, or 99% of the aqueous phase by volume in droplet size between about 15-45 ⁇ m, 20-40 ⁇ m, 20-45 ⁇ m, 25-40 ⁇ m, 20-35 ⁇ m, 30-40 ⁇ m, 35- 40 ⁇ m, or 25-45 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in step b) creates an emulsion that comprises at least about 60, 70, 80, 90,93, 95, 96, 97, 98, or 99% of the aqueous phase by volume in droplet size between about 15-45 ⁇ m, 20-40 ⁇ m, 20-45 ⁇ m, 25-40 ⁇ m, 20-35 ⁇ m, 30-40 ⁇ m, 35-40 ⁇ m, or 25-45 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in steps a) and/or b) creates an emulsion that comprises at least about 10-30% of the aqueous phase by volume in droplet size less than about 10 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase. In certain embodiments, the mixing in steps a) and/or b) creates an emulsion that comprises at least about 20-25% of the aqueous phase by volume in droplet size less than about 10 ⁇ m, wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in steps a) and/or b) creates an emulsion that comprises at least about 60-95% of the aqueous phase by volume in droplet size greater than about 10 ⁇ , wherein percentage of the aqueous phase is based on the total volume of the aqueous phase. In certain embodiments, the mixing in steps a) and/or b) creates an emulsion that comprises at least about 70-80% of the aqueous phase by volume in droplet size greater than about 10 ⁇ , wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- the mixing in steps a) and/or b) creates an emulsion that comprises at least about 90% of the aqueous phase by volume in average droplet size of about 20 ⁇ , wherein percentage of the aqueous phase is based on the total volume of the aqueous phase.
- step a) the calcium, magnesium, and iron salts of phosphatidic acid and phosphatidyl ethanolamine dissociate.
- the free calcium, magnesium, and iron cations react with, for example, citrate, acetate or phosphate anions from the acid, to form metal salts.
- step b) the metal cations from the base, for example sodium or potassium ions, form complexes with the phosphatidic acid or the phosphatidyl ethanolamine.
- the method further comprises addition of water followed by a high shear mixing to form a mechanical emulsion. The emulsified phospholipids are then removed by chemical degumming or reacted in the enzymatic degumming.
- mixing comprises shearing and agitation.
- the mixing device is an overhead mixer, including an IKA RW 20 digital mixer with a flat blade paddle.
- the mixing device is operated at about 50 rpm, 100 rpm, 150 rpm or 200 rpm for normal agitation and about 250 rpm, 300 rpm, 350 rpm, 400 rpm or more for vigorous agitation.
- the shear mixing is accomplished with IKA's Ultra- Turrax homogenizer T-50 basic with a S 50 N - G 45 G dispersion element at 10,000 rpm.
- the mixer is a rotor/stator high shear mixer with tip speed (radial velocity in the mixer chamber) of at least about 1400 cm/s.
- the power dissipated by the mixer is at least 1.0 KW/metric ton of product/h.
- oil/water emulsions in industrial scale are obtained with tip speeds ranging from about 1400 cm/s to 2300 cm/s, or even higher.
- the tip speed is about 1400 cm/s, 1600 cm/s, 1800 cm/s, 2000 cm/s, 2100 cm/s, 2300 cm/s, 2500 cm/s, 3000 cm/s, or 3500 cm/s.
- the tip speed is about 2300 cm/s.
- the power dissipated by the mixer is from about 1.0 to about 2.0 KW/metric ton of product/h.
- the power dissipated by the mixer is about 2.0 KW/metric ton of product/h. In certain embodiments, for a continuous process, 10 KW of effective power dissipation in the high shear mixer is required for 10 metric ton of oil per hour.
- mixing of acid comprises shearing for less than about 1 minute. In certain embodiments, mixing of acid comprises shearing for about 1 second, 3 seconds, 5 seconds, 8 seconds, 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds or 60 seconds. In certain embodiments, mixing of acid comprises shearing for at least about 1 minute. In certain embodiments, mixing of acid comprises shearing for at least about 1 second up to about 10 minutes, at least about 1 second up to about 10 minutes, at least about 1 second up to about 7 minutes, at least about 1 second up to about 5 minutes, at least about 1 second up to about 3 minutes or at least about 1 second up to about 2 minutes. In certain embodiments, mixing of acid comprises shearing for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes.
- mixing of acid comprises shearing followed by agitation from about 1 minute up to about 5 hours.
- the acidic mixture is agitated for at least about 1 minute.
- agitation of acid is continued from about 10 minutes to about 5 hours or more.
- agitation of acid is continued from about 30 minutes to about 5 hours or more.
- agitation of acid is continued from about 30 minutes to about 3 hours or more.
- agitation of acid is continued from about 30 minute to about 2 hours or more.
- agitation of acid is continued for about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 150 or 180 minutes.
- the acid used in step a) is selected from the group consisting of phosphoric acid, acetic acid, citric acid, tartaric acid, succinic acid, and mixtures thereof. In one embodiment, the acid is citric acid.
- the pH of the acidic mixture in step a) is about 1 to about 4. In certain embodiments, the pH of the acidic mixture in step a) is about 1, 1.5, 2, 2.5, 3, 3.5 or 4. In certain embodiments, mixing of acid is continued till the calcium, magnesium, and iron salts of phosphatidic acid and phosphatidyl ethanolamine dissociate.
- the aqueous acid used in the method comprises at least about 5% by weight acid based on the combined weight of acid and water. In certain embodiments, the aqueous acid used in the method comprises at least about 5 up to about 90%, about 5 up to about 80%, about 5 up to about 70%, about 10 up to about 90%, about 20 up to about 60%, about 30 up to about 60%, or about 40 up to about 60% by weight acid based on the combined weight of acid and water. In certain embodiments, the aqueous acid used in the method comprises at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55,60, 70, 80, 85, 90% by weight acid based on the combined weight of acid and water.
- the aqueous acid used in the methods comprises at least about 5% by weight citric acid based on the combined weight of citric acid and water. In certain embodiments, the aqueous acid used in the methods comprises at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60% by weight citric acid based on the combined weight of citric acid and water. In certain embodiments, the aqueous acid used in the methods comprises at least about 40, 45, 50, 55 or 60% by weight citric acid based on the combined weight of citric acid and water. In one embodiment, the aqueous acid used in the method comprises about 50% by weight citric acid based on the combined weight of citric acid and water.
- the aqueous acid used in the methods comprises at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 85, 90% by weight phosphoric acid based on the combined weight of phosphoric acid and water.
- the aqueous acid is used in at least about 0.01% by weight based on total weight of the oil. In certain embodiments, the aqueous acid is used in at least about 0.05% by weight based on total weight of the oil. In certain
- the aqueous acid is used in at least about 0.01 up to about 10%, about 0.01 up to about 5%, about 0.05 up to about 5%, about 0.05 up to about 3%, about 0.05 up to about 2% or about 0.1 up to about 2% by weight based on total weight of the oil.
- the aqueous acid is used in about 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.5, 1, 2, 5, 7 or 10% by weight based on total weight of the oil.
- a base is mixed with the acidic mixture to obtain a reacted mixture having pH of about 6-9 at the aqueous phase.
- the mixing is continued to allow the non hydratable phospholipids within a lipid matrix to migrate to an oil-water interface.
- Any base deemed suitable by one of skill in the art can be used in step b).
- the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium silicate, sodium carbonate, calcium carbonate, and a combination thereof.
- the base is sodium hydroxide.
- the base is added as a dilute aqueous solution such that the base does not saponify any neutral oil.
- the base is added as about 0.1 up to about 8 M, about 1 up to about 4 M, about 1 up to about 3 M, or about 0.5 up to about 3 M aqueous solution. In certain embodiments, the base is added as about 0.1 M, 0.5 M, 1 M, 2 M, 3 M, 4 M, 5 M, 6 M, 7 M or 8 M aqueous solution. In one embodiment, the minimum amount of base to be used for the removal of the NHPs to be effective is such that the pH of the aqueous phase is raised to at least about 6. In certain embodiments, the amount of base used is sufficient to raise the pH of the aqueous phase to about 6, 6.5, 7, 7.5 or 8. In certain embodiments, mixing of base is continued for at least about 1 minute. In certain embodiments, mixing of base is continued from about 1 minute to about 5 hours or more. In certain embodiments, mixing of base is continued for about 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 120, 150 or 180 minutes.
- the methods provided herein can be conducted at any temperature deemed suitable by one of skill in the art.
- the temperature during the process is in the range from about 20 °C to about 100 °C, about 20 °C to about 90 °C, about 40 °C to about 80 °C, or about 40 °C to about 70 °C. In certain embodiments, the temperature during the process is about 20, 30, 40, 50 60, 70, 80, 90 or 100 °C.
- water is added after reaction with the base in an amount from about 0.1 to 5 % or more based on the total volume of the reaction mixture followed by a high shear mixing to form a mechanical emulsion enabling either phospholipids to be emulsified in the chemical degumming or reacted in the enzymatic degumming. In certain embodiments, water is then added in about 0.1, 0.5, 1, 2, 3, 4, 5% or more based on the total volume of the reaction mixture.
- provided herein is a method wherein hydration of NHPs is followed by enzymatic treatment to remove various phospholipids and lecithins.
- Such methods can be practiced on either crude or water-degummed oils.
- an oil degumming method comprises: a) mixing an aqueous acid with an edible oil to obtain an acidic mixture having pH of about 1 to 4; b) mixing a base with the acidic mixture to obtain a reacted mixture having pH of about 6-9; and c) degumming the reacted mixture with water or an enzyme to obtain a degummed oil, wherein the mixing in steps a) and/or b) is carried out with a high shear mixer.
- an enzyme can be added to the oil either separately or together. Enzymatic reaction parameters including temperature, pH, and enzyme concentration can be controlled to optimize the reaction for a particular enzyme combination in a particular oil system. Many varieties of enzymes and their equivalents are suitable for use in the methods provided herein, including the phospholipase A and phospholipase C families that are available commercially. Exemplary enzymes are described elsewhere herein.
- the different phospholipases used together in the enzymatic degumming step are mixed together before addition to the oil to be treated.
- the enzymes are added to the oil separately, either sequentially or simultaneously.
- the amount of enzyme used in the methods provided herein depends on the reaction conditions, the type of oil and the type of enzyme use. In certain embodiments, the amount is in the range from 10 to 20,000 units, from 20 to 10,000 units, from 50 to 5,000 units, or from 100 to 2,000 units, per 1 kg of the oil.
- provided herein is a method for removing NHPs, hydratable phospholipids, and lecithins (known collectively as "gums") from vegetable oils to produce a degummed oil or fat product that can be used for food production and/or nonfood applications.
- the degumming methods provided herein utilize water, various acids and/or various bases or a combination thereof.
- methods provided herein are useful for removal of salts of phosphatidic acid and phosphatidyl ethanolamine from vegetable oils.
- calcium and magnesium citrate salts are formed in step a). The methods provided herein eliminate the problems associated with equipment fouling due to deposition of calcium and magnesium citrate salts on post-reaction equipments. The calcium and magnesium citrate salts are soluble at the pH at which the enzymatic reaction and further processing is carried out in the methods provided herein.
- provided herein are methods for enhancing the reaction rate of a phospholipase used in an enzymatic degumming, such that the enzyme reaction has a duration of less than about six, five, four, three, two or one hour.
- the enhancement in the reaction rate is achieved by a high shear mixing of the reacted mixture of step b) to form a mechanical emulsion which is then reacted with the enzyme. It is yet another aspect, provides herein is a method for degumming a vegetable oil composition in which both hydratable and non-hydratable phospholipids can be treated in a single process, wherein an enzyme reaction is completed in less than about one hour.
- the oil comprises Neochloris oleoabundans oil
- oils that can be treated include but are not limited to the following: canola oil, castor oil, coconut oil, coriander oil, corn oil, cottonseed oil, hazelnut oil, hempseed oil, linseed oil, mango kernel oil, meadowfoam oil, neat's foot oil, olive oil, palm oil, palm kernel oil, palm olein, peanut oil, rapeseed oil, rice bran oil, safflower oil, sasanqua oil, soybean oil, sunflower seed oil, tall oil, tsubaki oil, and vegetable oil.
- the methods provided herein reduce the phospholipids content of an oil to less than about 30 ppm phosphorus, less than about 20 ppm phosphorus, less than about 15 ppm phosphorus, less than about 10 ppm phosphorus, less than about 7 ppm phosphorus, less than about 5 ppm phosphorus or less than about 3 ppm phosphorus. In certain embodiments, the methods provided herein reduce the phospholipids content of an oil to less than about 30 ppm phosphorus, less than about 20 ppm phosphorus, less than about 15 ppm phosphorus, less than about 10 ppm phosphorus, less than about 7 ppm phosphorus, less than about 5 ppm phosphorus or less than about 3 ppm phosphorus. In certain embodiments, the methods provided herein reduce the methods provided herein reduce the
- phospholipid content of an oil to about 10 ppm phosphorus, about 7 ppm phosphorus, about 5 ppm phosphorus or about 3 ppm phosphorus.
- the degummed oil can be separated from the gums, and subjected to further processing steps known in the art including bleaching or deodorizing, as may be necessary or desirable depending on the end use for which the degummed oil product is intended.
- phospholipids comprising:
- steps a) and/or b) mixing a base with the acidic mixture to obtain a reacted mixture having pH of about 6-9, wherein the mixing in steps a) and/or b) creates an emulsion that comprises at least about 60% of an aqueous phase by volume in droplet size between about 15 ⁇ m to about 45 ⁇ m in size;
- phosphorus levels are reduced low enough for physical refining.
- the separation process can result in potentially higher yield losses than caustic refining.
- degumming processes may generate waste products that may not be sold as commercial lecithin, see, e.g., Figure 2 for an exemplary degumming process for physically refined oils. Therefore, these processes have not achieved a significant share of the market and caustic refining processes continue to dominate the industry for rice bran, soy, canola and sunflower. Note however, that a phospholipase C enzyme employed in a special degumming process would decrease gum formation and return the diglyceride portion of the phospholipid back to the oil.
- the invention provides methods using a PI-PLC of the invention in the gum fraction.
- oil is added to the crude oil to create an emulsion that results in the movement of the phosphatidylcholine, phosphatidyl- ethanolamine and phosphatidylinositol into the aqueous phase (water degumming).
- these phospholipids are major components of the aqueous gum fraction.
- the phospholipids in the gum fraction can be treated with phospholipase C or phospholipase D plus phosphatase (or other combinations, noted below) to generate diacylglycerol (DAG) and a phosphate ester.
- DAG diacylglycerol
- the DAG can be extracted from the other gum components and treated with a lipase under conditions suitable for the transesterification of the DAG to produce a desired triacylglycerol (structured lipid).
- the majority of the 1,2-DAG can be converted to 1,3-DAG by increasing the pH of the gum following the PLC reaction, for example, by adding caustic.
- the 1,3-DAG can then be extracted from the gum and reacted with a lipase under the appropriate conditions to transesterify the 1,3-DAG at the sn2 position to create the desired structured triacylglycerol.
- the fatty acids used in the transesterification reaction could come from a variety of sources including the free fatty acids found in the crude oil.
- the phospholipids from water degumming are used in combination with a PLC of the invention to create structured lipids.
- the water-degummed oil can be exposed to a PLC and/or PLD (either or both can be enzymes of the invention) plus phosphatase or one of these combinations followed by PLA (can be an enzyme of the invention) to reduce the phosphorus to levels suitable for caustic or physical refining.
- combination of enzymes that can be used in the methods of the invention, including these degumming processes include (where one, several or all of the enzymes in the combination comprise an enzyme of the instant invention):
- the invention provides processes using phospholipases (including enzymes of the invention) in caustic refining, where the enzymes are used as caustic refining aids.
- a PLC or PLD and/or a phosphatase are used in the processes as adrop-in, either before, during, or after a caustic neutralization refining process (either continuous or batch refining).
- the amount of enzyme added may vary according to the process.
- the water level used in the process can be low, e.g., about 0.5 to 5%.
- caustic is be added to the process multiple times.
- the process may be performed at different temperatures (25°C to 70°C), with different acids orcaustics, and at varying pH (4-12).
- Concentrated solutions of caustic e.g., more concentrated than the industrial standard of 11%, to decrease mass of gum can be used.
- the concentrated solution of caustic is between about 12% and 50% concentrated, e.g., about 20%, 30%, 40%, 50%, or 60% or more concentrated.
- a phospholipase C enzyme of the invention hydrolyzes a phosphatide at a glyceryl phosphoester bond to generate a diglyceride and water-soluble phosphate compound.
- the hydrolyzed phosphatide moves to the aqueous phase, leaving the diglyceride in the oil phase, as illustrated in Figure 3.
- One objective of the PLC "Caustic Refining Aid” is to convert the phospholipid gums formed during neutralization into a diacylglyceride that will migrate back into the oil phase.
- one objective of the "PLC Degumming Aid” is to reduce the phospholipids in crude oil to a phosphorus equivalent of less than 10 parts per million (ppm).
- Acids that may be used in a caustic refining process include, but are not limited to, phosphoric, citric, ascorbic, sulfuric, fumaric, maleic, hydrochloric and/or acetic acids. Acids are used to hydrate non-hydratable phospholipids.
- Caustics that may be used include, but are not limited to, KOH- and NaOH. Caustics are used to neutralize free fatty acids.
- phospholipases or more particularly a PLC or a PLD and a phosphatase, are used for purification of phytosterols from the gum/soapstock.
- An alternate embodiment of the invention to add the phospholipase before caustic refining is to express the phospholipase in a plant.
- the phospholipase is added during crushing of the plant, seeds or other plant part.
- the phospholipase is added following crushing, but prior to refining (i.e. in holding vessels).
- phospholipase is added as a refining pre-treatment, either with or without acid.
- phospholipase during a caustic refining process.
- the levels of acid and caustic are varied depending on the level of phosphorus and the level of free fatty acids.
- broad temperature and pH ranges are used in the process, dependent upon the type of enzyme used.
- the phospholipase is added after caustic refining ( Figure 5).
- the phospholipase is added in an intense mixer or in a retention mixer, prior to separation.
- the phospholipase is added following the heat step.
- the phospholipase is added in the centrifugation step.
- the phospholipase is added to the soapstock.
- the phospholipase is added to the washwater.
- the phospholipase is added during the bleaching and/or deodorizing steps.
- a phospholipase e.g., a phospholipase C
- a phospholipase C enzyme of the invention will hydrolyze the phosphatide from both hydratable and non-hydratable phospholipids in neutralized crude and degummed oils before bleaching and deodorizing.
- Exemplary "caustic refining" processes of the invention are illustrated in Figure 4 and Figure 6.
- Figure 4 includes exemplary times, temperature and pHs for static mixer (30 to 60 min, 50 to 60°C, pH 5 to 6.5) and retention mixer (3 to 10 min, 20 to 40°C).
- the target enzyme can be applied as a drop-in product in the existing caustic neutralization process, as illustrated in Figure 4.
- any phospholipase including, e.g., a phospholipase of the invention, such as a PLC, PI-PLC, PLB, PLA and/or PLC, can be used in a crude oil degumming process, as described, e.g., in Bailey's Industrial Oil & Fat Products v.4 (ed. Y. H. Hui).
- Figure 7 and Figure 8 illustrate variations of methods of the invention where two or three centrifugation steps, respectively, are used in the process, which can be used to process any oil, e.g., a vegetable oil such as crude soy oil, as shown in the figure.
- the exemplary method of Figure 8 has a centrifugation step before caustic refining (in addition to a centrifugation step after caustic refining and before the water wash, and, after the water wash), while the exemplary method of Figure 7 does not have a centrifugation step before caustic refining.
- Figure 9 illustrates another exemplary variation of this process using acid treatment and having a centrifugation step before a degumming step; this exemplary process can be used to process any oil, e.g., a vegetable oil such as crude soy oil, as shown in the figure.
- a vegetable oil such as crude soy oil
- a phospholipase of the invention enables phosphorus to be removed to the low levels acceptable in physical refining.
- a PLC of the invention will hydrolyze the phosphatide from both hydratable and non-hydratable phospholipids in crude oils before bleaching and deodorizing.
- the target enzyme can be applied as a drop- in product in an existing degumming operation, see, e.g., Figure 5. Given sub-optimal mixing in commercial equipment, it is likely that acid will be required to bring the non- hydratable phospholipids in contact with the enzyme at the oil/water interface. Therefore, in one aspect, an acid-stable PLC of the invention is used.
- a PLC Degumming Aid process of the invention can eliminate losses in one, or all three, areas noted in Table 4. Losses associated in a PLC process can be estimated to be about 0.8% versus 5.2% on a mass basis due to removal of the phosphatide.
- Oils processed (e.g., "degummed") by the methods of the invention include plant oilseeds, e.g., soybean oil, rapeseed oil, rice bran oil and sunflower oil.
- the "PLC Caustic Refining Aid” of the invention can save 1.2% over existing caustic refining processes.
- the refining aid application addresses soy oil that has been degummed for lecithin and these are also excluded from the value/load calculations.
- Performance targets of the processes of the invention can vary according to the applications and more specifically to the point of enzyme addition, see Table 5.
- a phospholipase A can convert non-hydratable native phospholipids to a hydratable form.
- the enzyme is sensitive to heat. This may be desirable, since heating the oil can destroy the enzyme.
- the degumming reaction must be adjusted to pH 4-5 and 60°C to accommodate this enzyme. At 300 Units/kg oil saturation dosage, this exemplary process is successful at taking previously water-degummed oil phosphorus content down to ⁇ 10 ppm P. Advantages can be decreased H 2 0 content and resultant savings in usage, handling and waste.
- Table 6 lists exemplary applications for industrial uses for enzymes of the invention:
- the phospholipases of the invention can be used in any vegetable oil processing step.
- phospholipase enzymes of the invention can be used in place of PLA, e.g., phospholipase A2, in any vegetable oil processing step.
- Oils that are "processed” or “degummed” in the methods of the invention include soybean oils, rapeseed oils, corn oils, oil from palm kernels, canola oils, sunflower oils, sesame oils, peanut oils, rice bran oil and the like.
- the main products from this process include triglycerides.
- the amount of phospholipase employed is about 10-10,000 units, or, alternatively, about, 100-2,000 units, per 1 kg of crude oil.
- the enzyme treatment is conducted for 5 min to 10 hours at a temperature of 30°C to 90°C, or, alternatively, about, 40°C to 70°C.
- the conditions may vary depending on the optimum temperature of the enzyme.
- the amount of water added to dissolve the enzyme is 5-1,000 wt. parts per 100 wt. parts of crude oil, or, alternatively, about, 10 to 200 wt. parts per 100 wt. parts of crude oil.
- the enzyme liquid is separated with an appropriate means such as a centrifugal separator and the processed oil is obtained.
- Phosphorus-containing compounds produced by enzyme decomposition of gummy substances in such a process are practically all transferred into the aqueous phase and removed from the oil phase.
- the processed oil can be additionally washed with water or organic or inorganic acid such as, e.g., acetic acid, citric acid, phosphoric acid, succinic acid, and equivalent acids, or with salt solutions.
- the enzyme is bound to a filter or the enzyme is added to an oil prior to filtration or the enzyme is used to periodically clean filters.
- a phospholipase-mediated physical refining aid water and enzyme are added to crude oil (e.g., crude vegetable oil).
- crude oil e.g., crude vegetable oil
- a PLC or a PLD of the invention and a phosphatase are used in the process.
- the water level can be low, i.e. 0.5 - 5% and the process time should be short (less than 2 hours, or, less than 60 minutes, or, less than 30 minutes, or, less than 15 minutes, or, less than 5 minutes).
- the process can be run at different temperatures (25°C to 70°C), using different acids and/or caustics, at different pHs (e.g., 3-10).
- water degumming is performed first to collect lecithin by centrifugation and then PLC or PLC and PLA of the invention is added to remove non- hydratable phospholipids (the process should be performed under low water
- water degumming of crude oil to less than 10 ppm (edible oils) and subsequent physical refining (less than 50 ppm for biodiesel) is performed.
- an emulsifier is added and/or the crude oil is subjected to an intense mixer to promote mixing.
- an emulsion-breaker is added and/or the crude oil is heated to promote separation of the aqueous phase.
- an acid is added to promote hydration of non-hydratable phospholipids.
- phospholipases can be used to mediate purification of phytosterols from the
- the invention provides compositions and methods (which can comprise use of phospholipases of the invention) for oil degumming comprising using varying amounts of acid and base without making soapstock.
- acid including phosphoric and/or citric
- high phosphorus oils including soybean, canola, and sunflower.
- the pH of the aqueous phase can be raised using caustic addition: the amount of caustic added can create a favorable pH for enzyme activity but will not result in the formation of a significant soapstock fraction in the oil. Because a soapstock is not formed, the free fatty acids in the oil can be removed downstream, following the degumming step, during bleaching and deodorization.
- Enzymes of the invention are used to improve oil extraction and oil degumming (e.g., vegetable oils).
- oil degumming e.g., vegetable oils.
- a PLC of the invention and at least one plant cell wall degrader e.g., a cellulase, a hemicellulase or the like, to soften walls and increase yield at extraction
- plant cell wall degrader e.g., a cellulase, a hemicellulase or the like, to soften walls and increase yield at extraction
- a phospholipase C of the invention as well as other hydrolases (e.g., a cellulase, a hemicellulase, an esterase, a protease and/or a phosphatase) are used during the crushing steps associated with oil production (including but not limited to soybean, canola, sunflower, rice bran oil).
- oil production including but not limited to soybean, canola, sunflower, rice bran oil.
- the reduction in non-hydratable phospholipids may result from conversion of potentially non-hydratable phospholipids to diacylglycerol and corresponding phosphate-ester prior to complexation with calcium or magnesium.
- the overall reduction of phospholipids in the crude oil will result in improved yields during refining with the potential for eliminating the requirement for a separate degumming step prior to bleaching and deodorization.
- the invention provides processes using a phospholipase of the invention (e.g., a phospholipase-specific phosphohydrolase of the invention), or another phospholipase, in a modified "organic refining process," which can comprise addition of the enzyme (e.g., a PI-PLC) in a citric acid holding tank.
- a phospholipase of the invention e.g., a phospholipase-specific phosphohydrolase of the invention
- a modified "organic refining process” which can comprise addition of the enzyme (e.g., a PI-PLC) in a citric acid holding tank.
- the enzymes of the invention can be used in any oil processing method, e.g., degumming or equivalent processes.
- the enzymes of the invention can be used in processes as described in U.S. Patent Nos. 5,558,781; 5,264,367; 6,001,640.
- the process described in USPN 5,558,781 uses either phospholipase Al, A2 or B, essentially breaking down lecithin in the oil that behaves as an emulsifier.
- the enzymes and methods of the invention can be used in processes for the reduction of phosphorus -containing components in edible oils comprising a high amount of non-hydratable phosphorus by using of a phospholipase of the invention, e.g., a polypeptide having a phospholipase A and/or B activity, as described, e.g., in EP Patent Number: EP 0869167.
- the edible oil is a crude oil, a so-called "non- degummed oil.”
- the method treat a non-degummed oil, including pressed oils or extracted oils, or a mixture thereof, from, e.g., rapeseed, soybean, sesame, peanut, corn, rice bran or sunflower.
- the phosphatide content in a crude oil can vary from 0.5 to 3% w/w corresponding to a phosphorus content in the range of 200 to 1200 ppm, or, in the range of 250 to 1200 ppm.
- the crude oil can also contain small concentrations of carbohydrates, sugar compounds and metal/phosphatide acid complexes of Ca, Mg and Fe.
- the process comprises treatment of a phospholipid or lysophospholipid with the phospholipase of the invention so as to hydrolyze fatty acyl groups.
- the phospholipid or lysophospholipid comprises lecithin or lysolecithin.
- the edible oil has a phosphorus content from between about 50 to 250 ppm, and the process comprises treating the oil with a phospholipase of the invention so as to hydrolyze a major part of the phospholipid and separating an aqueous phase containing the hydrolyzed
- the methods provide for the production of an animal feed comprising mixing the phospholipase of the invention with feed substances and at least one phospholipid.
- the enzymes and methods of the invention can be used in processes of oil degumming as described, e.g., in WO 98/18912.
- the phospholipases of the invention can be used to reduce the content of phospholipid in an edible oil.
- the process can comprise treating the oil with a phospholipase of the invention to hydrolyze a major part of the phospholipid and separating an aqueous phase containing the hydrolyzed phospholipid from the oil.
- This process is applicable to the purification of any edible oil, which contains a phospholipid, e.g. vegetable oils, such as soybean oil, rice bran oil, rapeseed oil and sunflower oil, fish oils, algae and animal oils and the like.
- the vegetable oil Prior to the enzymatic treatment, the vegetable oil is preferably pretreated to remove slime (mucilage), e.g. by wet refining.
- the oil can contain between about 50 to 250 ppm, or between 50 to about 1500 ppm, or more, of phosphorus, as phospholipid at the start of the treatment with phospholipase, and the process of the invention can reduce this value to below between about 5 to 10 ppm.
- the enzymes of the invention can be used in processes as described in JP
- ORP Organic Refining Process
- the enzymes of the invention can be used in processes for the treatment of an oil or fat, animal or vegetal, raw, semi -processed or refined, comprising adding to such oil or fat at least one enzyme of the invention that allows hydrolyzing and/or depolymerizing the non-glyceridic compounds contained in the oil, as described, e.g., in EP Application number: 82870032.8.
- Exemplary methods of the invention for hydrolysis and/or depolymerization of non-glyceridic compounds in oils are:
- the quantity of enzyme(s) necessary to be added to oils and fats, according to this process, may range, depending on the enzymes and the products to be processed, from between about 5 to 400 ppm, or between about 20 to 400 ppm; e.g., 0.005 kg to 0.4 kg of enzyme for 1000 kg of oil or fat, and preferably from 5 to 100 ppm, i.e., from 0.005 to 0.1 kg of enzyme for 1000 kg of oil, these values being understood to be for concentrated enzymes, i.e., without diluent or solvent.
- Palm oil can be pre-treated before treatment with an enzyme of the invention.
- an enzyme of the invention For example, about 30 kg of raw palm oil is heated to +50°C. 1% solutions were prepared in distilled water with cellulases and pectinases. 600 g of each of these was added to aqueous solutions of the oil under strong agitation for a few minutes. The oil is then kept at +50°C under moderate agitation, for a total reaction time of two hours. Then, temperature is raised to +90°C to deactivate the enzymes and prepare the mixture for filtration and further processing. The oil is dried under vacuum and filtered with a filtering aid.
- the enzymes of the invention can be used in processes as described in EP patent EP 0 513 709 B2.
- the invention provides a process for the reduction of the content process for the reduction of the content of phosphorus-containing components in animal and vegetable oils by enzymatic decomposition using a phospholipase of the invention.
- predemucilaginated animal and vegetable oil with a phosphorus content of between about of 50 to 1500 ppm, or, between about 50 to 250 ppm is agitated with an organic carboxylic acid and the pH value of the resulting mixture set to between about pH 4 to pH 6, an enzyme solution which contains phospholipase A ⁇ , A 2 , or B of the invention is added to the mixture in a mixing vessel under turbulent stirring and with the formation of fine droplets, where an emulsion with 0.5 to 5 % by weight relative to the oil is formed, said emulsion being conducted through at least one subsequent reaction vessel under turbulent motion during a reaction time of 0.1 to 10 hours at temperatures in the range of 20 to 80° C and where the treated oil, after separation of the aqueous solution, has a phosphorus content under 5 ppm.
- the organic refining process is applicable to both crude and degummed oil.
- the process uses inline addition of an organic acid under controlled process conditions, in conjunction with conventional centrifugal separation.
- the water separated naturally from the vegetable oil phospholipids ("VOP") is recycled and reused.
- the total water usage can be substantially reduced as a result of the Organic Refining Process.
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 6,162,623.
- the invention provides an amphiphilic enzyme. It can be immobilized, e.g., by preparing an emulsion containing a continuous hydrophobic phase and a dispersed aqueous phase containing the enzyme and a carrier for the enzyme and removing water from the dispersed phase until this phase turns into solid enzyme coated particles.
- the enzyme can be a lipase.
- the immobilized lipase can be used for reactions catalyzed by lipase such as interesterification of mono-, di- or triglycerides, de- acidification of a triglyceride oil, or removal of phospholipids from a triglyceride oil when the lipase is a phospholipase.
- the aqueous phase may contain a fermentation liquid
- an edible triglyceride oil may be the hydrophobic phase
- carriers include sugars, starch, dextran, water soluble cellulose derivatives and fermentation residues. This exemplary method can be used to process triglycerides, diglycerides,
- the process for the removal of phospholipids from triglyceride oil comprising mixing a triglyceride oil containing phospholipids with a preparation containing a phospholipase of the invention; hydrolyzing the phospholipids to lysophospholipid; separating the hydrolyzed phospholipids from the oil, wherein the phospholipase is an immobilized phospholipase.
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 6,127,137.
- This exemplary method hydrolyzes both fatty acyl groups in intact phospholipid.
- the phospholipase of the invention used in this exemplary method has no lipase activity and is active at very low pH. These properties make it very suitable for use in oil degumming, as enzymatic and alkaline hydrolysis (saponification) of the oil can both be suppressed.
- the invention provides a process for hydrolyzing fatty acyl groups in a phospholipid or lysophospholipid comprising treating the phospholipid or
- the phospholipase of the invention has a temperature optimum at about 50°C, measured at pH 3 to pH 4 for 10 minutes, and a pH optimum of about pH 3, measured at 40°C for about 10 minutes.
- the phospholipid or lysophospholipid comprises lecithin or lysolecithin.
- an aqueous phase containing the hydrolyzed phospholipid is separated from the oil.
- the invention provides a process for removing phospholipid from an edible oil, comprising treating the oil at pH 1.5 to 3 with a dispersion of an aqueous solution of the phospholipase of the invention, and separating an aqueous phase containing the hydrolyzed phospholipid from the oil.
- the oil is treated to remove mucilage prior to the treatment with the phospholipase.
- the oil prior to the treatment with the phospholipase contains the phospholipid in an amount corresponding to 50 to 250 ppm of phosphorus.
- the treatment with phospholipase is done at 30°C to 45°C for 1 to 12 hours at a phospholipase dosage of 0.1 to 10 mg/1 in the presence of 0.5 to 5% of water.
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 6,025,171.
- enzymes of the invention are immobilized by preparing an emulsion containing a continuous hydrophobic phase, such as a triglyceride oil, and a dispersed aqueous phase containing an amphiphilic enzyme, such as lipase or a phospholipase of the invention, and carrier material that is partly dissolved and partly undissolved in the aqueous phase, and removing water from the aqueous phase until the phase turns into solid enzyme coated carrier particles.
- a continuous hydrophobic phase such as a triglyceride oil
- an amphiphilic enzyme such as lipase or a phospholipase of the invention
- the undissolved part of the carrier material may be a material that is insoluble in water and oil, or a water soluble material in undissolved form because the aqueous phase is already saturated with the water soluble material.
- the aqueous phase may be formed with a crude lipase fermentation liquid containing fermentation residues and biomass that can serve as carrier materials.
- Immobilized lipase is useful for ester re-arrangement and de-acidification in oils.
- the immobilized enzyme can be regenerated for a subsequent reaction by adding water to obtain partial dissolution of the carrier, and with the resultant enzyme and carrier-containing aqueous phase dispersed in a hydrophobic phase evaporating water to again form enzyme coated carrier particles.
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 6,143,545.
- This exemplary method is used for reducing the content of phosphorus containing components in an edible oil comprising a high amount of non-hydratable phosphorus content using a phospholipase of the invention.
- the method is used to reduce the content of phosphorus containing components in an edible oil having a non-hydratable phosphorus content of at least 50 ppm measured by pre-treating the edible oil, at 60°C, by addition of a solution comprising citric acid monohydrate in water (added water vs.
- the method also can comprise contacting an oil at a pH from about pH 5 to 8 with an aqueous solution of a
- phospholipase A or B of the invention e.g., PLA1, PLA2, or a PLB
- PLA1, PLA2, or a PLB phospholipase A or B of the invention
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 5,532,163.
- the invention provides processes for the refining of oil and fat by which phospholipids in the oil and fat to be treated can be decomposed and removed efficiently.
- the invention provides a process for the refining of oil and fat which comprises reacting, in an emulsion, the oil and fat with an enzyme of the invention, e.g., an enzyme having an activity to decompose glycerol-fatty acid ester bonds in glycerophospholipids (e.g., a PLA2 of the invention); and another process in which the enzyme-treated oil and fat is washed with water or an acidic aqueous solution.
- the acidic aqueous solution to be used in the washing step is a solution of at least one acid, e.g., citric acid, acetic acid, phosphoric acid and salts thereof.
- the emulsified condition is formed using 30 weight parts or more of water per 100 weight parts of the oil and fat. Since oil and fat can be purified without employing the conventional alkali refining step, generation of washing waste water and industrial waste can be reduced. In addition, the recovery yield of oil is improved because loss of neutral oil and fat due to their inclusion in these wastes does not occur in the inventive process.
- the invention provides a process for refining oil and fat containing about 100 to 10,000 ppm of phospholipids which comprises: reacting, in an emulsified condition, said oil and fat with an enzyme of the invention having activity to decompose glycerol-fatty acid ester bonds in glycerophospholipids.
- the invention provides processes for refining oil and fat containing about 100 to 10,000 ppm of phospholipids which comprises reacting, in an emulsified condition, oil and fat with an enzyme of the invention having activity to decompose glycerol-fatty acid ester bonds in glycerophospholipids; and subsequently washing the treated oil and fat with a washing water.
- the phospholipases and methods of the invention can also be used in the enzymatic treatment of edible oils, as described, e.g., in U.S. Patent No. 5,264,367.
- the content of phosphorus-containing components and the iron content of an edible vegetable or animal oil, such as an oil, e.g., soybean oil, which has been wet-refined to remove mucilage, are reduced by enzymatic decomposition by contacting the oil with an aqueous solution of an enzyme of the invention, e.g., a phospholipase Al, A2, or B, and then separating the aqueous phase from the treated oil.
- an enzyme of the invention e.g., a phospholipase Al, A2, or B
- the invention provides an enzymatic method for decreasing the content of phosphorus- and iron-containing components in oils, which have been refined to remove mucilage.
- An oil, which has been refined to remove mucilage can be treated with an enzyme of the invention, e.g., phospholipase C, Al, A2, or B.
- Phosphorus contents below 5 ppm and iron contents below 1 ppm can be achieved.
- the low iron content can be advantageous for the stability of the oil.
- the phospholipases and methods of the invention can also be used for preparing transesterified oils, as described, e.g., in U.S. Patent No. 5,288,619.
- the invention provides methods for enzymatic transesterification for preparing a margarine oil having both low trans- acid and low intermediate chain fatty acid content.
- the method includes the steps of providing a transesterification reaction mixture containing a stearic acid source material and an edible liquid vegetable oil, transesterifying the stearic acid source material and the vegetable oil using a 1-, 3- positionally specific lipase, and then finally hydrogenating the fatty acid mixture to provide a recycle stearic acid source material for a recyclic reaction with the vegetable oil.
- the invention also provides a counter- current method for preparing a transesterified oil.
- the method includes the steps of providing a transesterification reaction zone containing a 1-, 3-positionally specific lipase, introducing a vegetable oil into the transesterification zone, introducing a stearic acid source material, conducting a supercritical gas or subcritical liquefied gas counter- current fluid, carrying out a transesterification reaction of the triglyceride stream with the stearic acid or stearic acid monoester stream in the reaction zone, withdrawing a transesterified triglyceride margarine oil stream, withdrawing a counter-current fluid phase,
- the highly unsaturated phospholipid compound may be converted into a triglyceride by appropriate use of a phospholipase C of the invention to remove the phosphate group in the sn-3 position, followed by 1,3 lipase acyl ester synthesis.
- the 2- substituted phospholipid may be used as a functional food ingredient directly, or may be subsequently selectively hydrolyzed in reactor 160 using an immobilized phospholipase C of the invention to produce a 1- diglyceride, followed by enzymatic esterification as described herein to produce a triglyceride product having a 2-substituted polyunsaturated fatty acid component.
- the phospholipases and methods of the invention can also be used in a vegetable oil enzymatic degumming process as described, e.g., in U.S. Patent No. 6,001,640.
- This method of the invention comprises a degumming step in the production of edible oils. Vegetable oils from which hydratable phosphatides have been eliminated by a previous aqueous degumming process are freed from non- hydratable phosphatides by enzymatic treatment using a phospholipase of the invention. The process can be gentle, economical and environment-friendly. Phospholipases that only hydrolyze lysolecithin, but not lecithin, are used in this degumming process.
- both phases, the oil phase and the aqueous phase that contain the enzyme must be intimately mixed. It may not be sufficient to merely stir them.
- Good dispersion of the enzyme in the oil is aided if it is dissolved in a small amount of water, e.g., 0.5-5 weight- (relative to the oil), and emulsified in the oil in this form, to form droplets of less than 10 micrometers in diameter (weight average).
- the droplets can be smaller than 1 micrometer.
- Turbulent stirring can be done with radial velocities above 100 cm/sec.
- the oil also can be circulated in the reactor using an external rotary pump.
- the aqueous phase containing the enzyme can also be finely dispersed by means of ultrasound action.
- a dispersion apparatus can be used.
- the enzymatic reaction probably takes place at the border surface between the oil phase and the aqueous phase. It is the goal of all these measures for mixing to create the greatest possible surface for the aqueous phase which contains the enzyme.
- the addition of surfactants increases the microdispersion of the aqueous phase. In some cases, therefore, surfactants with HLB values above 9, such as Na-dodecyl sulfate, are added to the enzyme solution, as described, e.g., in EP-A 0 513 709.
- a similar effective method for improving emulsification is the addition of lysolecithin.
- the amounts added can lie in the range of 0.001% to 1%, with reference to the oil.
- the temperature during enzyme treatment is not critical.
- Temperatures between 20°C and 80°C can be used, but the latter can only be applied for a short time.
- a phospholipase of the invention having a good temperature and/or low pH tolerance is used.
- Application temperatures of between 30°C and 50°C are optimal.
- the treatment period depends on the temperature and can be kept shorter with an increasing temperature. Times of 0.1 to 10 hours, or, 1 to 5 hours are generally sufficient.
- the reaction takes place in a degumming reactor, which can be divided into stages, as described, e.g., in DE-A 43 39 556. Therefore continuous operation is possible, along with batch operation.
- the reaction can be carried out in different temperature stages. For example, incubation can take place for 3 hours at 40°C, then for 1 hour at 60°C.
- the reaction proceeds in stages, this also opens up the possibility of adjusting different pH values in the individual stages.
- the pH of the solution can be adjusted to 7, for example, and in a second stage to 2.5, by adding citric acid.
- the pH of the enzyme solution must be below 4, or, below 3. If the pH was subsequently adjusted below this level, a deterioration of effect may be found. Therefore the citric acid can be added to the enzyme solution before the latter is mixed into the oil.
- the enzyme solution After completion of the enzyme treatment, the enzyme solution, together with the decomposition products of the NHP contained in it, can be separated from the oil phase, in batches or continuously, e.g., by means of centrifugation. Since the enzymes are characterized by a high level of stability and the amount of the decomposition products contained in the solution is slight (they may precipitate as sludge) the same aqueous enzyme phase can be used several times. There is also the possibility of freeing the enzyme of the sludge, see, e.g., DE-A 43 39 556, so that an enzyme solution which is essentially free of sludge can be used again. In one aspect of this degumming process, oils which contain less than 15 ppm phosphorus are obtained.
- One goal is phosphorus contents of less than 10 ppm; or, less than 5 ppm. With phosphorus contents below 10 ppm, further processing of the oil according to the process of distillative de-acidification is easily possible. A number of other ions, such as magnesium, calcium, zinc, as well as iron, can be removed from the oil, e.g., below 0.1 ppm. Thus, this product possesses ideal prerequisites for good oxidation resistance during further processing and storage.
- the phospholipases and methods of the invention also can also be used for reducing the amount of phosphorus-containing components in vegetable and animal oils as described, e.g., in EP patent EP 0513709.
- the content of phosphorus- containing components, especially phosphatides, such as lecithin, and the iron content in vegetable and animal oils, which have previously been deslimed, e.g. soya oil are reduced by enzymatic breakdown using a phospholipase Al, A2 or B of the invention.
- the phospholipases and methods of the invention can also be used for refining fat or oils as described, e.g., in JP 06306386.
- the invention provides processes for refining a fat or oil comprising a step of converting a phospholipid in a fat or an oil into a water- soluble phosphoric-group-containing substance and removing this substance.
- the action of an enzyme of the invention e.g., a PI-PLC
- gummy substances are converted into water-soluble substances and removed as water- soluble substances by adding an enzyme of the invention having a phospholipase C activity in the stage of degumming the crude oil and conducting enzymatic treatment.
- the phospholipase C of the invention has an activity that cuts ester bonds of glycerin and phosphoric acid in phospholipids.
- the method can comprise washing the enzyme-treated oil with water or an acidic aqueous solution.
- the enzyme of the invention is added to and reacted with the crude oil.
- the amount of phospholipase C employed can be 10 to 10,000 units, or, about 100 to 2,000 units, per 1 kg of crude oil.
- the phospholipases and methods of the invention can also be used for water- degumming processes as described, e.g., in Dijkstra, Albert J., et al., Oleagineux, Corporation Gras, Lipides (1998), 5(5), 367-370.
- the water-degumming process is used for the production of lecithin and for dry degumming processes using a degumming acid and bleaching earth.
- This method may be economically feasible only for oils with a low phosphatide content, e.g., palm oil, lauric oils, etc.
- the acid refining process is used, whereby this process is carried out at the oil mill to allow gum disposal via the meal.
- this acid refined oil is a possible "polishing" operation to be carried out prior to physical refining.
- the phospholipases and methods of the invention can also be used for degumming processes as described, e.g., in Dijkstra, et al., Res. Dev. Dep., N.V. Vandemoortele Coord. Cent, Izegem, Belg. JAOCS, J. Am. Oil Chem. Soc. (1989), 66:1002-1009.
- the total degumming process involves dispersing an acid such as H 3 PO 4 or citric acid into soybean oil, allowing a contact time, and then mixing a base such as caustic soda or Na silicate into the acid-in-oil emulsion. This keeps the degree of neutralization low enough to avoid forming soaps, because that would lead to increased oil loss.
- the oil passed to a centrifugal separator where most of the gums are removed from the oil stream to yield a gum phase with minimal oil content.
- the oil stream is then passed to a second centrifugal separator to remove all remaining gums to yield a dilute gum phase, which is recycled. Washing and drying or in-line alkali refining complete the process. After the adoption of the total degumming process, in comparison with the classical alkali refining process, an overall yield improvement of about 0.5% is realized.
- the totally degummed oil can be subsequently alkali refined, bleached and deodorized, or bleached and physically refined.
- the phospholipases and methods of the invention can also be used for the removal of nonhydratable phospholipids from a plant oil, e.g., soybean oil, as described, e.g., in Hvolby, et al., Sojakagefabr., Copenhagen, Den., J. Amer. Oil Chem. Soc. (1971) 48:503- 509.
- a plant oil e.g., soybean oil
- water-degummed oil is mixed at different fixed pH values with buffer solutions with and without Ca ++ , Mg/Ca-binding reagents, and surfactants.
- the nonhydratable phospholipids can be removed in a noncon verted state as a component of micelles or of mixed emulsifiers.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- General Preparation And Processing Of Foods (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Edible Oils And Fats (AREA)
- Hematology (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201205803A UA109884C2 (en) | 2009-10-16 | 2010-08-10 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD |
CN201080057899.0A CN102712671B (en) | 2009-10-16 | 2010-10-08 | Phospholipase, the nucleic acid encoding it and preparation and their method of use |
EP10823862.7A EP2488542B1 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
EA201200593A EA022979B1 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
CA2777699A CA2777699C (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
MX2012004469A MX339648B (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them. |
US13/502,069 US9394529B2 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
IN3226DEN2012 IN2012DN03226A (en) | 2009-10-16 | 2010-10-08 | |
ES10823862.7T ES2590037T3 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids that encode them and methods to obtain and use them |
BR112012008957A BR112012008957A2 (en) | 2009-10-16 | 2010-10-08 | phospholipases, nucleic acids encoding them and methods for making and using them |
US15/163,795 US10487316B2 (en) | 2009-10-16 | 2016-05-25 | Phospholipases, nucleic acids encoding them and methods for making and using them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25231309P | 2009-10-16 | 2009-10-16 | |
US61/252,313 | 2009-10-16 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/502,069 A-371-Of-International US9394529B2 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
US15/163,795 Continuation US10487316B2 (en) | 2009-10-16 | 2016-05-25 | Phospholipases, nucleic acids encoding them and methods for making and using them |
US15/163,795 Division US10487316B2 (en) | 2009-10-16 | 2016-05-25 | Phospholipases, nucleic acids encoding them and methods for making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011046812A1 true WO2011046812A1 (en) | 2011-04-21 |
Family
ID=43876450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/051903 WO2011046812A1 (en) | 2009-10-16 | 2010-10-08 | Phospholipases, nucleic acids encoding them and methods for making and using them |
Country Status (13)
Country | Link |
---|---|
US (2) | US9394529B2 (en) |
EP (1) | EP2488542B1 (en) |
CN (1) | CN102712671B (en) |
AR (2) | AR078583A1 (en) |
BR (1) | BR112012008957A2 (en) |
CA (2) | CA3185815A1 (en) |
EA (1) | EA022979B1 (en) |
ES (1) | ES2590037T3 (en) |
IN (1) | IN2012DN03226A (en) |
MX (1) | MX339648B (en) |
PL (1) | PL2488542T3 (en) |
UA (1) | UA109884C2 (en) |
WO (1) | WO2011046812A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160000436A (en) * | 2014-06-24 | 2016-01-04 | 한국생명공학연구원 | Method for producing lysophosphatidylethanolamine 18:1 from microorganisms |
US20170058235A1 (en) * | 2014-05-15 | 2017-03-02 | Novozymes A/S | Compositions Comprising Polypeptides Having Phospholipase C Activity and Use Thereof |
WO2017142904A1 (en) | 2016-02-19 | 2017-08-24 | Basf Se | Baking lipases |
WO2018200464A1 (en) | 2017-04-25 | 2018-11-01 | Bunge Oils, Inc. | Process for enzymatic degumming |
EP3325630A4 (en) * | 2015-07-17 | 2019-01-02 | Keclon S.A. | Compositions and methods for oil degumming |
WO2019063614A1 (en) | 2017-09-26 | 2019-04-04 | Bunge Global Innovation, Llc. | Enzymatic removal of chlorophyll substrates from triacylglycerol-based oils |
WO2019081976A2 (en) | 2017-10-25 | 2019-05-02 | Basf Se | Beta-amylase enzymes |
WO2019206994A1 (en) | 2018-04-26 | 2019-10-31 | Basf Se | Lipase enzymes |
WO2019211143A1 (en) | 2018-05-03 | 2019-11-07 | Basf Se | Amylase enzymes |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
WO2020135658A1 (en) * | 2018-12-28 | 2020-07-02 | 丰益(上海)生物技术研发中心有限公司 | Polypeptide having phospholipase c activity and use thereof |
WO2020169564A1 (en) | 2019-02-20 | 2020-08-27 | Basf Se | Industrial fermentation process for bacillus using defined medium and trace element feed |
WO2020169563A1 (en) | 2019-02-20 | 2020-08-27 | Basf Se | Industrial fermentation process for bacillus using defined medium and magnesium feed |
WO2020185737A1 (en) | 2019-03-11 | 2020-09-17 | Basf Se | Amylases and methods for making and using them |
WO2020193532A1 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Cleaning composition having amylase enzymes |
WO2020193535A2 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Amylase enzymes |
WO2020198212A1 (en) | 2019-03-27 | 2020-10-01 | Bunge Global Innovation, Llc | Silica adsorbent treatment for removal of chlorophyll derivatives from triacylglycerol-based oils |
WO2020193534A2 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Amylase enzymes |
WO2020249546A1 (en) | 2019-06-13 | 2020-12-17 | Basf Se | Method of recovering a protein from fermentation broth using a divalent cation |
WO2021004830A1 (en) | 2019-07-05 | 2021-01-14 | Basf Se | Industrial fermentation process for microbial cells using a fed-batch pre-culture |
WO2021032881A1 (en) | 2019-08-22 | 2021-02-25 | Basf Se | Amylase variants |
CN113215130A (en) * | 2021-05-11 | 2021-08-06 | 集美大学 | Phospholipase C mutant, preparation method and application thereof |
CN113508782A (en) * | 2021-07-27 | 2021-10-19 | 中国热带农业科学院热带作物品种资源研究所 | A feeding method capable of converting phytol into phytanic acid at higher ratio in ruminant rumen |
US11162086B2 (en) | 2017-05-12 | 2021-11-02 | Basf Se | Lipase enzymes |
WO2022006711A1 (en) * | 2020-07-06 | 2022-01-13 | Kemin Industries, Inc. | Method for the preparation of lysophosphatidylinositol |
EP4163354A2 (en) | 2014-03-19 | 2023-04-12 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
WO2023135541A1 (en) * | 2022-01-14 | 2023-07-20 | Keclon Sa | Mutated phospholipase c enzyme |
WO2023208768A1 (en) | 2022-04-26 | 2023-11-02 | Dsm Ip Assets B.V. | Method of producing cannabis distillate |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
DE102010055159A1 (en) * | 2010-12-18 | 2012-06-21 | Lurgi Gmbh | Process for the enzymatic purification of oils of vegetable or animal origin |
KR101272874B1 (en) * | 2011-11-17 | 2013-06-11 | 수도권매립지관리공사 | a method for hard float oils in food rubbish waste water |
CN102629304B (en) * | 2012-04-05 | 2015-02-04 | 天津大学 | Genome scale metabolic network model-based metabolic engineering design prediction method |
US9850512B2 (en) | 2013-03-15 | 2017-12-26 | The Research Foundation For The State University Of New York | Hydrolysis of cellulosic fines in primary clarified sludge of paper mills and the addition of a surfactant to increase the yield |
NZ718144A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
BR112016004437A2 (en) | 2013-09-13 | 2017-10-17 | Genentech Inc | immunotest and cell line selection methods, antibodies and kit |
CN104513838A (en) * | 2013-09-29 | 2015-04-15 | 丰益(上海)生物技术研发中心有限公司 | Lipositol, composition and product comprising same and preparation method of the product |
CN104630174B (en) * | 2013-11-07 | 2019-09-27 | 丰益(上海)生物技术研发中心有限公司 | Phospholipase C mutant and application thereof |
KR20230119048A (en) * | 2013-12-20 | 2023-08-14 | 디에스엠 아이피 어셋츠 비.브이. | Process for extracting lipids for use in production of biofuels |
US9951363B2 (en) | 2014-03-14 | 2018-04-24 | The Research Foundation for the State University of New York College of Environmental Science and Forestry | Enzymatic hydrolysis of old corrugated cardboard (OCC) fines from recycled linerboard mill waste rejects |
CN106459935A (en) * | 2014-03-27 | 2017-02-22 | 诺维信公司 | Polypeptides having phospholipase c activity and polynucleotides encoding same |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CN104991033A (en) * | 2015-08-05 | 2015-10-21 | 上海海虹实业(集团)巢湖今辰药业有限公司 | Method for measuring components of essential oil of ligusticum wallichii through quantitative analysis of multi-components by single marker |
CN105567713B (en) * | 2016-03-09 | 2019-01-08 | 河北省农林科学院粮油作物研究所 | 3 albumen of peanut AhPLD α and its encoding gene and application |
CN106119221A (en) * | 2016-06-28 | 2016-11-16 | 浙江省农业科学院 | Phosphatidylinositol-specific phospholipase C gene, carrier, engineering bacteria and application |
CN106318925B (en) * | 2016-08-19 | 2021-04-02 | 浙江省农业科学院 | Method for efficiently expressing PI-PLC gene by using bacillus subtilis |
CN108118039B (en) * | 2016-11-28 | 2022-10-04 | 丰益(上海)生物技术研发中心有限公司 | Phospholipase C mutant |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
US10344246B2 (en) | 2017-05-24 | 2019-07-09 | Arisyne Systems, Inc. | Oil degumming systems |
KR102114297B1 (en) * | 2017-11-30 | 2020-05-22 | 양승춘 | Hot water heating using fermentation heat |
CN108384768A (en) * | 2018-02-28 | 2018-08-10 | 江苏中酶生物科技有限公司 | A kind of mutant of phospholipase C and its application |
CN114842911B (en) * | 2022-06-21 | 2022-09-20 | 深圳市睿法生物科技有限公司 | Gene detection process optimization method and device based on precise medical treatment |
Citations (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE595219A (en) | 1959-09-21 | 1961-01-16 | Pellerins Margarinfabrik Ab | Process and installation for refining fats. |
US4049686A (en) | 1975-03-10 | 1977-09-20 | Lever Brothers Company | Degumming process for triglyceride oils |
US4240972A (en) | 1978-12-19 | 1980-12-23 | Canada Packers Limited | Continuous process for contacting of triglyceride oils with _an acid |
WO1981000857A1 (en) | 1979-09-28 | 1981-04-02 | Vsesoyuzny Ni Biotek Inst | Method of production of ethyl alcohol from starch raw material |
CA1102795A (en) | 1977-08-19 | 1981-06-09 | Kdre Larsson | Method of isolating polar lipids from a mixture of polar and non-polar cereal lipids |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4698185A (en) | 1985-03-18 | 1987-10-06 | Safinco Coordination Center N.V. | Process for producing degummed vegetable oils and gums of high phosphatidic acid content |
US4707364A (en) | 1984-01-27 | 1987-11-17 | Miles Laboratories, Inc. | Composition for accelerating cheese aging |
US4752483A (en) | 1986-05-30 | 1988-06-21 | Campbell Soup Company | Method for producing a highly flavored cheese ingredient |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5015580A (en) | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
WO1991016427A1 (en) | 1990-04-24 | 1991-10-31 | Stratagene | Methods for phenotype creation from multiple gene populations |
US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
EP0513709A2 (en) | 1991-05-16 | 1992-11-19 | Röhm Gmbh | Enzymatic method for reducing the amount of phosphorous-containing components in vegetable and animal oils |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5239096A (en) | 1990-08-23 | 1993-08-24 | Krupp Maschinentechnik Gmbh | Degumming process for plant oils |
US5286886A (en) | 1988-06-21 | 1994-02-15 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Method of refining glyceride oils |
US5288619A (en) | 1989-12-18 | 1994-02-22 | Kraft General Foods, Inc. | Enzymatic method for preparing transesterified oils |
JPH06306386A (en) | 1993-04-25 | 1994-11-01 | Showa Sangyo Co Ltd | Refining of fat or oil |
DE4339556C1 (en) | 1993-11-19 | 1995-02-02 | Metallgesellschaft Ag | Process for degumming vegetable oil by means of enzymes |
US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
US5434049A (en) | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
WO1995022625A1 (en) | 1994-02-17 | 1995-08-24 | Affymax Technologies N.V. | Dna mutagenesis by random fragmentation and reassembly |
WO1996017958A1 (en) | 1994-12-09 | 1996-06-13 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5532163A (en) | 1993-04-25 | 1996-07-02 | Showa Sangyo Co., Ltd. | Process for refining oil and fat |
US5536325A (en) | 1979-03-23 | 1996-07-16 | Brink; David L. | Method of treating biomass material |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
WO1996033207A1 (en) | 1995-04-18 | 1996-10-24 | Glaxo Group Limited | End-complementary polymerase reaction |
US5573933A (en) | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
WO1996039154A1 (en) | 1995-06-06 | 1996-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
WO1997003211A1 (en) | 1995-07-13 | 1997-01-30 | Isis Pharmaceuticals, Inc. | Antisense inhibition of hepatitis b virus replication |
US5608148A (en) | 1993-09-30 | 1997-03-04 | Agracetus, Inc. | Transgenic cotton plants producing heterologous peroxidase |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
WO1997020078A1 (en) | 1995-11-30 | 1997-06-05 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5639940A (en) | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
WO1997035966A1 (en) | 1996-03-25 | 1997-10-02 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5681730A (en) | 1991-08-02 | 1997-10-28 | Wisconsin Alumni Research Foundation | Particle-mediated transformation of gymnosperms |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5705369A (en) | 1994-12-27 | 1998-01-06 | Midwest Research Institute | Prehydrolysis of lignocellulose |
US5709796A (en) | 1990-05-07 | 1998-01-20 | Bio-Sep, Inc. | Process for digesting cellulose containing solid wastes |
US5712135A (en) | 1990-11-23 | 1998-01-27 | Plant Genetic Systems, N.V. | Process for transforming monocotyledonous plants |
US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
US5744305A (en) | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
WO1998018912A1 (en) | 1996-10-31 | 1998-05-07 | Novo Nordisk A/S | Novel phospholipase, production and use thereof |
WO1998026057A1 (en) | 1996-12-09 | 1998-06-18 | Novo Nordisk A/S | Reduction of phosphorus containing components in edible oils comprising a high amount of non-hydratable phosphorus by use of a phospholipase, a phospholipase from a filamentous fungus having phospholipase a and/or b activity |
US5770456A (en) | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
WO1998027230A1 (en) | 1996-12-18 | 1998-06-25 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
WO1998031837A1 (en) | 1997-01-17 | 1998-07-23 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
WO1998041622A1 (en) | 1997-03-18 | 1998-09-24 | Novo Nordisk A/S | Method for constructing a library using dna shuffling |
WO1998041653A1 (en) | 1997-03-18 | 1998-09-24 | Novo Nordisk A/S | An in vitro method for construction of a dna library |
WO1998042832A1 (en) | 1997-03-25 | 1998-10-01 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
WO1998042727A1 (en) | 1997-03-21 | 1998-10-01 | Sri International | Sequence alterations using homologous recombination |
US5824514A (en) | 1985-03-30 | 1998-10-20 | Stuart A. Kauffman | Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides |
US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
US5856164A (en) | 1994-03-29 | 1999-01-05 | Novo Nordisk A/S | Alkaline bacillus amylase |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
US5880327A (en) | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
US5880300A (en) | 1997-01-31 | 1999-03-09 | Cargill, Incorporated | Phospholipid-based removal of sterols from fats and oils |
US5891698A (en) | 1994-03-09 | 1999-04-06 | Abbott Laboratories | Oligosaccharides and glycoproteins produced in milk of transgenic non-human mammals |
US5892070A (en) | 1994-03-09 | 1999-04-06 | Abbott Laboratories | Transgenic non-human mammals producing oligosaccharides and glycoconjugates |
WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
WO1999023107A1 (en) | 1997-10-31 | 1999-05-14 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
WO1999029902A1 (en) | 1997-12-08 | 1999-06-17 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
US5922854A (en) | 1991-06-14 | 1999-07-13 | Kumar; Ramesh | Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids |
EP0932670A1 (en) | 1996-03-25 | 1999-08-04 | Maxygen, Inc. | Evolving cellular dna uptake by recursive sequence recombination |
US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
WO1999041368A2 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
US5955358A (en) | 1990-12-20 | 1999-09-21 | Ixsys, Incorporated | Optimization of binding proteins |
US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6001640A (en) | 1995-07-26 | 1999-12-14 | Roehm Gmbh | Vegetable oil enzymatic degumming process by means of aspergillus phospholipase |
WO1999066805A1 (en) | 1998-06-23 | 1999-12-29 | Societe Des Produits Nestle S.A. | Flavor enhancer |
WO2000000632A1 (en) | 1998-06-29 | 2000-01-06 | Phylos, Inc. | Methods for generating highly diverse libraries |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6025171A (en) | 1996-12-19 | 2000-02-15 | Lipton, Division Of Conopco, Inc. | Immobilizing enzymes and processing triglycerides with immobilized lipase |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
WO2000009679A1 (en) | 1998-08-12 | 2000-02-24 | Proteus (S.A.) | Method for obtaining in vitro recombined polynucleotide sequences, sequence banks and resulting sequences |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US6090595A (en) | 1997-06-09 | 2000-07-18 | Iogen Corporation | Pretreatment process for conversion of cellulose to fuel ethanol |
WO2000043496A1 (en) | 1999-01-25 | 2000-07-27 | Gie Agro Industrie | MULTI-ENZYME PRODUCT WITH GLUCOAMYLASE, PROTEOLYTIC AND XYLANASE ACTIVITIES AND METHOD FOR PRODUCING SAME BY SOLID STATE FERMENTATION OR WHEAT BRAN WITH $i(ASPERGILLUS NIGER) |
US6103505A (en) | 1996-12-09 | 2000-08-15 | Novo Nordisk A/S | Method for reducing phosphorus content of edible oils |
US6107541A (en) | 1991-03-11 | 2000-08-22 | The General Hospital Corporation | PRAD1 transgenic mice |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US6118044A (en) | 1997-11-14 | 2000-09-12 | Sankyo Company, Limited | Transgenic animal allergy models and methods for their use |
WO2000054601A1 (en) | 1999-03-16 | 2000-09-21 | Novozymes A/S | Process for producing cheese |
US6127137A (en) | 1996-10-31 | 2000-10-03 | Novo Nordisk A/S | Acidic phospholipase, production and methods using thereof |
US6156952A (en) | 1998-04-09 | 2000-12-05 | Constituent Institution Of The University Of Maryland System | HIV transgenic animals and uses therefor |
US6162623A (en) | 1995-06-27 | 2000-12-19 | Lipton, Division Of Conopco, Inc. | Processes for preparing and using immobilized lipases |
US6172247B1 (en) | 1998-11-20 | 2001-01-09 | Ip Holdings, L.L.C. | Methods for refining vegetable oils and byproducts thereof |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
US6190874B1 (en) | 1998-09-09 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds that bind to CSAPK-1 |
US6197070B1 (en) | 1996-05-15 | 2001-03-06 | The Procter & Gamble Company | Detergent compositions comprising alpha combination of α-amylases for malodor stripping |
US6204232B1 (en) | 1997-10-30 | 2001-03-20 | Novo Nordisk A/S | α-amlase mutants |
US6211428B1 (en) | 1994-09-01 | 2001-04-03 | Merck & Co., Inc. | Transgenic mouse expressing a familial form of human amyloid precursor protein |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US20010012537A1 (en) | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US20010014448A1 (en) | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
US20010014449A1 (en) | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US20010016322A1 (en) | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US6280926B1 (en) | 1995-07-18 | 2001-08-28 | Diversa Corporation | Gene expression library produced from DNA from uncultivated microorganisms and methods for making the same |
US20010018642A1 (en) | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
US20010019827A1 (en) | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US6287862B1 (en) | 1997-01-17 | 2001-09-11 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6297038B1 (en) | 1995-02-03 | 2001-10-02 | Novozymes A/S | Amylase variants |
US6303803B1 (en) | 1997-01-31 | 2001-10-16 | Cargill, Incorporated | Removal of sterols from fats and oils |
US6309871B1 (en) | 1999-03-31 | 2001-10-30 | Novozymes A/S | Polypeptides having alkaline α-amylase activity |
US6309872B1 (en) | 2000-11-01 | 2001-10-30 | Novozymes Biotech, Inc | Polypeptides having glucoamylase activity and nucleic acids encoding same |
US6326341B1 (en) | 1996-09-11 | 2001-12-04 | The Procter & Gamble Company | Low foaming automatic dishwashing compositions |
US6329333B1 (en) | 1997-01-30 | 2001-12-11 | Henkel-Ecolab Gmbh & Co. Ohg | Pastelike detergent and cleaning agent |
US6333301B1 (en) | 1998-07-22 | 2001-12-25 | Akira Kamiya | Environmental protection-type particulate detergent compositions |
US6333181B1 (en) | 1997-04-07 | 2001-12-25 | University Of Florida Research Foundation, Inc. | Ethanol production from lignocellulose |
US6355693B1 (en) | 1995-09-22 | 2002-03-12 | Scotia Lipidteknik Ab | Fractionated vegetable oil |
US6365561B1 (en) | 1996-12-20 | 2002-04-02 | Procter & Gamble Company | Dishwashing detergent compositions containing organic diamines for improved grease cleaning sudsing, low temperature stability and dissolution |
US6380147B1 (en) | 1998-06-03 | 2002-04-30 | Henkel Kommanditgesellschaft Auf Aktien | Detergents containing amylase and protease |
US6399121B1 (en) | 1999-03-16 | 2002-06-04 | Novozymes A/S | Process for producing cheese |
US6399561B1 (en) | 1998-05-01 | 2002-06-04 | Novozymes A/S | Methods and compositions for bleaching a dye in solution |
US6409841B1 (en) | 1999-11-02 | 2002-06-25 | Waste Energy Integrated Systems, Llc. | Process for the production of organic products from diverse biomass sources |
US6413928B1 (en) | 1997-11-10 | 2002-07-02 | The Procter & Gamble Company | Process for preparing a detergent tablet |
US6423145B1 (en) | 2000-08-09 | 2002-07-23 | Midwest Research Institute | Dilute acid/metal salt hydrolysis of lignocellulosics |
US20020164730A1 (en) | 2000-02-24 | 2002-11-07 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) | Procedure for the production of ethanol from lignocellulosic biomass using a new heat-tolerant yeast |
US6489127B1 (en) | 2000-01-14 | 2002-12-03 | Exelixis, Inc. | Methods for identifying anti-cancer drug targets |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6511824B1 (en) | 1999-03-17 | 2003-01-28 | Exelixis, Inc. | Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use |
US6515109B1 (en) | 2000-10-12 | 2003-02-04 | Exelixis, Inc. | Human ECT2 polypeptide |
US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
WO2003070013A1 (en) | 2002-02-20 | 2003-08-28 | Novozymes A/S | Process for producing cheese |
US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
US20030190651A1 (en) * | 2000-07-31 | 2003-10-09 | Sophia Kossida | Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
US6712866B2 (en) | 1996-05-10 | 2004-03-30 | Stephen Paul | Alternative fuel |
US20050059130A1 (en) | 1998-11-27 | 2005-03-17 | Novozymes A/S | Lipolytic enzyme variants |
US20050108789A1 (en) * | 2002-04-19 | 2005-05-19 | Diversa Corporation | Phosholipases, nucleic acids encoding them and methods for making and using them |
US20050130160A1 (en) | 2002-02-13 | 2005-06-16 | Dow Global Technologies Inc | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
US20050186666A1 (en) | 2003-11-19 | 2005-08-25 | Dow Global Technologies Inc. | Protein expression systems |
US20060014260A1 (en) | 2004-05-07 | 2006-01-19 | Zhiliang Fan | Lower cellulase requirements for biomass cellulose hydrolysis and fermentation |
US20060110747A1 (en) | 2004-07-26 | 2006-05-25 | Dow Global Technologies Inc. | Process for improved protein expression by strain engineering |
US20070134777A1 (en) | 2003-12-19 | 2007-06-14 | Dayton Chris L | Process for improving enzymatic degumming of vegetable oils and reducing fouling of downstream processing equipment |
US20080058262A1 (en) | 2006-05-30 | 2008-03-06 | Rasochova Lada L | rPA optimization |
WO2008036863A2 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US20080182322A1 (en) | 2007-01-30 | 2008-07-31 | Dayton Christopher L G | Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases |
US7494676B2 (en) | 2002-05-30 | 2009-02-24 | Council Of Scientific And Industrial Research | Process for the pre-treatment of vegetable oils for physical refining |
US20090069587A1 (en) | 2007-09-11 | 2009-03-12 | Dayton Christopher L G | Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases with Reduced Reaction Time |
US9409174B2 (en) | 2013-06-21 | 2016-08-09 | Bio-Rad Laboratories, Inc. | Microfluidic system with fluid pickups |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040005674A1 (en) * | 2002-04-30 | 2004-01-08 | Athenix Corporation | Methods for enzymatic hydrolysis of lignocellulose |
WO2005079193A2 (en) * | 2003-09-19 | 2005-09-01 | Novozymes North America, Inc. | Processes for making ethanol |
-
2010
- 2010-08-10 UA UAA201205803A patent/UA109884C2/en unknown
- 2010-10-08 EA EA201200593A patent/EA022979B1/en not_active IP Right Cessation
- 2010-10-08 ES ES10823862.7T patent/ES2590037T3/en active Active
- 2010-10-08 CA CA3185815A patent/CA3185815A1/en active Pending
- 2010-10-08 US US13/502,069 patent/US9394529B2/en active Active
- 2010-10-08 BR BR112012008957A patent/BR112012008957A2/en not_active Application Discontinuation
- 2010-10-08 CN CN201080057899.0A patent/CN102712671B/en active Active
- 2010-10-08 AR ARP100103698A patent/AR078583A1/en active IP Right Grant
- 2010-10-08 PL PL10823862.7T patent/PL2488542T3/en unknown
- 2010-10-08 CA CA2777699A patent/CA2777699C/en active Active
- 2010-10-08 EP EP10823862.7A patent/EP2488542B1/en active Active
- 2010-10-08 IN IN3226DEN2012 patent/IN2012DN03226A/en unknown
- 2010-10-08 WO PCT/US2010/051903 patent/WO2011046812A1/en active Application Filing
- 2010-10-08 MX MX2012004469A patent/MX339648B/en active IP Right Grant
-
2016
- 2016-05-25 US US15/163,795 patent/US10487316B2/en active Active
-
2017
- 2017-10-13 AR ARP170102871A patent/AR109953A2/en unknown
Patent Citations (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE595219A (en) | 1959-09-21 | 1961-01-16 | Pellerins Margarinfabrik Ab | Process and installation for refining fats. |
US4049686A (en) | 1975-03-10 | 1977-09-20 | Lever Brothers Company | Degumming process for triglyceride oils |
CA1102795A (en) | 1977-08-19 | 1981-06-09 | Kdre Larsson | Method of isolating polar lipids from a mixture of polar and non-polar cereal lipids |
US4240972A (en) | 1978-12-19 | 1980-12-23 | Canada Packers Limited | Continuous process for contacting of triglyceride oils with _an acid |
US5536325A (en) | 1979-03-23 | 1996-07-16 | Brink; David L. | Method of treating biomass material |
WO1981000857A1 (en) | 1979-09-28 | 1981-04-02 | Vsesoyuzny Ni Biotek Inst | Method of production of ethyl alcohol from starch raw material |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4707364A (en) | 1984-01-27 | 1987-11-17 | Miles Laboratories, Inc. | Composition for accelerating cheese aging |
US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
US4698185A (en) | 1985-03-18 | 1987-10-06 | Safinco Coordination Center N.V. | Process for producing degummed vegetable oils and gums of high phosphatidic acid content |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US5824514A (en) | 1985-03-30 | 1998-10-20 | Stuart A. Kauffman | Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4752483A (en) | 1986-05-30 | 1988-06-21 | Campbell Soup Company | Method for producing a highly flavored cheese ingredient |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5573933A (en) | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
US5015580A (en) | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5286886A (en) | 1988-06-21 | 1994-02-15 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Method of refining glyceride oils |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5770456A (en) | 1989-06-07 | 1998-06-23 | Affymetrix, Inc. | Cyclic nucleic acid and polypeptide arrays |
US5744305A (en) | 1989-06-07 | 1998-04-28 | Affymetrix, Inc. | Arrays of materials attached to a substrate |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6261776B1 (en) | 1989-06-07 | 2001-07-17 | Affymetrix, Inc. | Nucleic acid arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5288619A (en) | 1989-12-18 | 1994-02-22 | Kraft General Foods, Inc. | Enzymatic method for preparing transesterified oils |
WO1991016427A1 (en) | 1990-04-24 | 1991-10-31 | Stratagene | Methods for phenotype creation from multiple gene populations |
US5709796A (en) | 1990-05-07 | 1998-01-20 | Bio-Sep, Inc. | Process for digesting cellulose containing solid wastes |
US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
US5239096A (en) | 1990-08-23 | 1993-08-24 | Krupp Maschinentechnik Gmbh | Degumming process for plant oils |
US5712135A (en) | 1990-11-23 | 1998-01-27 | Plant Genetic Systems, N.V. | Process for transforming monocotyledonous plants |
US5955358A (en) | 1990-12-20 | 1999-09-21 | Ixsys, Incorporated | Optimization of binding proteins |
US6107541A (en) | 1991-03-11 | 2000-08-22 | The General Hospital Corporation | PRAD1 transgenic mice |
EP0513709A2 (en) | 1991-05-16 | 1992-11-19 | Röhm Gmbh | Enzymatic method for reducing the amount of phosphorous-containing components in vegetable and animal oils |
US5264367A (en) | 1991-05-16 | 1993-11-23 | Rohm Gmbh | Enzymatic treatment of edible oils |
EP0513709B2 (en) | 1991-05-16 | 1999-10-06 | Röhm Gmbh | Enzymatic method for reducing the amount of phosphorous-containing components in vegetable and animal oils |
US5922854A (en) | 1991-06-14 | 1999-07-13 | Kumar; Ramesh | Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids |
US5681730A (en) | 1991-08-02 | 1997-10-28 | Wisconsin Alumni Research Foundation | Particle-mediated transformation of gymnosperms |
US5434049A (en) | 1992-02-28 | 1995-07-18 | Hitachi, Ltd. | Separation of polynucleotides using supports having a plurality of electrode-containing cells |
US5532163A (en) | 1993-04-25 | 1996-07-02 | Showa Sangyo Co., Ltd. | Process for refining oil and fat |
JPH06306386A (en) | 1993-04-25 | 1994-11-01 | Showa Sangyo Co Ltd | Refining of fat or oil |
US5608148A (en) | 1993-09-30 | 1997-03-04 | Agracetus, Inc. | Transgenic cotton plants producing heterologous peroxidase |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US20010014449A1 (en) | 1993-11-01 | 2001-08-16 | Michael I. Nerenberg | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
DE4339556C1 (en) | 1993-11-19 | 1995-02-02 | Metallgesellschaft Ag | Process for degumming vegetable oil by means of enzymes |
US5558781A (en) | 1993-11-19 | 1996-09-24 | Metallgesellschaft Aktiengesellschaft | Process for enzymatically degumming vegetable oil |
US5830721A (en) | 1994-02-17 | 1998-11-03 | Affymax Technologies N.V. | DNA mutagenesis by random fragmentation and reassembly |
WO1995022625A1 (en) | 1994-02-17 | 1995-08-24 | Affymax Technologies N.V. | Dna mutagenesis by random fragmentation and reassembly |
EP0752008A1 (en) | 1994-02-17 | 1997-01-08 | Affymax Technologies N.V. | Dna mutagenesis by random fragmentation and reassembly |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6291242B1 (en) | 1994-02-17 | 2001-09-18 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6287861B1 (en) | 1994-02-17 | 2001-09-11 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5811238A (en) | 1994-02-17 | 1998-09-22 | Affymax Technologies N.V. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5639940A (en) | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
US5892070A (en) | 1994-03-09 | 1999-04-06 | Abbott Laboratories | Transgenic non-human mammals producing oligosaccharides and glycoconjugates |
US5891698A (en) | 1994-03-09 | 1999-04-06 | Abbott Laboratories | Oligosaccharides and glycoproteins produced in milk of transgenic non-human mammals |
US5856164A (en) | 1994-03-29 | 1999-01-05 | Novo Nordisk A/S | Alkaline bacillus amylase |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
US6211428B1 (en) | 1994-09-01 | 2001-04-03 | Merck & Co., Inc. | Transgenic mouse expressing a familial form of human amyloid precursor protein |
US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
US5880327A (en) | 1994-09-21 | 1999-03-09 | American National Red Cross | Transgenic mammals expressing human coagulation factor VIII |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
WO1996017958A1 (en) | 1994-12-09 | 1996-06-13 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5705369A (en) | 1994-12-27 | 1998-01-06 | Midwest Research Institute | Prehydrolysis of lignocellulose |
US6297038B1 (en) | 1995-02-03 | 2001-10-02 | Novozymes A/S | Amylase variants |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
WO1996033207A1 (en) | 1995-04-18 | 1996-10-24 | Glaxo Group Limited | End-complementary polymerase reaction |
WO1996039154A1 (en) | 1995-06-06 | 1996-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US6162623A (en) | 1995-06-27 | 2000-12-19 | Lipton, Division Of Conopco, Inc. | Processes for preparing and using immobilized lipases |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
WO1997003211A1 (en) | 1995-07-13 | 1997-01-30 | Isis Pharmaceuticals, Inc. | Antisense inhibition of hepatitis b virus replication |
US6280926B1 (en) | 1995-07-18 | 2001-08-28 | Diversa Corporation | Gene expression library produced from DNA from uncultivated microorganisms and methods for making the same |
US6001640A (en) | 1995-07-26 | 1999-12-14 | Roehm Gmbh | Vegetable oil enzymatic degumming process by means of aspergillus phospholipase |
US6355693B1 (en) | 1995-09-22 | 2002-03-12 | Scotia Lipidteknik Ab | Fractionated vegetable oil |
US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
WO1997020078A1 (en) | 1995-11-30 | 1997-06-05 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
WO1997035966A1 (en) | 1996-03-25 | 1997-10-02 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
EP0932670A1 (en) | 1996-03-25 | 1999-08-04 | Maxygen, Inc. | Evolving cellular dna uptake by recursive sequence recombination |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6712866B2 (en) | 1996-05-10 | 2004-03-30 | Stephen Paul | Alternative fuel |
US6197070B1 (en) | 1996-05-15 | 2001-03-06 | The Procter & Gamble Company | Detergent compositions comprising alpha combination of α-amylases for malodor stripping |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US6258606B1 (en) | 1996-07-09 | 2001-07-10 | Nanogen, Inc. | Multiplexed active biologic array |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6326341B1 (en) | 1996-09-11 | 2001-12-04 | The Procter & Gamble Company | Low foaming automatic dishwashing compositions |
WO1998018912A1 (en) | 1996-10-31 | 1998-05-07 | Novo Nordisk A/S | Novel phospholipase, production and use thereof |
US6127137A (en) | 1996-10-31 | 2000-10-03 | Novo Nordisk A/S | Acidic phospholipase, production and methods using thereof |
US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
EP0869167A2 (en) | 1996-12-09 | 1998-10-07 | Novo Nordisk A/S | Reduction of phosphorus containing components in edible oils comprising a high amount of non-hydratable phosphorus by use of a phospholipase, a phospholipase from a filamentous fungus having phospholipase A and/or B activity |
US6143545A (en) | 1996-12-09 | 2000-11-07 | Novo Nordisk A/S | Method for reducing phosphorus content of edible oils |
WO1998026057A1 (en) | 1996-12-09 | 1998-06-18 | Novo Nordisk A/S | Reduction of phosphorus containing components in edible oils comprising a high amount of non-hydratable phosphorus by use of a phospholipase, a phospholipase from a filamentous fungus having phospholipase a and/or b activity |
US6103505A (en) | 1996-12-09 | 2000-08-15 | Novo Nordisk A/S | Method for reducing phosphorus content of edible oils |
WO1998027230A1 (en) | 1996-12-18 | 1998-06-25 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6025171A (en) | 1996-12-19 | 2000-02-15 | Lipton, Division Of Conopco, Inc. | Immobilizing enzymes and processing triglycerides with immobilized lipase |
US6365561B1 (en) | 1996-12-20 | 2002-04-02 | Procter & Gamble Company | Dishwashing detergent compositions containing organic diamines for improved grease cleaning sudsing, low temperature stability and dissolution |
WO1998031837A1 (en) | 1997-01-17 | 1998-07-23 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6287862B1 (en) | 1997-01-17 | 2001-09-11 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6329333B1 (en) | 1997-01-30 | 2001-12-11 | Henkel-Ecolab Gmbh & Co. Ohg | Pastelike detergent and cleaning agent |
US5880300A (en) | 1997-01-31 | 1999-03-09 | Cargill, Incorporated | Phospholipid-based removal of sterols from fats and oils |
US6303803B1 (en) | 1997-01-31 | 2001-10-16 | Cargill, Incorporated | Removal of sterols from fats and oils |
WO1998041622A1 (en) | 1997-03-18 | 1998-09-24 | Novo Nordisk A/S | Method for constructing a library using dna shuffling |
WO1998041653A1 (en) | 1997-03-18 | 1998-09-24 | Novo Nordisk A/S | An in vitro method for construction of a dna library |
WO1998042727A1 (en) | 1997-03-21 | 1998-10-01 | Sri International | Sequence alterations using homologous recombination |
WO1998042832A1 (en) | 1997-03-25 | 1998-10-01 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US6333181B1 (en) | 1997-04-07 | 2001-12-25 | University Of Florida Research Foundation, Inc. | Ethanol production from lignocellulose |
US6090595A (en) | 1997-06-09 | 2000-07-18 | Iogen Corporation | Pretreatment process for conversion of cellulose to fuel ethanol |
US20010018642A1 (en) | 1997-07-25 | 2001-08-30 | David Balaban | Method and system for providing a probe array chip design database |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
US20010019827A1 (en) | 1997-09-11 | 2001-09-06 | Dawson Elliott P. | Method of making high density arrays |
US20010014448A1 (en) | 1997-09-30 | 2001-08-16 | Surmodics, Inc. | Target molecule attachment to surfaces |
WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
US6204232B1 (en) | 1997-10-30 | 2001-03-20 | Novo Nordisk A/S | α-amlase mutants |
WO1999023107A1 (en) | 1997-10-31 | 1999-05-14 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
US6413928B1 (en) | 1997-11-10 | 2002-07-02 | The Procter & Gamble Company | Process for preparing a detergent tablet |
US6118044A (en) | 1997-11-14 | 2000-09-12 | Sankyo Company, Limited | Transgenic animal allergy models and methods for their use |
WO1999029902A1 (en) | 1997-12-08 | 1999-06-17 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO1999041402A2 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
WO1999041368A2 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
WO1999041369A2 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Genetic vaccine vector engineering |
WO1999051773A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6156952A (en) | 1998-04-09 | 2000-12-05 | Constituent Institution Of The University Of Maryland System | HIV transgenic animals and uses therefor |
US6399561B1 (en) | 1998-05-01 | 2002-06-04 | Novozymes A/S | Methods and compositions for bleaching a dye in solution |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6380147B1 (en) | 1998-06-03 | 2002-04-30 | Henkel Kommanditgesellschaft Auf Aktien | Detergents containing amylase and protease |
WO1999066805A1 (en) | 1998-06-23 | 1999-12-29 | Societe Des Produits Nestle S.A. | Flavor enhancer |
WO2000000632A1 (en) | 1998-06-29 | 2000-01-06 | Phylos, Inc. | Methods for generating highly diverse libraries |
US6333301B1 (en) | 1998-07-22 | 2001-12-25 | Akira Kamiya | Environmental protection-type particulate detergent compositions |
WO2000009679A1 (en) | 1998-08-12 | 2000-02-24 | Proteus (S.A.) | Method for obtaining in vitro recombined polynucleotide sequences, sequence banks and resulting sequences |
US6190874B1 (en) | 1998-09-09 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds that bind to CSAPK-1 |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6172247B1 (en) | 1998-11-20 | 2001-01-09 | Ip Holdings, L.L.C. | Methods for refining vegetable oils and byproducts thereof |
US6172248B1 (en) | 1998-11-20 | 2001-01-09 | Ip Holdings, L.L.C. | Methods for refining vegetable oils and byproducts thereof |
US20050059130A1 (en) | 1998-11-27 | 2005-03-17 | Novozymes A/S | Lipolytic enzyme variants |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
WO2000043496A1 (en) | 1999-01-25 | 2000-07-27 | Gie Agro Industrie | MULTI-ENZYME PRODUCT WITH GLUCOAMYLASE, PROTEOLYTIC AND XYLANASE ACTIVITIES AND METHOD FOR PRODUCING SAME BY SOLID STATE FERMENTATION OR WHEAT BRAN WITH $i(ASPERGILLUS NIGER) |
US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
US6399121B1 (en) | 1999-03-16 | 2002-06-04 | Novozymes A/S | Process for producing cheese |
WO2000054601A1 (en) | 1999-03-16 | 2000-09-21 | Novozymes A/S | Process for producing cheese |
US6551635B2 (en) | 1999-03-16 | 2003-04-22 | Novozymes, A/S | Process for producing cheese |
US6511824B1 (en) | 1999-03-17 | 2003-01-28 | Exelixis, Inc. | Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use |
US6309871B1 (en) | 1999-03-31 | 2001-10-30 | Novozymes A/S | Polypeptides having alkaline α-amylase activity |
US20010016322A1 (en) | 1999-04-27 | 2001-08-23 | Caren Michael P. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US20010012537A1 (en) | 1999-07-30 | 2001-08-09 | Anderson Norman G. | Dry deposition of materials for microarrays using matrix displacement |
US6409841B1 (en) | 1999-11-02 | 2002-06-25 | Waste Energy Integrated Systems, Llc. | Process for the production of organic products from diverse biomass sources |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
US6489127B1 (en) | 2000-01-14 | 2002-12-03 | Exelixis, Inc. | Methods for identifying anti-cancer drug targets |
US20020164730A1 (en) | 2000-02-24 | 2002-11-07 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (C.I.E.M.A.T.) | Procedure for the production of ethanol from lignocellulosic biomass using a new heat-tolerant yeast |
US20050069998A1 (en) | 2000-02-24 | 2005-03-31 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas (C.I.E.M.A.T.) | Procedure for the production of ethanol from lignocellulosic biomass using a new heat-tolerant yeast |
US20030190651A1 (en) * | 2000-07-31 | 2003-10-09 | Sophia Kossida | Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
US6660506B2 (en) | 2000-08-09 | 2003-12-09 | Midwest Research Institute | Ethanol production with dilute acid hydrolysis using partially dried lignocellulosics |
US6423145B1 (en) | 2000-08-09 | 2002-07-23 | Midwest Research Institute | Dilute acid/metal salt hydrolysis of lignocellulosics |
US6515109B1 (en) | 2000-10-12 | 2003-02-04 | Exelixis, Inc. | Human ECT2 polypeptide |
US6309872B1 (en) | 2000-11-01 | 2001-10-30 | Novozymes Biotech, Inc | Polypeptides having glucoamylase activity and nucleic acids encoding same |
US20050130160A1 (en) | 2002-02-13 | 2005-06-16 | Dow Global Technologies Inc | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
WO2003070013A1 (en) | 2002-02-20 | 2003-08-28 | Novozymes A/S | Process for producing cheese |
US20050108789A1 (en) * | 2002-04-19 | 2005-05-19 | Diversa Corporation | Phosholipases, nucleic acids encoding them and methods for making and using them |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US7494676B2 (en) | 2002-05-30 | 2009-02-24 | Council Of Scientific And Industrial Research | Process for the pre-treatment of vegetable oils for physical refining |
US20050186666A1 (en) | 2003-11-19 | 2005-08-25 | Dow Global Technologies Inc. | Protein expression systems |
US20070134777A1 (en) | 2003-12-19 | 2007-06-14 | Dayton Chris L | Process for improving enzymatic degumming of vegetable oils and reducing fouling of downstream processing equipment |
US20060014260A1 (en) | 2004-05-07 | 2006-01-19 | Zhiliang Fan | Lower cellulase requirements for biomass cellulose hydrolysis and fermentation |
US20060110747A1 (en) | 2004-07-26 | 2006-05-25 | Dow Global Technologies Inc. | Process for improved protein expression by strain engineering |
US20080058262A1 (en) | 2006-05-30 | 2008-03-06 | Rasochova Lada L | rPA optimization |
WO2008036863A2 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US20080182322A1 (en) | 2007-01-30 | 2008-07-31 | Dayton Christopher L G | Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases |
US20090069587A1 (en) | 2007-09-11 | 2009-03-12 | Dayton Christopher L G | Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases with Reduced Reaction Time |
US9409174B2 (en) | 2013-06-21 | 2016-08-09 | Bio-Rad Laboratories, Inc. | Microfluidic system with fluid pickups |
Non-Patent Citations (232)
Title |
---|
"Analytical Profiling of Small Scale Reactions of phospholipase-C mediated Vegetable Oil Degumming", 2007, AMERICAN OIL CHEMISTS SOCIETY |
"Antisense Therapeutics", 1996, HUMANA PRESS |
"AOCS Official Method Cd 1 1d-96", article "Mono- and Diglycerides Determination by HPLC-ELSD" |
"AOCS Official Method Cd 1 lb-91", article "Determination of Mono- and Diglycerides by Capillary Gas Chromatography" |
"BASIC AND CLINICAL IMMUNOLOGY", LANGE MEDICAL PUBLICATIONS |
"CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1997, JOHN WILEY & SONS, INC. |
"Fundamental Immunology", 1993, RAVEN PRESS |
"Gene Transfer to Plants", 1995, SPRINGER-VERLAG |
"Immobilization of Enzymes and Cells", 1997, HUMANA PRESS |
"Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure", 1978, NATIONAL BIOMEDICAL RESEARCH FOUNDATION |
"Methods in Enzymology, Immobilized Enzymes and Cells", vol. 136, 1987, ACADEMIC PRESS |
"MOLECULAR CLONING: A LABORATORY MANUAL", vol. 1-3, 1989, COLD SPRING HARBOR LABORATORY |
"Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis", PROC. NATL. ACAD. SCI. USA, vol. 83, pages 7177 - 7181 |
"PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS", 1990, ACADEMIC PRESS |
"PCR STRATEGIES", 1995, ACADEMIC PRESS, INC. |
"Posttranslational Covalent Modification of Proteins", 1983, ACADEMIC PRESS, pages: 1 - 12 |
"Technology and Solvents for Extracting Oilseeds and Nonpetroleum Oils", 1997, AOCS |
"Theory and Nucleic Acid Preparation", 1993, ELSEVIER, article "LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES" |
A. BATEMAN, E. BIRNEY; L. CERRUTI; R. DURBIN; L. ETWILLER; S.R. EDDY; S. GRIFFITHS-JONES; K.L. HOWE; M. MARSHALL; E.L.L. SONNHAMME, NUCLEIC ACIDS RESEARCH, vol. 30, no. 1, 2002, pages 276 - 280 |
ADAMS, J. AM. CHEM. SOC., vol. 105, 1983, pages 661 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NATURE GENETICS, vol. 3, 1993, pages 266 - 272 |
ALTSCHUL, J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL, NUC. ACIDS RES, vol. 25, 1977, pages 3389 - 3402 |
ARKIN, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 7811 - 7815 |
ARNOLD, CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, 1993, pages 450 - 455 |
ARNOLD: "Protein engineering for unusual environments", CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, 1993, pages 450 - 455, XP023601352, DOI: doi:10.1016/0958-1669(93)90011-K |
BACA, INT. J. PARASITOL., vol. 30, 2000, pages 113 - 118 |
BAGUISI, NAT. BIOTECHNOL., vol. 17, 1999, pages 456 - 461 |
BANGA, A.K.: "Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems", 1995, TECHNOMIC PUBLISHING CO. |
BARRINGER, GENE, vol. 89, 1990, pages 117 |
BASS ET AL.: "Mutant Trp repressors with new DNA-binding specificities", SCIENCE, vol. 242, 1988, pages 240 - 245, XP000700229, DOI: doi:10.1126/science.3140377 |
BEAUCAGE, TETRA. LETT., vol. 22, 1981, pages 1859 |
BELOUSOV, NUCLEIC ACIDS RES., vol. 25, 1997, pages 3440 - 3444 |
BERGER, METHODS ENZYMOL., vol. 152, 1987, pages 307 - 316 |
BERKA, INFECT. IMMUN., vol. 34, 1981, pages 1071 - 1074 |
BINDING: "Regeneration of Plants, Plant Protoplasts", 1985, CRC PRESS, pages: 21 - 73 |
BLOMMERS, BIOCHEMISTRY, vol. 33, 1994, pages 7886 - 7896 |
BOTSTEIN; SHORTLE: "Strategies and applications of in vitro mutagenesis", SCIENCE, vol. 229, 1985, pages 1193 - 1201, XP001314554 |
BOWTELL, NATURE GENETICS SUPP., vol. 21, 1999, pages 25 - 32 |
BRINDISI, J. OF FOOD SCI., vol. 66, 2001, pages 1100 - 1107 |
BROWN, METH. ENZYMOL., vol. 68, 1979, pages 109 |
BUCHOLD ET AL., FETT WISSENSCHAFT TECHNOLOGIE, vol. 95, no. 8, 1993, pages 300 - 304 |
BUENROSTRO, BIOTECH. LETTERS, vol. 8, no. 7, 1986, pages 505 - 506 |
BURG, MOL. CELL. PROBES, vol. 10, 1996, pages 257 - 271 |
C. MARTINEZ AMEZCUA, POULTRY SCIENCE, vol. 83, 2004, pages 971 - 976 |
CALDWELL, R. C.; JOYCE G.F., PCR METHODS APPLIC., vol. 2, 1992, pages 28 - 33 |
CARMEN, G., J. BIOL. CHEM., vol. 270, 1995, pages 18711 - 18714 |
CARTER ET AL.: "Improved oligonucleotide site-directed mutagenesis using M13 vectors", NUCL. ACIDS RES., vol. 13, 1985, pages 4431 - 4443 |
CARTER: "Improved oligonucleotide-directed mutagenesis using M13 vectors", METHODS IN ENZYMOL., vol. 154, 1987, pages 382 - 403 |
CARTER: "Site-directed mutagenesis", BIOCHEM. J., vol. 237, 1986, pages 1 - 7 |
CARUTHERS, NUCLEIC ACIDS RES. SYMP. SER., 1980, pages 215 - 223 |
CHANG: "Evolution of a cytokine using DNA family shuffling", NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 793 - 797, XP002165178, DOI: doi:10.1038/70147 |
CHONG, TRANSGENIC RES., vol. 6, 1997, pages 289 - 296 |
CHRISTIANS: "Directed evolution ofthymidine kinase for AZT phosphorylation using DNA family shuffling", NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 259 - 264, XP002154178, DOI: doi:10.1038/7003 |
CHRISTOU, PLANT MOL. BIOL., vol. 35, 1997, pages 197 - 203 |
CLAUSEN, KIM; NIELSEN, MUNK, NOVOZYMES A/S, DEN. DANSK KEMI, vol. 83, no. 2, 2002, pages 24 - 27 |
CLEENEWERCK ET AL., IZEGEM, BELG. FETT WISSENSCHAFT TECHNOLOGIE, vol. 94, 1992, pages 317 - 22 |
COLE: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, INC., pages: 77 - 96 |
COLIGAN: "CURRENT PROTOCOLS IN IMMUNOLOGY", 1991, WILEY/GREENE |
CRAMERI ET AL.: "Construction and evolution of antibody-phage libraries by DNA shuffling", NATURE MEDICINE, vol. 2, 1996, pages 100 - 103 |
CRAMERI ET AL.: "Improved green fluorescent protein by molecular evolution using DNA shuffling", NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 315 - 319, XP000791095, DOI: doi:10.1038/nbt0396-315 |
CRAMERI, BIOTECHNIQUES, vol. 18, 1995, pages 194 - 196 |
CRAMERI: "DNA shuffling of a family of genes from diverse species accelerates directed evolution", NATURE, vol. 391, 1998, pages 288 - 291, XP055092965, DOI: doi:10.1038/34663 |
CRAMERI: "Molecular evolution of an arsenate detoxification pathway by DNA shuffling", NATURE BIOTECHNOLOGY, vol. 15, 1997, pages 436 - 438, XP002912510, DOI: doi:10.1038/nbt0597-436 |
CREIGHTON, T.E.: "Proteins - Structure and Molecular Properties", 1993, W.H. FREEMAN AND COMPANY |
DALE ET AL.: "Oligonucleotide-directed random mutagenesis using the phosphorothioate method", METHODS MOL. BIOL., vol. 57, 1996, pages 369 - 374 |
DAVIS, L.; DIBNER, M.; BATTEY, I., BASIC METHODS IN MOLECULAR BIOLOGY, 1986 |
DELEGRAVE, BIOTECHNOLOGY RES., vol. 11, 1993, pages 1548 - 1552 |
DIAZ: "Direct fluorescence-based lipase activity assay", BIOTECHNIQUES, vol. 27, 1999, pages 696 - 700 |
DIJKSTRA, ALBERT J ET AL., OLEAGINEUX, CORPS GRAS, LIPIDES, vol. 5, no. 5, 1998, pages 367 - 370 |
DIJKSTRA; N.V. VANDEMOORTELE ET AL., J. AM. OIL CHEM. SOC., vol. 66, 1989, pages 1002 - 1009 |
DOBELI, PROTEIN EXPR. PURIF., vol. 12, 1998, pages 404 - 414 |
EGHTEDARZADEH: "Use of oligonucleotides to generate large deletions", NUCL. ACIDS RES., vol. 14, 1986, pages 5115 |
EVANS ET AL.: "Protoplasts Isolation and Culture, Handbook of Plant Cell Culture", 1983, MACMILLILAN PUBLISHING COMPANY, pages: 124 - 176 |
FENG, BIOCHEMISTRY, vol. 39, 2000, pages 15399 - 15409 |
FRALEY, PROC. NATL. ACAD. SCI USA, vol. 80, 1983, pages 4803 |
FRALEY, PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 4803 |
FRENKEL, FREE RADIC. BIOL. MED., vol. 19, 1995, pages 373 - 380 |
FRITZ ET AL.: "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro", NUCL. ACIDS RES., vol. 16, 1988, pages 6987 - 6999 |
GATES ET AL.: "Affinity selective isolation of ligands from peptide libraries through display on a lac repressor 'headpiece dimer", JOURNAL OF MOLECULAR BIOLOGY, vol. 255, 1996, pages 373 - 386, XP002941960, DOI: doi:10.1006/jmbi.1996.0031 |
GODING: "MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE", 1986, ACADEMIC PRESS |
GOLD, J. OF BIOL. CHEM., vol. 270, 1995, pages 13581 - 13584 |
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 1445 |
GOODE: "Evidence for cell surface and internal phospholipase activity in ascidian eggs", DEVELOP. GROWTH DIFFER., vol. 39, 1997, pages 655 - 660 |
GRUNDSTROM ET AL.: "Oligonucleotide-directed mutagenesis bymicroscale 'shot-gun' gene synthesis", NUCL. ACIDS RES., vol. 13, 1985, pages 3305 - 3316 |
GUATELLI, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 |
GUERRIER-TAKADA, CELL, vol. 35, 1983, pages 849 |
H. M. GEYSEN ET AL., PROC. NATL. ACAD. SCI., USA, vol. 81, 1984, pages 3998 |
HALE, PROTEIN EXPR. PURIF, vol. 12, 1998, pages 185 - 188 |
HAMPEL, BIOCHEMISTRY, vol. 28, 1989, pages 4929 |
HAMPEL, NUC. ACIDS RES., vol. 18, 1990, pages 299 |
HARLOW: "ANTIBODIES, A LABORATORY MANUAL", 1988, COLD SPRING HARBOR PUBLICATIONS |
HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1989, pages 10915 |
HENIKOFF; HENIKOFF, PROTEINS, vol. 17, 1993, pages 49 - 61 |
HEYNINCK, METHODS MOL. BIOL., vol. 282, 2004, pages 223 - 41 |
HIEI, PLANT MOL. BIOL., vol. 35, 1997, pages 205 - 218 |
HIGGINS ET AL., METHODS ENZYMOL., vol. 266, 1996, pages 383 - 402 |
HO, METHODS ENZYMOL., vol. 314, 2000, pages 168 - 183 |
HOOGENBOOM, TRENDS BIOTECHNOL., vol. 15, 1997, pages 62 - 70 |
HORN, NUCLEIC ACIDS RES. SYMP. SER, 1980, pages 225 - 232 |
HORSCH, SCIENCE, vol. 233, 1984, pages 496 |
HORSCH, SCIENCE, vol. 233, 1984, pages 496 - 498 |
HUMPHREYS, PROTEIN EXPR. PURIF., vol. 20, 2000, pages 252 - 264 |
HVOLBY ET AL., J. AMER. OIL CHEM. SOC, vol. 48, 1971, pages 503 - 509 |
IBRAHIM: "Evidence implicating phospholipase as a virulence factor of Candida albicans", INFECT. IMMUN., vol. 63, 1995, pages 1993 - 1998 |
JERZEWSKA ET AL., INST. PRZEMYSLU MIESNEGO I TLUSZCZOWEGO, WARSAW, POL., TLUSZCZE JADALNE, vol. 36, no. 3/4, 2001, pages 97 - 110 |
JIANAG, Y., J. BIOL. CHEM, vol. 271, 1996, pages 29528 - 29532 |
JIMENEZ, BIOTECHNOL. PROG, vol. 18, 2002, pages 635 - 640 |
JIMENEZ, LIPIDS, vol. 36, 2001, pages 1169 - 1174 |
JOHNSTON, CURR. BIOL, vol. 8, 1998, pages R171 - R174 |
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
KASAI, J. AGRIC. FOOD CHEM., vol. 51, 2003, pages 6217 - 6222 |
KATZ, ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 26, 1997, pages 27 - 45 |
KAUFFMANN: "Conversion of Bacillus thermocatenulatus lipase into an efficient phospholipase with increased activity towards long-chain fatty acyl substrates by directed evolution and rational design", PROTEIN ENGINEERING, vol. 14, 2001, pages 919 - 928 |
KERN, BIOTECHNIQUES, vol. 23, 1997, pages 120 - 124 |
KLEE, ANN. REV. OF PLANT PHYS., vol. 38, 1987, pages 467 - 486 |
KLEIN, NATURE, vol. 327, 1987, pages 70 - 73 |
KOHLER, NATURE, vol. 256, 1975, pages 495 |
KORBSRISATE, J. CLIN. MICROBIOL., vol. 37, 1999, pages 3742 - 3745 |
KRAMER ET AL.: "Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations", NUCL. ACIDS RES., vol. 16, 1988, pages 7207 |
KRAMER ET AL.: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCL. ACIDS RES., vol. 12, 1984, pages 9441 - 9456, XP002026371 |
KRAMER: "Point Mismatch Repair", CELL, vol. 38, 1984, pages 879 - 887 |
KRAMER; FRITZ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA", METHODS IN ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KROLL, DNA CELL. BIOL., vol. 12, 1993, pages 441 - 53 |
KUNKEL ET AL.: "Rapid and efficient site-specific mutagenesis without phenotypic selection", METHODS IN ENZYMOL., vol. 154, 1987, pages 367 - 382 |
KUNKEL: "Nucleic Acids & Molecular Biology", 1987, SPRINGER VERLAG, article "The efficiency of oligonucleotide directed mutagenesis" |
KUNKEL: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492 |
KWOH, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173 |
LANDEGREN, SCIENCE, vol. 241, 1988, pages 1077 |
LEUNG, D.W. ET AL., TECHNIQUE, vol. 1, 1989, pages 11 - 15 |
LING ET AL.: "Approaches to DNA mutagenesis: an overview", ANAL BIOCHEM., vol. 254, no. 2, 1997, pages 157 - 178, XP002948670, DOI: doi:10.1006/abio.1997.2428 |
LIPIDES, vol. 4, no. 1, 1997, pages 55 - 57 |
MATA, TOXICOL. APPL. PHARMACOL, vol. 144, 1997, pages 189 - 197 |
MATA, TOXICOLAPPL..PHARMACOL., vol. 144, 1997, pages 189 - 197 |
MCGLONE, J. OF FOOD SCI., vol. 51, 1986, pages 695 - 697 |
MERRIFIELD, METHODS ENZYMOL., vol. 289, 1997, pages 3 - 13 |
MERRIFIELD, R. B., J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154 |
METHODS IN ENZYMOL., vol. 100, 1983, pages 468 - 500 |
METHODS IN ENZYMOL., vol. 154, 1987, pages 329 - 350 |
METHODS IN ENZYMOLOGY, vol. 154 |
MIAO, PLANT J, vol. 7, 1995, pages 359 - 365 |
MILLER, METHODS MOL. BIOL., vol. 261, 2004, pages 247 - 62 |
MINSHULL: "Protein evolution by molecular breeding", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 3, 1999, pages 284 - 290 |
MOLECULAR PROBES PRODUCT SHEET, 2001 |
MONTEDORO, ACTA VITAMIN. ENZYMOL. (MILANO, vol. 30, 1976, pages 13 |
MUNCH, ERNST W: "Proceedings of the World Conference on Oilseed Processing Utilization", 2000, pages: 17 - 20 |
NAKAMAYE: "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis", NUCL. ACIDS RES., vol. 14, 1986, pages 9679 - 9698 |
NAMBIAR ET AL.: "Total synthesis and cloning of a gene coding for the ribonuclease S protein", SCIENCE, vol. 223, 1984, pages 1299 - 1301 |
NARANG, METH. ENZYMOL., vol. 68, 1979, pages 90 |
NARUM, INFECT. IMMUN., vol. 69, 2001, pages 7250 - 7253 |
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
NESS, NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 893 - 896 |
NIELSEN ET AL.: "Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites", PROTEIN ENGINEERING, vol. 10, no. 1, 1997, pages 1 - 6, XP002200196, DOI: doi:10.1093/protein/10.1.1 |
NILSSON-JOHANSSON ET AL.: "Fats Oils Div., Alfa-Laval Food Eng. AB, Tumba", SWED. FETT WISSENSCHAFT TECHNOLOGIE, vol. 90, no. 11, 1988, pages 447 - 51 |
OUHIDA, J. AGRIC. FOOD CHEM., vol. 50, 2002, pages 1933 - 1938 |
OUTCHKOUROV, PROTEIN EXPR. PURIF., vol. 24, 2002, pages 18 - 24 |
PALMGREN, TRENDS GENET., vol. 13, 1997, pages 348 |
PANDEY, NEUROPSYCHOPHARMACOLOGY, vol. 26, 2002, pages 216 - 228 |
PARK, PLANT MOL. BIOL., vol. 32, 1996, pages 1135 - 1148 |
PATTEN ET AL.: "Applications of DNA Shuffling to Pharmaceuticals and Vaccines", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002920749, DOI: doi:10.1016/S0958-1669(97)80127-9 |
PAWLOWSKI, MOL. BIOTECHNOL., vol. 6, 1996, pages 17 - 30 |
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, no. 8, 1988, pages 2444 - 2448 |
PERROTTA, BIOCHEMISTRY, vol. 31, 1992, pages 16 |
PERSON; LIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PINSIRODOM, J. AGRIC. FOOD CHEM, vol. 48, 2000, pages 155 - 160 |
POLLOCK, J. IMMUNOL. METHODS, vol. 231, 1999, pages 147 - 157 |
PORTA: "Use of viral replicons for the expression of genes in plants", MOL. BIOTECHNOL, vol. 5, 1996, pages 209 - 221, XP001096010, DOI: doi:10.1007/BF02900359 |
REIDHAAR-OLSON, SCIENCE, vol. 241, 1988, pages 53 - 57 |
REYNOLDS, METHODS IN ENZYMOL., vol. 197, 1991, pages 3 - 13 |
RICE, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 5467 - 5471 |
ROBERGE, SCIENCE, vol. 269, 1995, pages 202 |
ROSENFELD, NAT. GENET, vol. 15, 1997, pages 333 - 335 |
ROSENTHAL, ENZYME AND MICROB. TECH., vol. 28, 2001, pages 499 - 509 |
ROSSI, AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, 1992, pages 183 |
ROUWENDAL, PLANT MOL. BIOL., vol. 33, 1997, pages 989 - 999 |
SAKAMAR; KHORANA: "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin", NUCL. ACIDS RES., vol. 14, 1988, pages 6361 - 6372 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SAMSTAG, ANTISENSE NUCLEIC ACID DRUG DEV, vol. 6, 1996, pages 153 - 156 |
SANO ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 281, 2001, pages 844 - 851 |
SAYERS ET AL.: "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide", NUCL. ACIDS RES., vol. 16, 1988, pages 803 - 814 |
SAYERS ET AL.: "Y-T Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis", NUCL. ACIDS RES., vol. 16, 1988, pages 791 - 802, XP001314878 |
SCHUMMER, BIOTECHNIQUES, vol. 23, 1997, pages 1087 - 1092 |
See also references of EP2488542A4 |
SEGERS, J.C. ET AL.: "Edible fats and Oils processing: basic principals and modem practices: World conference proceedings", 1990, AMERICAN OIL CHEMISTS'S SOCIETY, article "Degumming - Theory and Practice", pages: 88 - 93 |
SEN GUPTA, A. K., FETTE SEIFEN ANSTRICHMITTEL, vol. 88, 1986, pages 79 - 86 |
SHUEY, DRUG DISCOV. TODAY, vol. 7, 2002, pages 1040 - 1046 |
SMITH, EUR. J. PHARM. SCI., vol. 11, 2000, pages 191 - 198 |
SMITH, J. CLIN. MICROBIOL, vol. 35, 1997, pages 1477 - 1491 |
SMITH: "In vitro mutagenesis", ANN. REV. GENET., vol. 19, 1985, pages 423 - 462 |
SMITH; WATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
SOLINAS-TOLDO, GENES, CHROMOSOMES & CANCER, vol. 20, 1997, pages 399 - 407 |
SOOKNANAN, BIOTECHNOLOGY, vol. 13, 1995, pages 563 - 564 |
SOSULSKI, PROC. CAN. INST. FOOD SCI. TECHNOL., vol. 3, 1990, pages 656 |
SPATOLA: "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins", vol. 7, 1983, MARCELL DEKKER, article "Peptide Backbone Modifications", pages: 267 - 357 |
SPYROS, A.; DAIS, P: "Application of P NMR Spectroscopy in Food Analysis. 1. Quantitative Determination of the Mono- and Diglyceride Composition of Olive Oils", J. AGRIC. FOOD CHEM., vol. 48, 2000, pages 802 - 805 |
STEMMER ET AL.: "Single-step assembly of a gene and entire plasmid form large numbers of oligodeoxyribonucleotides", GENE, vol. 164, 1995, pages 49 - 53 |
STEMMER, PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 10747 - 10751 |
STEMMER: "Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes", BIOTECHNIQUES, vol. 18, 1995, pages 194 - 195 |
STEMMER: "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 10747 - 10751, XP002912215, DOI: doi:10.1073/pnas.91.22.10747 |
STEMMER: "Molecular breeding of viruses for targeting and other clinical properties", TUMOR TARGETING, vol. 4, 1999, pages 1 - 4 |
STEMMER: "Rapid evolution of a protein in vitro by DNA shuffling", NATURE, vol. 370, 1994, pages 389 - 391, XP002082182, DOI: doi:10.1038/370389a0 |
STEMMER: "Searching Sequence Space", BIO/TECHNOLOGY, vol. 13, 1995, pages 549 - 553, XP002095510, DOI: doi:10.1038/nbt0695-549 |
STEMMER: "The Encyclopedia of Molecular Biology", 1996, VCH PUBLISHERS, article "Sexual PCR and Assembly PCR", pages: 447 - 457 |
STEMMER: "The Evolution of Molecular Computation", SCIENCE, vol. 270, 1995, pages 1510, XP001032709, DOI: doi:10.1126/science.270.5241.1510 |
STEWART, J. M.; YOUNG, J. D.: "Solid Phase Peptide Synthesis", PIERCE CHEMICAL CO., pages: 11 - 12 |
STRAUSS-SOUKUP, BIOCHEMISTRY, vol. 36, 1997, pages 8692 - 8698 |
STREPP, PROC NATL. ACAD. SCI. USA, vol. 95, 1998, pages 4368 - 4373 |
STRYER, LUBERT: "Biochemistry", W. H FREEMAN & CO. |
TAGUCHI, BIOCHIM. BIOPHYS. ACTA, vol. 409, 1975, pages 75 - 85 |
TAGUCHI: "Phospholipase from Clostridium novyi type A.I", BIOCHIM. BIOPHYS. ACTA, vol. 409, 1975, pages 75 - 85 |
TAKUMI, GENES GENET. SYST., vol. 72, 1997, pages 63 - 69 |
TAN ET AL., BIOCHEMISTRY, vol. 37, 1998, pages 4275 - 4279 |
TAYLOR ET AL.: "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA", NUCL. ACIDS RES., vol. 13, 1985, pages 8765 - 8787 |
TAYLOR ET AL.: "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA", NUCL. ACIDS RES., vol. 13, 1985, pages 8749 - 8764, XP000654371 |
THOMPSON ET AL., NUCLEIC ACIDS RES., vol. 22, no. 2, 1994, pages 4673 - 4680 |
TITBALL, MICROBIOL. REV., vol. 57, 1993, pages 347 - 366 |
VAN DE VEN, CRIT. REV. ONCOG., vol. 4, no. 2, 1993, pages 115 - 136 |
VIGLI, G.; PHILIPPIDS, A.; SPYROS, A.; DAIS, P.: "Classification of Edible Oils by Employing 31p and H NMR Spectroscopy in Combination with Multivariate Statistical Analysis. A Proposal for the Detection of Seed Oil Adulteration in Virgin Olive Oils", J. AGRIC. FOOD CHEM., vol. 51, 2003, pages 5715 - 5722, XP002315061, DOI: doi:10.1021/jf030100z |
WAGGONER, D., J. BIOL. CHEM., vol. 270, 1995, pages 19422 - 19429 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
WELLS ET AL.: "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites", GENE, vol. 34, 1985, pages 315 - 323, XP023539300, DOI: doi:10.1016/0378-1119(85)90140-4 |
WELLS ET AL.: "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin", PHIL. TRANS. R. SOC. LOND. A, vol. 317, 1986, pages 415 - 423 |
WILLIAMS, BIOCHEMISTRY, vol. 34, 1995, pages 1787 - 1797 |
WILSON, J. IMMUNOL. METHODS, vol. 175, 1994, pages 267 - 273 |
WOON, GENOMICS, vol. 50, 1998, pages 306 - 316 |
WU, GENOMICS, vol. 4, 1989, pages 560 |
YARMUSH, J. BIOCHEM. BIOPHYS. METHODS, vol. 25, 1992, pages 85 - 97 |
ZHANG: "Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening", PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 4504 - 4509, XP002087464, DOI: doi:10.1073/pnas.94.9.4504 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 3 vectors", METHODS IN ENZYMOL., vol. 100, 1983, pages 468 - 500, XP001088749, DOI: doi:10.1016/0076-6879(83)00074-9 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any DNA fragment", NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 6500 |
ZOLLER; SMITH: "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template", METHODS IN ENZYMOL., vol. 154, 1987, pages 329 - 350, XP000615890, DOI: doi:10.1016/0076-6879(87)54083-6 |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4163354A2 (en) | 2014-03-19 | 2023-04-12 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
US20170058235A1 (en) * | 2014-05-15 | 2017-03-02 | Novozymes A/S | Compositions Comprising Polypeptides Having Phospholipase C Activity and Use Thereof |
KR101661706B1 (en) | 2014-06-24 | 2016-10-04 | 한국생명공학연구원 | Method for producing lysophosphatidylethanolamine 18:1 from microorganisms |
US10030256B2 (en) | 2014-06-24 | 2018-07-24 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing lysophosphatidylethanolamine 18:1 from microorganism of Pseudomonas sp |
KR20160000436A (en) * | 2014-06-24 | 2016-01-04 | 한국생명공학연구원 | Method for producing lysophosphatidylethanolamine 18:1 from microorganisms |
EP3325630A4 (en) * | 2015-07-17 | 2019-01-02 | Keclon S.A. | Compositions and methods for oil degumming |
WO2017142904A1 (en) | 2016-02-19 | 2017-08-24 | Basf Se | Baking lipases |
WO2018200464A1 (en) | 2017-04-25 | 2018-11-01 | Bunge Oils, Inc. | Process for enzymatic degumming |
US10501703B2 (en) | 2017-04-25 | 2019-12-10 | Bunge Oils, Inc. | Process for enzymatic degumming |
EP3401383A1 (en) | 2017-05-08 | 2018-11-14 | Bunge Oils, Inc. | Process for enzymatic degumming |
US11162086B2 (en) | 2017-05-12 | 2021-11-02 | Basf Se | Lipase enzymes |
US11214777B2 (en) | 2017-05-12 | 2022-01-04 | Basf Se | Method for using lipase enzymes for cleaning |
WO2019063613A1 (en) | 2017-09-26 | 2019-04-04 | Dsm Ip Assets B.V. | Enzymatic removal of chlorophyll substrates from triacylglycerol-based oils |
WO2019063614A1 (en) | 2017-09-26 | 2019-04-04 | Bunge Global Innovation, Llc. | Enzymatic removal of chlorophyll substrates from triacylglycerol-based oils |
WO2019081976A2 (en) | 2017-10-25 | 2019-05-02 | Basf Se | Beta-amylase enzymes |
WO2019206994A1 (en) | 2018-04-26 | 2019-10-31 | Basf Se | Lipase enzymes |
WO2019211143A1 (en) | 2018-05-03 | 2019-11-07 | Basf Se | Amylase enzymes |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
WO2020135658A1 (en) * | 2018-12-28 | 2020-07-02 | 丰益(上海)生物技术研发中心有限公司 | Polypeptide having phospholipase c activity and use thereof |
WO2020169564A1 (en) | 2019-02-20 | 2020-08-27 | Basf Se | Industrial fermentation process for bacillus using defined medium and trace element feed |
WO2020169563A1 (en) | 2019-02-20 | 2020-08-27 | Basf Se | Industrial fermentation process for bacillus using defined medium and magnesium feed |
WO2020185737A1 (en) | 2019-03-11 | 2020-09-17 | Basf Se | Amylases and methods for making and using them |
WO2020193534A2 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Amylase enzymes |
WO2020193532A1 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Cleaning composition having amylase enzymes |
WO2020193535A2 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Amylase enzymes |
WO2020198212A1 (en) | 2019-03-27 | 2020-10-01 | Bunge Global Innovation, Llc | Silica adsorbent treatment for removal of chlorophyll derivatives from triacylglycerol-based oils |
WO2020249546A1 (en) | 2019-06-13 | 2020-12-17 | Basf Se | Method of recovering a protein from fermentation broth using a divalent cation |
WO2021004830A1 (en) | 2019-07-05 | 2021-01-14 | Basf Se | Industrial fermentation process for microbial cells using a fed-batch pre-culture |
WO2021032881A1 (en) | 2019-08-22 | 2021-02-25 | Basf Se | Amylase variants |
WO2022006711A1 (en) * | 2020-07-06 | 2022-01-13 | Kemin Industries, Inc. | Method for the preparation of lysophosphatidylinositol |
CN113215130A (en) * | 2021-05-11 | 2021-08-06 | 集美大学 | Phospholipase C mutant, preparation method and application thereof |
CN113508782A (en) * | 2021-07-27 | 2021-10-19 | 中国热带农业科学院热带作物品种资源研究所 | A feeding method capable of converting phytol into phytanic acid at higher ratio in ruminant rumen |
CN113508782B (en) * | 2021-07-27 | 2022-11-25 | 中国热带农业科学院热带作物品种资源研究所 | A feeding method capable of converting phytol into phytanic acid at higher ratio in ruminant rumen |
WO2023135541A1 (en) * | 2022-01-14 | 2023-07-20 | Keclon Sa | Mutated phospholipase c enzyme |
WO2023208768A1 (en) | 2022-04-26 | 2023-11-02 | Dsm Ip Assets B.V. | Method of producing cannabis distillate |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Also Published As
Publication number | Publication date |
---|---|
CN102712671A (en) | 2012-10-03 |
ES2590037T3 (en) | 2016-11-17 |
EA201200593A1 (en) | 2012-12-28 |
IN2012DN03226A (en) | 2015-10-23 |
US20120210467A1 (en) | 2012-08-16 |
PL2488542T3 (en) | 2016-12-30 |
EA022979B1 (en) | 2016-04-29 |
EP2488542A1 (en) | 2012-08-22 |
BR112012008957A2 (en) | 2017-09-19 |
US9394529B2 (en) | 2016-07-19 |
CN102712671B (en) | 2016-11-09 |
CA3185815A1 (en) | 2011-04-21 |
AR109953A2 (en) | 2019-02-06 |
MX339648B (en) | 2016-06-02 |
CA2777699C (en) | 2023-03-14 |
AR078583A1 (en) | 2011-11-16 |
EP2488542A4 (en) | 2013-07-31 |
UA109884C2 (en) | 2015-10-26 |
US20160326503A1 (en) | 2016-11-10 |
CA2777699A1 (en) | 2011-04-21 |
US10487316B2 (en) | 2019-11-26 |
MX2012004469A (en) | 2012-08-08 |
EP2488542B1 (en) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10487316B2 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them | |
US9512382B2 (en) | Oil degumming methods | |
US8637290B2 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them | |
AU2005221136B2 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them | |
AU2003243157C1 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them | |
EP2216403A2 (en) | Esterases and related nucleic acids and methods | |
US7943360B2 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them | |
AU2011218662B2 (en) | Phospholipases, nucleic acids encoding them and methods for making and using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080057899.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10823862 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2777699 Country of ref document: CA Ref document number: 3226/DELNP/2012 Country of ref document: IN Ref document number: 13502069 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/004469 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010823862 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201205803 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201200593 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012008957 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012008957 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012008957 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120416 |